Nucleic acid oligomers and uses therefor

ABSTRACT

Disclosed are nucleic acid oligomer compounds and to their use in compositions and methods for inhibiting proliferation, survival or viability of cancer cells including prostate, lung, pancreatic, breast, cervical and bone cancer cells.

FIELD OF THE INVENTION

This application claims priority to Australian Provisional ApplicationNo. 2015905380 entitled “Nucleic acid oligomers and uses therefor” filed23 Dec. 2015, the contents of which are incorporated herein by referencein their entirety.

This invention relates generally to nucleic acid oligomer compounds andto their use in compositions and methods for inhibiting proliferation,survival or viability of cancer cells including prostate, lung,pancreatic, breast, cervical and bone cancer cells.

BACKGROUND OF THE INVENTION

Cancer is the single biggest health problem globally. It is estimatedthat by 2030 half of all global deaths will be from cancer and that ourmathematical chance of getting cancer in our lifetime is now approaching70%.

Drug developments have hit a number of hurdles. Chemotherapeutic drugsprimarily target genome stability either directly or through inhibitionof cell division. As all cancers show genomic instability these drugscan push these cells into apoptosis or necrosis. Chemotherapeutic drugs,however, demonstrate toxicity to the patient's normal cells and themajority of patients develop resistance to these drugs. Cancer therapieshave also been developed, which are directed to subtypes of patientswhose cancer is driven by an oncoprotein with a specific drugablemutation. Examples include HER2 overexpression in breast cancer, andEGFR mutations and ALK rearrangements in lung cancer. More recentlyimmune checkpoint inhibitors have been developed that target CTLA4 andthe PD1/PDL1 pathway, which are effective against a proportion of solidtumours, but the majority of these inhibitors are only effective againsta subset of tumours and, again, in many cases, patients becomerefractory to them.

There remains a pressing need in the art for new approaches to thetreatment or prevention of cancers.

SUMMARY OF THE INVENTION

The present invention is based on the discovery that nucleic acidoligomer compounds of a specified length with a particular backbonechemistry and base composition can bind to cellular proteins involved inDNA repair and/or nuclear export of RNA molecules to the proteinsynthesis machinery of a cell. Surprisingly, it has also been discoveredthat these compounds are able to significantly inhibit the proliferationor stimulate the death of tumor cells, including tumor cells associatedwith prostate, lung, pancreatic, breast, cervical or bone cancer. Thesediscoveries have been reduced to practice in novel compounds,compositions and methods, as described hereafter.

Accordingly, in one aspect, the present invention provides methods forinhibiting proliferation, survival or viability of a tumor cell (e.g., amammalian tumor cell such as a human tumor cell). These methodsgenerally comprise, consist or consist essentially of introducing intothe tumor cell a nucleic acid oligomer that is characterized by:

-   -   a) a backbone comprising phosphorothioate internucleoside        linkages;    -   b) (i) a purine content of at least about 50%, or (ii) a purine        content of at least about 45% with a guanosine-cytosine (GC)        content of at least about 50%; and    -   c) a length of at least 14 nucleobases and no more than 29        nucleobases,        wherein the oligomer binds to one or both of a THO complex        subunit 4 (THOC4) protein and a single-stranded DNA-binding        protein 1 (SSB1).

Representative purine contents of at least about 45% encompass at least6 purines in a 14-nucleobase oligomer, at least 7 purines in a15-nucleobase oligomer, at least 7 purines in a 16-nucleobase oligomer,at least 8 purines in a 17-nucleobase oligomer, at least 8 purines in a18-nucleobase oligomer, at least 9 purines in a 19-nucleobase oligomer,at least 9 purines in a 20-nucleobase oligomer, at least 9 purines in a21-nucleobase oligomer, at least 10 purines in a 22-nucleobase oligomer,at least 10 purines in a 23-nucleobase oligomer, at least 11 purines ina 24-nucleobase oligomer, at least 11 purines in a 25-nucleobaseoligomer, at least 12 purines in a 26-nucleobase oligomer, at least 12purines in a 27-nucleobase oligomer, at least 13 purines in a28-nucleobase oligomer and at least 13 purines in a 29-nucleobaseoligomer.

Representative purine contents of at least about 50% encompass at least7 purines in a 14-nucleobase oligomer, at least 8 purines in a15-nucleobase oligomer, at least 8 purines in a 16-nucleobase oligomer,at least 9 purines in a 17-nucleobase oligomer, at least 9 purines in a18-nucleobase oligomer, at least 10 purines in a 19-nucleobase oligomer,at least 10 purines in a 20-nucleobase oligomer, at least 11 purines ina 21-nucleobase oligomer, at least 11 purines in a 22-nucleobaseoligomer, at least 12 purines in a 23-nucleobase oligomer, at least 12purines in a 24-nucleobase oligomer, at least 13 purines in a25-nucleobase oligomer, at least 13 purines in a 26-nucleobase oligomer,at least 14 purines in a 27-nucleobase oligomer, at least 14 purines ina 28-nucleobase oligomer and at least 15 purines in a 29-nucleobaseoligomer.

Representative GC contents of at least about 50% encompass at least 7G/C in a 14-nucleobase oligomer, at least 8 G/C in a 15-nucleobaseoligomer, at least 8 G/C in a 16-nucleobase oligomer, at least 9 G/C ina 17-nucleobase oligomer, at least 9 G/C in a 18-nucleobase oligomer, atleast 10 G/C in a 19-nucleobase oligomer, at least 10 G/C in a20-nucleobase oligomer, at least 11 G/C in a 21-nucleobase oligomer, atleast 11 G/C in a 22-nucleobase oligomer, at least 12 G/C in a23-nucleobase oligomer, at least 12 G/C in a 24-nucleobase oligomer, atleast 13 G/C in a 25-nucleobase oligomer, at least 13 G/C in a26-nucleobase oligomer, at least 14 G/C in a 27-nucleobase oligomer, atleast 14 G/C in a 28-nucleobase oligomer and at least 15 G/C in a29-nucleobase oligomer.

In some embodiments, the oligomer is further characterized in that itblocks translocation of mRNA from the nucleus to the cytoplasm of thetumor cell.

In some embodiments, the oligomer is further characterized in that it ispreferentially taken up by the tumor cell, as compared to its uptake bya non-tumor cell.

Suitably, the oligomer is further characterized in that it causesapoptosis or necrosis of the tumor cell. In illustrative examples ofthis type, the oligomer causes more death of tumor cells of the sametype as the tumor cell than of non-tumor cells.

In specific embodiments, the oligomer is further characterized in thatit binds to one or both of THOC4 and SSB1 with higher affinity than acontrol oligomer, suitably under conditions as defined herein.

The introduction of the oligomer into the tumor cell can occur in vivoor in vitro.

Suitably, at least about 70% of the internucleoside linkages of thebackbone comprise phosphorothioate internucleoside linkages. In specificembodiments, all internucleoside linkages of the backbone comprisephosphorothioate internucleoside linkages.

In some embodiments, the oligomer is further characterized in that has amelting temperature (Tm) of at least about 45° C.

In some embodiments, the backbone of the oligomer comprises at least one2′-O-alkyl modified sugar moiety, which is also referred to herein as a“2′-O-alkyl nucleoside” (e.g., 2′-O-methyl nucleoside). In specificexamples, the oligomer comprises at least one 2′-O-methylribonucleoside. Suitably, at least about 50% of the nucleosides of theoligomer are each a 2′-O-alkyl nucleoside (e.g., 2′-O-methylnucleoside). In specific embodiments, all nucleosides of the oligomerare each a 2′-O-alkyl nucleoside (e.g., 2′-O-methyl nucleoside).

In some embodiments, the nucleobase sequence over the length of theoligomer lacks substantial complementarity to the transcriptome.Suitably, no more than about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%,55%, 50%, 45%, 40%, 35% 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% ofthe nucleobases of the oligomer are able to engage in base-pairing withthe transcriptome. In illustrative examples of this type, an oligomer of14 to 29 nucleobases with no more than 95% of its nucleobases able toengage in base-pairing with the transcriptome has at least onenon-complementary nucleobase that is unable to base-pair with anucleobase of a reference nucleobase sequence of the transcriptome. Inother illustrative examples, an oligomer of 14 to 29 nucleobases with nomore than 90% of its nucleobases able to engage in base-pairing with thetranscriptome has at least 1, 2 or 3 non-complementary nucleobases,depending on the length of the oligomer, as for example calculated fromTABLE 1 infra, which are unable to base-pair with a nucleobase of areference nucleobase sequence of the transcriptome.

In some embodiments, the nucleobase sequence over the length of theoligomer lacks substantial complementarity to the genome of a mammalfrom which the tumor cell is suitably derived. Suitably, no more thanabout 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of the nucleobases of theoligomer are able to engage in base-pairing with the genome. Inillustrative examples of this type, an oligomer of 14 to 29 nucleobaseswith no more than 95% of its nucleobases able to engage in base-pairingwith the genome has at least one non-complementary nucleobase that isunable to base-pair with a nucleobase of a reference nucleobase sequenceof the genome. In other illustrative examples, an oligomer of 14 to 29nucleobases with no more than 90% of its nucleobases able to engage inbase-pairing with the genome has at least 1, 2 or 3 non-complementarynucleobases, depending on the length of the oligomer, as for examplecalculated from TABLE 1 infra, which are unable to base-pair with anucleobase of a reference nucleobase sequence of the genome.

In some embodiments, the nucleobase sequence over the length of theoligomer lacks homology to the genome of a mammal from which the tumorcell is suitably derived. Suitably, the nucleobase sequence over thelength of the oligomer has no more than about 95%, 90%, 85%, 80%, 75%,70%, 65%, 60%, 55%, 50%, 45%, 40%, 35% 30%, 25%, 20%, 15%, 10%, 5%, 4%,3%, 2%, 1% sequence identity to any equal length of contiguousnucleobases defining a reference nucleobase sequence in the genome. Inillustrative examples of this type, an oligomer of 14 to 29 nucleobaseswith no more than 95% sequence identity to the reference nucleobasesequence in the genome has at least one nucleobase that is not identicalto, or does not have the same or equivalent nucleobase-pairing abilityas, a nucleobase at a matching position of the reference nucleobasesequence. In other illustrative examples, an oligomer of 14 to 29nucleobases with no more than 90% sequence identity to the referencenucleobase sequence in the genome has at least 1, 2 or 3 nucleobases,depending on the length of the oligomer, as for example calculated fromTABLE 1 infra, which are not identical to, or do not have the same orequivalent nucleobase-pairing ability as, a nucleobase at a matchingposition of the reference nucleobase sequence.

Oligomer compounds that lack substantial complementarity to thetranscriptome or that lack substantial complementarity or homology tothe genome are referred to herein as “non-targeting oligomers”. In someembodiments, a non-targeting oligomer of the invention comprises anucleobase sequence selected from any one of SEQ ID NO: 1, 2, 3, 5, 7,36, 37, 38, 39, 40, 41, 44, 45, 51, 52, 53, 54, 55, 56, 59, 61, 62, 63,64, 66, 67, 68, 69, 70, 71, 72, 73, 79, 80, 81, 82, 83, 84, 85, 91, 92,93, 94, 98, 100, 103, 104, 105, 107, 108, 109, 110, 111, 113, 114, 115,117, 118, 119, 120, 121, 122, 131, 132, 133, 134, 135, 137, 138, 143,144, 145, 152, 153, 155, 156, 158, 159, 160, 161, 162, 164, 165, 166,167, 168, 169, 170, 171, 172, 173, 174, 175, 177, 180, 181, 182, 183,184, 185, 191, 192, 196, 198, 203, 206, 207, 209, 210, 211, 223, 224,225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238,239, 240, 244, 245, 247, 248, 249, 250, 251, 252, 253, 256, 258, 259,261, 263, 264, 265, 269, 270, 271, 272, 274, 277, 281, 282, 283, 286,287, 290, 291, 292, 293, 295, 296, 298, 300, 301 and 303.

In other embodiments, the nucleobase sequence over the length of theoligomer has substantial complementarity to an antisense strand of aselected gene. In these embodiments, the nucleobase sequence is suitablycomplementary to and hybridizes to a target sequence of the selectedgene or transcript thereof, including a pre-mRNA or mRNA moleculeencoded by the selected gene, under high stringency conditions. Oligomercompounds of this type are also referred to herein as “antisenseoligomers”. In some embodiments, an antisense oligomer of the inventioncomprises a nucleobase sequence selected from any one of SEQ ID NO: 6,10, 12, 14, 15, 16, 17, 21, 22, 23, 24, 25, 27, 28, 29, 31, 32, 33, 34,35, 101, 278, 279, 280, 284, 285, 288, 289, 297 and 299.

These oligomers have significant activity for inhibiting proliferation,survival or viability of tumor cells. Some of these however, have higherinhibitory activity than others and in preferred embodiments, theoligomer has a nucleobase sequence selected from any one of SEQ ID NO:1, 2, 3, 5, 6, 10, 12, 14, 15, 16, 17, 21, 22, 23, 24, 25, 28, 32, 31,34, 35, 36, 38, 39, 41, 44, 52, 56, 53, 54, 59, 61, 63, 64, 66, 67, 68,69, 70, 71, 72, 73, 79, 80, 81, 82, 83, 84, 91, 92, 93, 98, 100, 103,104, 107, 109, 110, 111, 113, 114, 117, 118, 119, 120, 121, 122, 131,132, 133, 134, 135, 143, 144, 145, 153, 155, 156, 158, 159, 160, 161,162, 164, 165, 167, 168, 169, 170, 171, 172, 180, 181, 182, 191, 192,203, 224, 225, 226, 227, 229, 230, 233, 234, 235, 236, 238, 239, 240,245, 247, 251, 252, 253, 258, 259, 261, 263, 264, 269, 271, 272, 274,285, 286, 287, 288, 289, 290, 291, 292, 293, 295, 296, 297, 298, 299,300, 301 and 303. In more preferred embodiments, the oligomer has anucleobase sequence selected from any one of SEQ ID NO: 1, 2, 3, 5, 14,16, 17, 31, 34, 35, 36, 38, 39, 52, 56, 67, 68, 69, 70, 71, 79, 80, 81,82, 83, 91, 92, 93, 100, 103, 109, 110, 111, 114, 119, 131, 133, 134,135, 143, 153, 155, 158, 159, 161, 164, 168, 169, 171, 181, 182, 203,253, 272, 300, 301 and 303.

The tumor cell can be any cell having neoplastic cell growth andproliferation, whether malignant or benign. It can be pre-cancerous orcancerous. In specific embodiments, the tumor cell is selected fromprostate, lung, pancreatic, breast, cervical or bone tumor cells.

The oligomer compound preferentially binds to or has affinity for one orboth of THOC4 and hSSB1. The THOC4 and SSB1 proteins are preferablyhuman (i.e., hTHOC4 and hSSB1). In specific embodiments, the oligomercompound preferentially binds to THOC4 (e.g., hTHOC4) with a K_(D) ofabout 50 nM or less and/or binds to SSB1 (e.g., hSSB1) with a K_(D) ofabout 3 nM or less, suitably in an aqueous solution containing 10 nMTris-HCl (pH8.0) and 100 mM NaCl at 37° C.

Another aspect of the present invention provides an oligomer as broadlydescribed above and elsewhere herein.

In yet another aspect, the present invention provides a pharmaceuticalcomposition that comprises an oligomer as broadly described above andelsewhere herein, and a pharmaceutically acceptable carrier.

Still another aspect of the present invention provides methods fortreating or preventing a cancer in a subject. These methods generallycomprise, consist or consist essentially of administering to the subjectan effective amount of an oligomer as broadly described above andelsewhere herein.

The cancer may be a solid tumor or bloodborne tumor, including cancersof skin, tissues, organs, bone, cartilage, blood, and vessels. Thecancer may be a primary cancer or a metastatic cancer. In specificembodiments, the cancer is selected from prostate, lung, pancreatic,breast, cervical and bone cancer.

In some embodiments, the methods comprise concurrently administeringwith the oligomer at least one ancillary agent selected from ananti-infective agent (e.g., selected from antibiotics, amebicides,antifungals, antiprotozoals, antimalarials, antituberculotics andantivirals, etc.), a chemotherapeutic agent (e.g., selected fromantiproliferative/antineoplastic drugs, cytostatic agents, agents thatinhibit cancer cell invasion, inhibitors of growth factor function,anti-angiogenic agents, vascular damaging agents, etc.), and animmunotherapeutic agent (e.g., cytokines, cytokine-expressing cells,antibodies, etc.).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a photographic representation showing bright field microscopyimages of various cell lines as indicated. The images were taken at16-36 hr post control oligomer or non-targeting oligomer transfections.Non-targeting oligomer compounds (“LSA”) had a significant impact oncell viability as shown by loss of adherence and low confluency comparedto control oligonucleotide transfected cells.

FIG. 2 is a photographic representation showing Western blots of HeLaand U2OS cells transfected with 100 nM of ctrl, In2E2LSA, In3E3LSA,E3E4LSA, ATGLSA oligomer compounds and a mix of all four LSA sequences(only HeLa cells). Cells were harvested at 24 hrs post transfection.PARP cleavage as marker of apoptosis was evident in LSA transfectedcells, as was yH2AX induction as a marker for DNA damage. hSSB1 proteinlevels were decreased to various extents following LSA transfection.Actin was used as loading control.

FIG. 3 is a photographic representation showing induction of apoptosisin U2OS cells transfected with LSAs and ASOs. Western blots showphosphorylation of H2AX that correlates with PARP cleavage, confirminginduction of DNA damage and apoptosis in cells transfected with thetoxic LSA/ASOs. hSSB1 protein levels are also depleted followingtransfection with the toxic LSA/ASOs. Actin was used as loading control.

FIG. 4 is a graphic representation showing treatment with several cancercell lines with the most effective LSAs, ATGLSA or In3LSA (drug) ascompared to non-effective oligonucleotide (control). Cell growth wasmeasured by IncuCyte over 72 hr.

FIG. 5 is a photographic and graphic representation showing THOC4 andhSSB1 EMSAs. EMSAs showing increasing concentrations of THOC4 (A) andhSSB1 (B) proteins vs. 10 nmol of FAM-labeled LSA_In3E3 or negativecontrol (Neg_C). The lower bands represent free unbound oligo, thehigher bands and smear represent oligo bound to proteins, (C)quantification of triplicate EMSA experiments expressed as thepercentage of oligo bound to the protein. Purified hSSB1 or THOC4protein was incubated with 10 nmol of labeled oligo for 15 min at 37° C.in a buffer consisting of 10 mM Tris-HCl (pH8.0), 100 mM NaCl, 0.01%IGEPAL, 1 mM EDTA and 100 ng/μL BSA. Samples were separated byelectrophoresis on a 10% PAGE gel in TBE buffer for 60 min at 80V at 4°C.

FIG. 6 is a graphic representation showing a GFP expression assay inHeLa-BCL2 cells transfected with ASOs or LSAs (100 nM). A correlationbetween oligomer compounds that induce cell death (ATGLSA, In3LSA,In3LSACU, etc.) and low GFP fluorescence is observed. Non death inducingoligonucleotides such as CTRL, NEGC, NEGC GAP, NEGC 50 nM, In3LSA_CT5,OPEN_LSA1, CDCA3_LSA_IN2E2 do not significantly affect GFP fluorescenceas compared to cells transfected with GFP plasmid only (GFP). Areduction in GFP fluorescence indicates an inhibition of geneexpression, consistent with inhibition of mRNA translocation.

FIG. 7 is a photographic representation showing that IN3LSA oligomercompound inhibits polyA mRNA export from the nucleus. HeLa BCL2 cellswere transfected with FAM labeled IN3LSA oligomer compound or NEGColigonucleotide and mRNA FISH was performed at 24 hr post transfection.PolyA mRNA was stained in red and DAPI was used to stain the nuclei.

FIG. 8 is a graphic representation showing results of a screen todetermine optimal oligomer compound length. Oligomer compounds werestepwise truncated 1 bp at the time from 5′ or 3′ ends of parentsequences. Data shown is the percentage of cells with condensed nucleias a marker of apoptosis (data was normalized to the minimum and maximumscores for each plate on a scale of 0-1, 0=lowest death score, 1=highestdeath score).

FIG. 9 is a graphic representation showing that purine contentcorrelates with cell death. Dot plots comparing markers of cellulartoxicity (nuclear condensation and PI-positive staining). Data wasaveraged between HeLa and U2OS cells and normalized to the minimum andmaximum scores for each plate, 0=lowest PI-positive, 1=highestPI-positive).

FIG. 10 is a graphic representation showing tumor growth retardation forSCID mice treated with cell death induction effective oligomer compoundsIN3LSA (In3, grey triangles) and ATGLSA (ATG, white diamonds) vs. noneffective control oligonucleotide (ctrl) and PBS (black dots) over 4weeks (2 intravenous injections per week). The graph show the averagechange in tumor volume for at least 7 mice per group+/−SEM. Starsrepresent statistically significant reduced tumor volumes (ANOVA,α=0.05,* P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001)

FIG. 11 is a graphic representation showing weight variation of SCIDmice treated with oligomer compounds IN3LSA (In3, grey triangles) andATGLSA (ATG, white diamonds) vs. non effective control oligonucleotide(ctrl) and PBS (black dots) over 4 weeks (2 intravenous injections perweek). The graph represents the average weight variation+/−SEM for atleast 7 mice per group. The black arrow shows the start of treatment.

FIG. 12 is a graphic representation showing weight variation for the 3mice with the most reduced tumors for IN3LSA (In3, mice #110 H-1, 119J-2 and 84 A-3, left panel) and ATGLSA (ATG, mice #114 I-1, 120 J-3, 91C-2, right panel) comparing to control and PBS after a 4-week treatment.

FIG. 13 is a graphic representation showing fluorescent signal at tumorsite over time from a Cy 5.5 labeled In3LSA oligomer compound.Intravenous (i.v.) delivery shows a strong and persistent signal at thetumor site while signal post intraperitoneal (i.p.) injection isundetectable at the tumor site.

FIG. 14 is a photographic representation showing whole animal imaging ofa mouse administered IN3LSA. One mouse with an established tumor (volume˜900 mm³) was administered a single intravenous injection of Cy5.5labeled IN3LSA at a dose of 20 mg/kg. The image shows the animalpre-injection, as well as 5 days post-injection in which signalassociated with the oligomer compound can be clearly observed. Alsoshown is the excised tumor at day 8 post injection.

FIG. 15 is a graphic representation of hSSB1 EMSAs showing increasingconcentrations of hSSB1 protein vs. 5 nM of FAM-labeled LSA_In3E3sequence in either phosphorothioate (PS) or phosphodiester (PD)chemistry, or negative control sequence (Neg_C) in phosphorothioatechemistry. Graphs represent quantification of at least triplicateexperiments, expressed as the fraction of oligomer compound bound to theprotein. Purified protein was incubated with 5 nM of labeled oligomercompound for 15 min at 37° C. in a buffer consisting of 10 mM Tris-HCl(pH7.5), 100 mM KCl, 0.01% IGEPAL, 1 mM EDTA and 50 ng/μL BSA. Sampleswere separated by electrophoresis on a 15% PAGE gel in TBE buffer for120 min at 80V at 4° C.

FIG. 16 is a graphic representation of a single EMSA showing increasingconcentrations of hSSB2 protein vs. 5 nM of FAM-labeled LSA_In3E3sequence or negative control sequence (Neg_C) in phosphorothioatechemistry. Graphs represent the fraction of oligo bound to the protein.Purified protein was incubated with 5 nM of labeled oligo for 15 min at37° C. in a buffer consisting of 10 mM Tris-HCl (pH7.5), 100 mM KCl,0.01% IGEPAL, 1 mM EDTA and 50 ng/μL BSA. Samples were separated byelectrophoresis on a 15% PAGE gel in TBE buffer for 120 min at 80V at 4°C.

FIG. 17 is a schematic and graphic representation illustrating thatmolecular simulation of hSSB1 binding to oligomer compounds can be usedto screen for sequences with a greater hSSB1 binding affinity. A. ATGLSAoligomer in yellow and its unmodified RNA sequence in blue. B. NEGColigomer in pink and its unmodified RNA sequence in blue. C. AverageSSB-oligomer compound binding energies generated from a stableconformation between 200 to 500 ps. D. Binding energies of each oligorelative to its unmodified RNA nucleotide sequence over a 1 nssimulation.

Binding energy calculated as, Ebinding=E(complex)−[E(receptor)+E(ligand)]

FIG. 18 is a graphic representation showing that ATGLSA (ATG) oligomercompound suppresses tumor growth in a lung cancer xenograft model. MaleSCID mice bearing H460 lung cancer subcutaneous tumors were treated withvehicle control PBS (open dots, n=7) or ATGLSA oligomer (dark triangles,n=8) at 80 mg/kg, twice weekly for four weeks via intravenous tailvein/retro orbital injection. Graph shows the average percentage change(+/−sem) in tumor volume during the course of the treatment ****:P-value <0.0001 in a Two-way ANOVA.

FIG. 19 s a photographic representation showing bioluminescence imagingof parental lung H460 xenograft treated with control PBS or ATGLSA (ATG)oligomer compound. Mouse tumor bioluminescence signal from cancer cellsluciferase activity was measured before start and at 16 days oftreatment. SCID males received a 200 μL intraperitoneal injection ofD-luciferine 15 min before signal acquisition with the IVIS system.Three representative mice are shown for PBS treated group (A, B and C),and ATGLSA (ATG) treated group (D, E and F) before (top panels) and at16 days of treatment (bottom panels). Heat signal represents theluminescence scale.

FIG. 20 is a graphic representation showing weight monitoring of controlPBS vs ATGLSA (ATG) treated mice (parental H460 tumor model). Eachanimal was weighed twice weekly during the course of the study. Graphrepresents the average percentage of weight variation (+/−sem) ascompared to the first day of treatment for PBS treated cohort (opendots) and ATGLSA (ATG) treated cohort (black triangles).

FIG. 21 is a graphic representation showing parental and cisplatinresistant lung H460 cancer cells proliferation after treatment withATGLSA oligomer compound. H460 Parental (H460 P, dots) cells andcisplatin resistant (H460 R, squares) cells were treated with controlPBS (open symbols) vs 100 nM ATGLSA (dark symbols). Proliferation ratiois calculated by cell confluency at 24 and 48 h reported to the initialcell confluency (+/−sem).

FIG. 22 is a graphic representation showing that ATGLSA (ATG) oligomercompound suppresses tumor growth in a cisplatin resistant lung cancerxenograft model. Male SCID mice bearing subcutaneous H460 cisplatinresistant tumors were treated with vehicle control PBS (open dots, n=6)or with ATGLSA oligomer (ATG, black triangles, n=6) at 80 mg/kg, twiceweekly for four weeks via intravenous tail vein/retro orbital injection.Graph shows the average percentage change in tumor volume (+/−sem)during the course of the treatment. **: P-value <0.01 in a Two-wayANOVA.

FIG. 23 s a photographic representation showing bioluminescence imagingof cisplatin-resistant lung H460 xenograft treated with control PBS orATGLSA (ATG) oligomer compound. Mouse tumor bioluminescence signal fromcancer cells luciferase activity was measured before and at 18 days oftreatment. SCID males received a 200 μL intraperitoneal injection ofD-luciferine 15 min before signal acquisition with the IVIS system.Three representative mice are shown for PBS treated group (A, B and C),and ATGLSA (ATG) treated group (D, E and F) before (top panels) and at16 days of treatment (bottom panels). Heat signal represents theluminescence scale.

FIG. 24 is a graphic representation showing weight monitoring of controlPBS vs ATGLSA (ATG) treated mice of cisplatin resistant H460 tumormodel. Each animal was weighed twice weekly during the course of thestudy. Graph represents the average percentage of weight variation(+/−sem) as compared to the first day of treatment for PBS treatedcohort (open dots) and ATGLSA (ATG) treated cohort (black triangles).

FIG. 25 is a Kaplan-Meier graph showing a long term assessment of ATGLSA(ATG) treatment effect on cisplatin-sensitive H460 lung xenograft. MaleSCID mice were monitored from the beginning of the treatment with ATGLSA(80 mg/kg) until their tumor reach the maximum final volume of 1000 mm³(determined by calipers measurements). ** P-value <0.01 in Rank-Loganalysis.

FIG. 26 is a Kaplan-Meier graph showing a long term assessment of ATGLSA(ATG) treatment effect on Cisplatin-resistant H460 lung xenograft. MaleSCID mice were monitored from the beginning of the treatment with ATGLSA(80 mg/kg) until their tumor reach the final maximum volume of 1000 mm3(determined by calipers measurements).

FIG. 27 is a graphic representation showing that ATGLSA (ATG) oligomercompound reduces tumor growth in lung tumor xenograft model. Male SCIDmice bearing subcutaneous tumors were treated with ATGLSA oligomer (ATG,green triangles, n=5), cisplatin (black diamonds) or combination ofATGLSA+Cisplatin (red squares) for 3 weeks (dashed line). Treatments foreach group were switched at week 4: Combination animals were treatedwith control vehicle PBS, ATGLSA animals were treated with cisplatin,and Cisplatin animals were treated with ATGLSA. Graph shows the averagepercentage change (+/−sem) in tumor volume during the course of thetreatment ****: P-value <0.0001 in a Two-way ANOVA.

FIG. 28 is a graphic representation showing weight monitoring of controlPBS, ATGLSA (ATG), Cisplatin and Combination of ATGLSA+Cisplatin (Combo)treated mice in H460 tumor model. Each animal was weighed twice weeklyduring the course of the study. Graph represents the average percentageof weight variation (+/−sem) as compared to the first day of treatmentfor PBS treated cohort (open blue dots), ATGLSA (ATG) then Cisplatintreated cohort (green triangles), Cisplatin then ATGLSA treated cohort(black diamonds) and combined ATGLSA+Cisplatin (Combo) then PBS treatedcohort (red squares).

DETAILED DESCRIPTION OF THE INVENTION 1. Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by those of ordinary skillin the art to which the invention belongs. Although any methods andmaterials similar or equivalent to those described herein can be used inthe practice or testing of the present invention, preferred methods andmaterials are described. For the purposes of the present invention, thefollowing terms are defined below.

The articles “a” and “an” are used herein to refer to one or to morethan one (i.e., to at least one) of the grammatical object of thearticle. By way of example, “an element” means one element or more thanone element.

As used herein, “and/or” refers to and encompasses any and all possiblecombinations of one or more of the associated listed items, as well asthe lack of combinations when interpreted in the alternative (or).

Further, the term “about”, as used herein when referring to a measurablevalue such as an amount, dose, time, temperature, activity, level,number, frequency, percentage, dimension, size, amount, weight,position, length and the like, is meant to encompass variations of ±15%,±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified amount, dose,time, temperature, activity, level, number, frequency, percentage,dimension, size, amount, weight, position, length and the like.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range is encompassed within the invention. The upper and lowerlimits of these smaller ranges may independently be included in thesmaller ranges is also encompassed within the invention, subject to anyspecifically excluded limit in the stated range. Where the stated rangeincludes one or both of the limits, ranges excluding either both ofthose included limits are also included in the invention.

An agent is “actively taken up by mammalian cells” when the agent canenter the cell by a mechanism other than passive diffusion across thecell membrane. The agent may be transported, for example, by “activetransport”, referring to transport of agents across a mammalian cellmembrane by e.g., an ATP-dependent transport mechanism, or by“facilitated transport”, referring to transport of antisense agentsacross the cell membrane by a transport mechanism that requires bindingof the agent to a transport protein, which then facilitates passage ofthe bound agent across the membrane. For active or facilitatedtransport, the oligomers of the present invention may be naked or may beformulated in a complexed form, such as an agent having an anionicbackbone complexed with cationic lipids or liposomes, which can be takeninto cells by an endocytotic mechanism. The oligomer also may beconjugated, e.g., at its 5′ or 3′ end, to an arginine-rich peptide,e.g., a portion of the HIV TAT protein, or polyarginine, to facilitatetransport into the target host cell as described (Moulton et al.,Bioconjug Chem, 2004, 15(2): 290-299; Nelson et al., Bioconjug Chem,2005, 16(4): 959-966). The compound may also have one or more cationiclinkages to enhance antisense activity and/or cellular uptake.

The terms “administration concurrently” or “administering concurrently”or “co-administering” and the like refer to the administration of asingle composition containing two or more actives, or the administrationof each active as separate compositions and/or delivered by separateroutes either contemporaneously or simultaneously or sequentially withina short enough period of time that the effective result is equivalent tothat obtained when all such actives are administered as a singlecomposition. By “simultaneously” is meant that the active agents areadministered at substantially the same time, and desirably together inthe same formulation. By “contemporaneously” it is meant that the activeagents are administered closely in time, e.g., one agent is administeredwithin from about one minute to within about one day before or afteranother. Any contemporaneous time is useful. However, it will often bethe case that when not administered simultaneously, the agents will beadministered within about one minute to within about eight hours andsuitably within less than about one to about four hours. Whenadministered contemporaneously, the agents are suitably administered atthe same site on the subject. The term “same site” includes the exactlocation, but can be within about 0.5 to about 15 centimeters,preferably from within about 0.5 to about 5 centimeters. The term“separately” as used herein means that the agents are administered at aninterval, for example at an interval of about a day to several weeks ormonths. The active agents may be administered in either order. The term“sequentially” as used herein means that the agents are administered insequence, for example at an interval or intervals of minutes, hours,days or weeks. If appropriate the active agents may be administered in aregular repeating cycle.

As used herein, the term “affinity” refers to the non-random interactionof two molecules. Affinity, or the strength of the interaction, can beexpressed quantitatively as a dissociation constant (K_(D)). Bindingaffinity can be determined using standard techniques. In particularembodiments, the oligomers of this invention have a higher affinity fora target molecule (e.g., THOC4 or SSB1) than a control oligomer and thuspreferentially bind the target molecule relative to the controloligomer. For example, oligomer compounds of the invention bind THOC4(e.g., hTHOC4) with a K_(D) of about 50 nM or less and/or bind SSB1(e.g., hSSB1) with a K_(D) of about 3 nM or less in an aqueous solutioncontaining 10 nM Tris-HCl (pH8.0) and 100 mM NaCl at 37° C.

The term “alkyl”, as used herein, refers to a saturated straight orbranched hydrocarbon radical containing up to twenty four carbon atoms.Examples of alkyl groups include, but are not limited to, methyl, ethyl,propyl, butyl, isopropyl, n-hexyl, octyl, decyl, dodecyl and the like.Alkyl groups typically include from 1 to about 6 carbon atoms, moretypically from 1 to about 3 carbon atoms with from 1 to about 2 carbonatoms being more preferred. Alkyl groups as used herein may optionallyinclude one or more further substitutent groups.

The term “ancillary agent” includes a compound that induces a desiredpharmacological and/or physiological effect. The term also encompasspharmaceutically acceptable and pharmacologically active ingredients ofthose compounds specifically mentioned herein including but not limitedto salts, esters, amides, prodrugs, active metabolites, analogs and thelike. When the above term is used, then it is to be understood that thisincludes the active agent per se as well as pharmaceutically acceptable,pharmacologically active salts, esters, amides, prodrugs, metabolites,analogs, etc. The term “ancillary agent” is not to be construed narrowlybut extends to small molecules, proteinaceous molecules such aspeptides, polypeptides and proteins as well as compositions comprisingthem and genetic molecules such as RNA, DNA and mimetics and chemicalanalogs thereof as well as cellular agents. The term “ancillary agent”includes a cell that is capable of producing and secreting a polypeptideas well as a polynucleotide comprising a nucleotide sequence thatencodes that polypeptide. For example, the cell can be tumor cell intowhich a construct has been introduced, which expresses animmunostimulatory molecule sich as B7.1 or 4-1BBL. Thus, the term“ancillary agent” extends to nucleic acid constructs including vectorssuch as viral or non-viral vectors, expression vectors and plasmids forexpression in and secretion in a range of cells.

The term “antisense” refers to a nucleotide sequence whose sequence ofnucleotide residues is in reverse 5′ to 3′ orientation in relation tothe sequence of deoxynucleotide residues in a sense strand of a nucleicacid (e.g., DNA or RNA) duplex. A “sense strand” of a DNA duplex refersto a strand in a DNA duplex which is transcribed by a cell in itsnatural state into a “sense mRNA.” Thus an “antisense” sequence istypically substantially complementary to the coding strand in a DNAduplex and has homology to the non-coding strand in a DNA duplex.

The terms “antisense oligomer” and “antisense compound” are usedinterchangeably herein to refer to a compound having a targetingsequence of nucleobases and a subunit-to-subunit backbone that allowsthe antisense oligomer to hybridize to a target nucleic acid sequence bybase-pairing, including Watson-Crick base-pairing, to form anRNA:oligomer or DNA:oligomer heteroduplex within the target nucleic acidsequence. The antisense oligomer typically includes a sequence of purineand pyrimidine heterocyclic bases, supported by a backbone, which areeffective to hydrogen-bond to corresponding, contiguous bases in atarget nucleic acid sequence. The backbone is typically composed ofsubunit backbone moieties supporting the purine and pyrimidineheterocyclic bases at positions that allow such hydrogen bonding. Thesebackbone moieties are cyclic moieties of 5 to 7 atoms in length, linkedtogether by phosphorous-containing linkages one to three atoms long.Antisense oligomers typically interfere with the synthesis of a geneexpression product including nucleic acid expression products such asmRNA and miRNA and polypeptides. In general, targeting sequence of anantisense oligomer binds to a target sequence corresponding to the“sense” strand of a target gene (e.g., polynucleotides such as DNA, mRNA(including pre-mRNA)) molecules. Antisense oligomers can bind to anyregion of a target gene or nucleic acid expression product, includinge.g., introns, exons, 5′, or 3′ untranslated regions. For example,antisense oligomers that work as steric blockers preferentially bindwithin a splice junction, 5′ untranslated region, or the start region ofa nucleic acid target molecule. Antisense oligomers that work byactivating RNase H preferably bind within an intron, an exon, the 5′untranslated region, or the 3′ untranslated region of a target nucleicacid.

The terms “cap structure” or “terminal cap moiety” as used herein, referto chemical modifications, which can be attached to one or both of thetermini of an oligomeric compound.

As used herein, “complementary” and “complementarity” in reference tooligomeric compounds (e.g., linked nucleosides, oligonucleotides, ornucleic acids) means the capacity of such oligomeric compounds orregions thereof to hybridize to a reference nucleic acid sequencethrough nucleobase complementarity. As used herein, “nucleobasecomplementarity” or “complementarity” when in reference to nucleobasesmeans a nucleobase that is capable of base-pairing with anothernucleobase, typically by Watson-Crick base-pairing. For example, if anucleobase at a certain position of an oligomer compound is capable ofhydrogen bonding with a nucleobase at a certain position of a targetnucleic acid, then the position of hydrogen bonding between the oligomercompound and the target nucleic acid is considered to be complementaryat that nucleobase pair. Thus, a modified nucleobase may maintain theability to pair with a counterpart nucleobase and thus, are stillcapable of nucleobase-pairing or nucleobase complementarity. Bycontrast, “non-complementary” or “mismatch” nucleobases refer to a pairof nucleobases that do not form hydrogen bonds with one another, or areotherwise “unable to base pair”. The terms “complementary” or“complementarity”, also refer to the natural binding of nucleic acidunder permissive salt and temperature conditions by base-pairing.Complementarity between two single stranded molecules (also referred toherein as “nucleobase polymers”) may be “partial”, in which only some ofthe nucleobases base pair, or it may be “complete” when totalcomplementarity exists between the single stranded molecules eitheralong the full length of the molecules or along a portion or region ofthe single stranded molecules. The degree of complementarity betweennucleic acid strands has significant effects on the efficiency andstrength of hybridization between nucleic acid strands. The term“complementary” includes within its scope nucleic acid sequences thatare “fully complementary”, “substantially complementary” or “partiallycomplementary”. As used herein, the term “fully complementary” indicatesthat 100% of the nucleobases in a particular nucleobase oligomer orpolymer are able to engage in base-pairing with another nucleobaseoligomer or polymer. As used herein, the term “substantiallycomplementary”, or its grammatical equivalents, indicates that greaterthan 95%, 96%, 97%, 98% or 99% of the nucleobases in a particularnucleobase oligomer or polymer are able to engage in base-pairing withanother nucleobase oligomer or polymer. This term can also mean that twonucleic acid sequences can hybridize under high stringency conditions,as defined for example herein. As used herein, the term “partiallycomplementary”, or its grammatical equivalents, indicates that no morethan about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%,35% 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of the nucleobases in aparticular nucleobase oligomer or polymer are able to engage inbase-pairing with another nucleobase oligomer or polymer. This term canalso mean that two nucleic acid sequences are unable to hybridize underhigh stringency conditions, as defined for example herein, but are ableto hybridize or not under low or medium stringency conditions, asdefined for example herein.

Throughout this specification, unless the context requires otherwise,the words “comprise,” “comprises” and “comprising” will be understood toimply the inclusion of a stated step or element or group of steps orelements but not the exclusion of any other step or element or group ofsteps or elements. Thus, use of the term “comprising” and the likeindicates that the listed elements are required or mandatory, but thatother elements are optional and may or may not be present. By“consisting of” is meant including, and limited to, whatever follows thephrase “consisting of”. Thus, the phrase “consisting of” indicates thatthe listed elements are required or mandatory, and that no otherelements may be present. By “consisting essentially of” is meantincluding any elements listed after the phrase, and limited to otherelements that do not interfere with or contribute to the activity oraction specified in the disclosure for the listed elements. Thus, thephrase “consisting essentially of” indicates that the listed elementsare required or mandatory, but that other elements are optional and mayor may not be present depending upon whether or not they affect theactivity or action of the listed elements.

As used herein, the term “contiguous” in the context of a nucleic acidsequence means that the sequence is a single sequence, uninterrupted byany intervening sequence or sequences.

By “corresponds to” or “corresponding to” is meant a nucleic acidsequence that displays substantial sequence identity to a referencenucleic acid sequence (e.g., at least about 50, 51, 52, 53, 54, 55, 56,57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 97, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98, 99% or even up to 100% sequence identity to allor a portion of the reference nucleic acid sequence).

By “effective amount”, in the context of treating or preventing acondition is meant the administration of an amount of an agent orcomposition to an individual in need of such treatment or prophylaxis,either in a single dose or as part of a series, that is effective forthe prevention of incurring a symptom, holding in check such symptoms,and/or treating existing symptoms, of that condition. The effectiveamount will vary depending upon the health and physical condition of theindividual to be treated, the taxonomic group of individual to betreated, the formulation of the composition, the assessment of themedical situation, and other relevant factors. It is expected that theamount will fall in a relatively broad range that can be determinedthrough routine trials.

The term “expression” refers the biosynthesis of a gene product. Forexample, in the case of a coding sequence, expression involvestranscription of the coding sequence into mRNA and translation of mRNAinto one or more polypeptides. Conversely, expression of a non-codingsequence involves transcription of the non-coding sequence into atranscript only.

As used herein, the term “gapmer” refers to a chimeric oligomericcompound comprising a central region (a “gap”) and a region on eitherside of the central region (the “wings”), wherein the gap comprises atleast one modification that is different from that of each wing. Suchmodifications include nucleobase, monomeric linkage, and sugarmodifications as well as the absence of modification (unmodified). Thus,in certain embodiments, the nucleoside linkages in each of the wings aredifferent than the nucleoside linkages in the gap. In certainembodiments, nucleotides in the gap are unmodified and nucleotides inthe wings are modified. In certain embodiments, the modification(s) ineach wing are the same. In certain embodiments, the modification(s) inone wing are different from the modification(s) in the other wing.

As used herein, the term “gene” refers to a nucleic acid moleculecapable of being used to produce mRNA, antisense RNA, siRNA, shRNA,miRNA, and the like. Genes may or may not be capable of being used toproduce a functional protein. Genes can include both coding andnon-coding regions (e.g., introns, regulatory elements includingpromoters, enhancers, termination sequences and 5′ and 3′ untranslatedregions). A gene may be “isolated” by which is meant a nucleic acidmolecule that is substantially or essentially free from componentsnormally found in association with the nucleic acid molecule in itsnatural state. Such components include other cellular material, culturemedium from recombinant production, and/or various chemicals used inchemically synthesizing the nucleic acid molecule. Reference to a “gene”also includes within its scope reference to genes having a contiguoussequence, thus defining contiguous nucleic acid entities, as definedherein, or a non-contiguous sequence thus defining a non-contiguousnucleic acid entity as defined herein. In certain embodiments, the term“gene” includes within its scope the open reading frame encodingspecific polypeptides, introns, and adjacent 5′ and 3′ non-codingnucleotide sequences involved in the regulation of expression. In thisregard, the gene may further comprise control sequences such aspromoters, enhancers, termination and/or polyadenylation signals thatare naturally associated with a given gene, or heterologous controlsequences. The gene sequences may be cDNA or genomic DNA or a fragmentthereof. The gene may be introduced into an appropriate vector forextrachromosomal maintenance or for introduction into a host.

“Genome” as used herein refers to the entirety of an organism'shereditary information, represented by genes and non-coding sequences ofDNA, either chromosomal or non-chromosomal genetic elements such as,linear polynucleotides, e.g., including the gene(s) to be assembledand/or recombined. Thus, the term “genome” is intended to include theentire DNA complement of an organism, including the nuclear DNAcomponent, chromosomal or extrachromosomal DNA, as well as thecytoplasmic domain (e.g., mitochondrial DNA).

As used herein the term “heterocyclic base moiety” refers to nucleobasesand modified or substitute nucleobases used to form nucleosidesencompassed by the present invention. The term “heterocyclic basemoiety” includes unmodified nucleobases such as the native purine basesadenine (A) and guanine (G), and the pyrimidine bases thymine (T),cytosine (C) and uracil (U). The term is also intended to include allmanner of modified or substitute nucleobases including but not limitedto synthetic and natural nucleobases such as xanthine, hypoxanthine,2-aminopyridine and 2-pyridone, 5-methylcytosine (5-me-C),5-hydroxymethylenyl cytosine, 2-amino and 2-fluoroadenine, 2-propyl andother alkyl derivatives of adenine and guanine, 2-thio cytosine, uracil,thymine, 3-deaza guanine and adenine, 4-thiouracil, 5-uracil(pseudouracil), 5-propynyl (—C≡C—CH₃) uracil and cytosine and otheralkynyl derivatives of pyrimidine bases, 5-halo particularly 5-bromo,5-trifluoromethyl and other 5-substituted uracils and cytosines,6-methyl and other alkyl derivatives of adenine and guanine, 6-azouracil, cytosine and thymine, 7-methyl adenine and guanine, 7-deazaadenine and guanine, 8-halo, 8-amino, 8-aza, 8-thio, 8-thioalkyl,8-hydroxyl and other 8-substituted adenines and guanines, universalbases, hydrophobic bases, promiscuous bases, size-expanded bases, andfluorinated bases as defined herein. Further modified nucleobasesinclude tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one) and phenothiazine cytidine(1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one).

As used herein the terms “homolog”, “homolog” or “homologous” refer tothe level of similarity between two or more nucleic acid sequences interms of percent of sequence identity. Generally, homologs, homologoussequences or sequences with homology refer to nucleic acid sequencesthat exhibit greater than 95%, 96%, 97%, 98%, 99% sequence identity toone another. Alternatively, or in addition, homologs, homologoussequences or sequences with homology refer to nucleic acid sequencesthat hybridize under high stringency conditions, as defined for exampleherein, to one another. By contrast, the terms “non-homologous”,“non-homologous sequences” or “sequences that lack homology” and thelike refer to nucleic acid sequences that exhibit no more than 95%, 90%,85%, 80%, 75% 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35% 30%, 25%, 20%, 15%,10%, 5%, 4%, 3%, 2%, 1% sequence identity to one another. Alternatively,or in addition, non-homologous”, “non-homologous sequences” or“sequences that lack homology” and the like refer to nucleic acidsequences that do not hybridize under high stringency conditions, asdefined for example herein, to one another but are able to hybridize ornot under medium or low stringency conditions to one another.

“Hybridization” is used herein to denote the pairing of complementarynucleotide sequences to produce a DNA-DNA hybrid or a DNA-RNA hybrid.Complementary nucleobase sequences are those sequences that are relatedby the base-pairing rules. In DNA, A pairs with T and C pairs with G. InRNA U pairs with A and C pairs with G. In this regard, the terms “match”and “mismatch” as used herein refer to the hybridization potential ofpaired nucleotides in complementary nucleic acid strands. Matchednucleotides hybridize efficiently, such as the classical A-T and G-Cbase pair mentioned above. Mismatches are other combinations ofnucleotides that do not hybridize efficiently. In the present invention,the preferred mechanism of pairing involves hydrogen bonding, which maybe Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding,between complementary nucleoside or nucleotide bases (nucleobases) ofthe strands of oligomeric compounds. For example, adenine and thymineare complementary nucleobases which pair through the formation ofhydrogen bonds. Hybridization can occur under varying circumstances asknown to those of skill in the art.

As used herein, the term “in vitro” refers to events that occur in anartificial environment, e.g., in a test tube or reaction vessel, in cellculture, in a Petri dish, etc., rather than within an organism (e.g.,animal, plant, or microbe).

As used herein, the term “in vivo” refers to events that occur within anorganism (e.g., animal, plant, or microbe or cell or tissue thereof).

As used herein “internucleoside linkage” refers to a covalent linkagebetween adjacent nucleosides. The internucleoside linkages constitutethe backbone of a nucleic acid molecule, including the oligomers of thepresent invention.

“Introducing” in the context of a host cell including a mammalian cell,mammalian part, mammalian organ, or whole mammal means contacting anucleic acid molecule (e.g., an oligonucleotide as described herein)with the mammalian cell, mammalian part, mammalian organ, or wholemammal in such a manner that the nucleic acid molecule gains access tothe interior of the mammalian cell, mammalian part, mammalian organ, orwhole mammal.

The term “modified sugar”, as used herein, refers to a substitution orchange from a natural sugar and encompasses modifications of nativeribofuranose and deoxyribofuranose sugars used in the nucleosides andoligomeric compounds of the invention. Modified sugars comprisenucleosides where the heterocyclic base moiety or modified heterocyclicbase moiety is usually maintained for hybridization with an appropriatetarget nucleic acid. Such “modified sugars” are often desired over thenaturally occurring forms because of advantageous properties they canimpart to an oligomeric compound such as, for example, enhanced cellularuptake, enhanced affinity for nucleic acid target and increasedstability to nuclease degradation. The term “modified sugar” is intendedto include all manner of modifications known in the art includingwithout limitation modifications to ring atoms and/or addition ofsubstituent groups.

As used herein, the term “nucleobase” refers to the base portion of anucleoside. A nucleobase is typically a heterocyclic moiety and maycomprise any atom or group of atoms capable of hydrogen bonding to abase of another nucleic acid. The term “nucleobase” encompasses naturalnucleobases and modified nucleobases. Nucleobase (or base) modificationsor substitutions are structurally distinguishable from, yet functionallyinterchangeable with, naturally occurring or synthetic unmodifiednucleobases. Both natural and modified nucleobases are capable ofparticipating in hydrogen bonding. Such nucleobase modifications mayimpart nuclease stability, binding affinity or some other beneficialbiological property to antisense compounds. Modified nucleobases includesynthetic and natural nucleobases such as, for example, 5-methylcytosine(5-me-C). Certain nucleobase substitutions, including 5-methylcytosinesubstitutions, are particularly useful for increasing the bindingaffinity of an antisense compound for a target nucleic acid. Forexample, 5-methylcytosine substitutions have been shown to increasenucleic acid duplex stability by 0.6-1.2.degree. C. (Sanghvi, Y. S.,Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications,CRC Press, Boca Raton, 1993, pp. 276-278). Additional unmodifiednucleobases include 5-hydroxymethyl cytosine, xanthine, hypoxanthine,2-aminoadenine, 6-methyl and other alkyl derivatives of adenine andguanine, 2-propyl and other alkyl derivatives of adenine and guanine,2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil andcytosine, 5-propynyl (—C=C—CH₃) uracil and cytosine and other alkynylderivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine,5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol,8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines,5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituteduracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine,2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Heterocyclic basemoieties may also include those in which the purine or pyrimidine baseis replaced with other heterocycles, for example 7-deaza-adenine,7-deazaguanosine, 2-aminopyridine and 2-pyridone. Nucleobases that areparticularly useful for increasing the binding affinity of antisensecompounds include 5-substituted pyrimidines, 6-azapyrimidines and N-2,N-6 and 0-6 substituted purines, including 2 aminopropyladenine,5-propynyluracil and 5-propynylcytosine.

The term “nucleoside”, as used herein, refers to a base-sugarcombination. The base portion of the nucleoside is normally aheterocyclic base moiety. The two most common classes of suchheterocyclic nucleobases are purines and pyrimidines. “Nucleotides” arenucleosides that further include a phosphate group covalently linked tothe sugar portion of the nucleoside. For those nucleosides that includea pentofuranosyl sugar, the phosphate group can be linked to either the2′, 3′ or 5′ hydroxyl moiety of the sugar. Within the oligonucleotidestructure, the phosphate groups are commonly referred to as forming theinternucleoside linkages of the oligonucleotide, or in conjunction withthe sugar ring, the backbone of the oligonucleotide. In formingoligonucleotides, the phosphate groups covalently link adjacentnucleosides to one another to form a linear polymeric compound. Thenormal internucleoside linkage of RNA and DNA is a 3′ to 5′phosphodiester linkage. In the context of this invention, the term“oligonucleoside” refers to a sequence of nucleosides that are joined byinternucleoside linkages that do not have phosphorus atoms.

The term “OB-fold protein” refers to any polypeptide which comprises orconsists of a domain having OB-fold topology, as described for exampleby (Murzin, 1993, Embo J 12: 861-86) and (Arcus, 2002, Curr Opin StructBiol 12: 794-801), and facilitates binding to ssDNA. This topologycorresponds to an architecture which comprises a five-stranded (8-barrelcapped at one end by an amphiphilic α-helix. Referring to the CATHprotein structure classification (Pearl et al., 2003, Nucleic Acids Res31: 452-455), the OB-fold topology corresponds to the 2.40.50 foldfamily (CATH database version 3.0.0: Released May 2006). Such an OB-foldprotein can be either a native protein (i.e., an isolated, purified orrecombinant protein having the same sequence as a natural protein), oran engineered protein (like, for example, a fragment of a nativeprotein, or a fusion protein comprising an OB-fold domain from a firstprotein, and another moiety from another protein). Non-limitativeexamples of OB-fold proteins which can be used according to theinvention encompass single stranded DNA binding proteins (SSBs)including simple SSBs, which contain one OB-fold per polypeptide, andhigher order SSBs, which contain multiple OB-folds (which may be ondifferent polypeptides). Representative simple SSBs includesingle-stranded DNA binding proteins 1 and 2 (e.g., hSSB1 and 2) and themitochondrial SSB (mtSSB), while higher order SSBs are represented byheterotrimeric replication protein A (RPA). In addition, other proteinshave also adopted the ssDNA-binding-OB-fold structure within theirpolypeptides and may be considered members of the SSB family. Forinstance the serine/threonine kinase receptor associated protein (Strap)structurally contains one DNA binding OB fold as do the simple SSBs,while the TPP1-protection of telomeres 1 (POT1) breast cancer 2, earlyonset (BRCA2) and the CST complex form complexes reminiscent of higherorder SSBs. Numerous OB-fold proteins are known in the art, illustrativeexamples of which are disclosed in Ashton et al. (2013, BMC MolecularBiology 14: 9) and Flynn et al. (2010, Crit Rev Biochem Mol Biol. 45(4):266-275).

The term “oligonucleotide” as used herein refers to a polymer to anoligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid(DNA) composed of naturally occurring nucleobases, sugars andphosphodiester internucleoside linkages.

The terms “oligomer”, “oligomer compound” and “oligomeric compound” areused interchangeably herein to refer to a plurality of naturallyoccurring and/or non-naturally occurring nucleosides, joined together ina specific sequence, to form a polymeric structure. Included in theterms “oligomer” and “oligomeric compound” are oligonucleotides,oligonucleotide analogs, oligonucleotide mimetics, oligonucleosides andchimeric combinations of these, and are thus intended to be broader thanthe term “oligonucleotide”, including all oligomers having all manner ofmodifications including but not limited to those known in the art.Oligomeric compounds are typically structurally distinguishable from,yet functionally interchangeable with, naturally-occurring or syntheticwild-type oligonucleotides. Thus, oligomeric compounds include all suchstructures that function effectively to mimic the structure and/orfunction of a desired RNA or DNA strand, for example, by hybridizing toa target. Such non-naturally occurring oligonucleotides are oftendesired over the naturally occurring forms because they often haveenhanced properties, such as for example, enhanced cellular uptake,enhanced affinity for nucleic acid target and increased stability in thepresence of nucleases.

The terms “patient”, “subject”, “host” or “individual” usedinterchangeably herein, refer to any subject, particularly a vertebratesubject, and even more particularly a mammalian subject, for whomtherapy or prophylaxis is desired. Suitable vertebrate animals that fallwithin the scope of the invention include, but are not restricted to,any member of the subphylum Chordata including primates (e.g., humans,monkeys and apes, and includes species of monkeys such from the genusMacaca (e.g., cynomologus monkeys such as Macaca fascicularis, and/orrhesus monkeys (Macaca mulatta)) and baboon (Papio ursinus), as well asmarmosets (species from the genus Callithrix), squirrel monkeys (speciesfrom the genus Saimiri) and tamarins (species from the genus Saguinus),as well as species of apes such as chimpanzees (Pan troglodytes)),rodents (e.g., mice rats, guinea pigs), lagomorphs (e.g., rabbits,hares), bovines (e.g., cattle), ovines (e.g., sheep), caprines (e.g.,goats), porcines (e.g., pigs), equines (e.g., horses), canines (e.g.,dogs), felines (e.g., cats), avians (e.g., chickens, turkeys, ducks,geese, companion birds such as canaries, budgerigars etc.), marinemammals (e.g., dolphins, whales), reptiles (snakes, frogs, lizardsetc.), and fish. In specific embodiments, the subject is a primate suchas a human. However, it will be understood that the aforementioned termsdo not imply that symptoms are present.

Percentages are used herein to refer to an approximate proportion ofnucleobases or internucleoside linkages over the length of an oligomer,which have a certain characteristic or feature. The number ofnucleobases with these features or characteristics can be easilycalculated from these percentages based on the number of nucleobases inthe oligomer. Representative calculations are provided in TABLE 1 below,in which the listed values are rounded up or down to the nearestinteger.

TABLE 1 Percentage of nucleobases or internucleoside linkages withfeatures Oligo 45% 50% 55% 60% 65% 70% 75% 80% 85% 90% 95% LengthCalculated number of nucleobases or internucleoside linkages withfeatures 14 6 7 8 8 9 10 11 11 12 13 13 15 7 8 8 9 10 11 11 12 13 14 1416 7 8 9 10 10 11 12 13 14 14 15 17 8 9 9 10 11 12 13 14 14 15 16 18 8 910 11 12 13 14 14 15 16 17 19 9 10 10 11 12 13 14 15 16 17 18 20 9 10 1112 13 14 15 16 17 18 19 21 9 11 12 13 14 15 16 17 18 19 20 22 10 11 1213 14 15 17 18 19 20 21 23 10 12 13 14 15 16 17 18 20 21 22 24 11 12 1314 16 17 18 19 20 22 23 25 11 13 14 15 16 18 19 20 21 23 24 26 12 13 1416 17 18 20 21 22 23 25 27 12 14 15 16 18 19 20 22 23 24 26 28 13 14 1517 18 20 21 22 24 25 27 29 13 15 16 17 19 20 22 23 25 26 28

By “pharmaceutically acceptable carrier” is meant a pharmaceuticalvehicle comprised of a material that is not biologically or otherwiseundesirable, i.e., the material may be administered to a subject alongwith the selected active agent without causing any or a substantialadverse reaction. Generally, a pharmaceutically acceptable carrier issubstantially nontoxic and non-inflammatory in subjects. Carriers mayinclude excipients and other additives such as diluents, detergents,coloring agents, wetting or emulsifying agents, pH buffering agents,preservatives, transfection agents and the like. In some embodiments,pharmaceutically acceptable carriers are vehicles capable of suspendingand/or dissolving active agents. Carriers may include, for example:antiadherents, antioxidants, binders, coatings, compression aids,disintegrants, dyes (colors), emollients, emulsifiers, fillers(diluents), film formers or coatings, flavors, fragrances, glidants(flow enhancers), lubricants, preservatives, printing inks, sorbents,suspending or dispersing agents, sweeteners, and waters of hydration.Exemplary carriers include, but are not limited to: butylatedhydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic),calcium stearate, Croscarmellose, crosslinked polyvinyl pyrrolidone,citric acid, crospovidone, cysteine, ethylcellulose, gelatin,hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose,magnesium stearate, maltitol, mannitol, methionine, methylcellulose,methyl paraben, microcrystalline cellulose, polyethylene glycol,polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben,retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch(corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A,vitamin E, vitamin C and xylitol.

The terms “polynucleotide,” “genetic material,” “genetic forms,”“nucleic acids” and “nucleotide sequence” include RNA, cDNA, genomicDNA, synthetic forms and mixed polymers, single stranded, doublestranded, both sense and antisense strands, and may be chemically orbiochemically modified or may contain non-natural or derivatizednucleobases, as will be readily appreciated by those skilled in the art.

The term “preferentially” in the context of uptake of an oligomer by atumor cell means that the oligomer is taken up by the tumor cell at ahigher level than by a non-tumor or normal cell under the sameconditions, which can be in vivo or in vitro. Alternatively, the term“preferentially” in the context of binding of an oligomer to a targetmolecule means that the oligomer binds to the target molecule withgreater affinity than it binds to an unrelated or non-target molecule,or that the target molecule binds to the oligomer with greater affinitythan a control oligomer, under the same conditions, which can be in vivoor in vitro. Oligomer uptake can be at least 1-fold greater, at least2-fold greater, at least 3-fold greater, at least 4-fold greater, atleast 5-fold greater, at least 6-fold greater, at least 7-fold greater,at least 8-fold greater, at least 9-fold greater, 10-fold greater, atleast 20-fold greater, at least 30-fold greater, at least 40-foldgreater, at least 50-fold greater, at least 60-fold greater, at least70-fold greater, at least 80-fold greater, at least 90-fold greater, atleast 100-fold greater, or at least 1000-fold greater by a tumor cellthan by a non-tumor or normal cell. Likewise, oligomer affinity can beat least 1-fold greater, at least 2-fold greater, at least 3-foldgreater, at least 4-fold greater, at least 5-fold greater, at least6-fold greater, at least 7-fold greater, at least 8-fold greater, atleast 9-fold greater, 10-fold greater, at least 20-fold greater, atleast 30-fold greater, at least 40-fold greater, at least 50-foldgreater, at least 60-fold greater, at least 70-fold greater, at least80-fold greater, at least 90-fold greater, at least 100-fold greater, orat least 1000-fold greater to a target molecule than the affinity of theoligomer for an unrelated or non-target molecule. Alternatively, targetmolecule affinity can be at least 1-fold greater, at least 2-foldgreater, at least 3-fold greater, at least 4-fold greater, at least5-fold greater, at least 6-fold greater, at least 7-fold greater, atleast 8-fold greater, at least 9-fold greater, 10-fold greater, at least20-fold greater, at least 30-fold greater, at least 40-fold greater, atleast 50-fold greater, at least 60-fold greater, at least 70-foldgreater, at least 80-fold greater, at least 90-fold greater, at least100-fold greater, or at least 1000-fold greater to an oligomer than theaffinity of the target molecule for a control oligomer. Generaltechniques for measuring oligomer uptake or affinity are known to theskilled person. The measured uptake or affinity and otheroligomer-binding parameters can vary if measured under differentconditions, e.g., salt concentration, pH, etc. Thus measurement ofuptake or affinity and other oligomer-binding parameters, e.g., K_(D),IC₅₀, are preferably made with standardized solutions of oligomer andtarget cells or molecules, and a standardized buffer.

As used herein, the terms “prevent”, “prevented”, or “preventing”, referto a prophylactic treatment which increases the resistance of a subjectto developing the disease or condition or, in other words, decreases thelikelihood that the subject will develop the disease or condition aswell as a treatment after the disease or condition has begun in order toreduce or eliminate it altogether or prevent it from becoming worse.These terms also include within their scope preventing the disease orcondition from occurring in a subject which may be predisposed to thedisease or condition but has not yet been diagnosed as having it.

The terms “reduce”, “inhibit”, “decrease,” and grammatical equivalentswhen used in reference to the level of a substance and/or phenomenon ina first sample relative to a second sample, mean that the quantity ofsubstance and/or phenomenon in the first sample is lower than in thesecond sample by any amount that is statistically significant using anyart-accepted statistical method of analysis. In one embodiment, thereduction may be determined subjectively, for example when a patientrefers to their subjective perception of disease symptoms, such as pain,fatigue, etc. In another embodiment, the reduction may be determinedobjectively, for example when the number of tumor cells in a sample froma patient is lower than in an earlier sample from the patient. Inanother embodiment, the quantity of substance and/or phenomenon in thefirst sample is at least 10% lower than the quantity of the samesubstance and/or phenomenon in a second sample. In another embodiment,the quantity of the substance and/or phenomenon in the first sample isat least 25% lower than the quantity of the same substance and/orphenomenon in a second sample. In yet another embodiment, the quantityof the substance and/or phenomenon in the first sample is at least 50%lower than the quantity of the same substance and/or phenomenon in asecond sample. In a further embodiment, the quantity of the substanceand/or phenomenon in the first sample is at least 75% lower than thequantity of the same substance and/or phenomenon in a second sample. Inyet another embodiment, the quantity of the substance and/or phenomenonin the first sample is at least 90% lower than the quantity of the samesubstance and/or phenomenon in a second sample. Alternatively, adifference may be expressed as an “n-fold” difference.

The term “sequence identity” as used herein refers to the extent thatsequences are identical or has the same nucleobase-pairing ability on anucleobase-by-nucleobase basis over a window of comparison. Thus, a“percentage of sequence identity” or “percent identity” is calculated bycomparing two optimally aligned sequences over the window of comparison,determining the number of positions at which the identical nucleobase ornucleobase with equivalent base-pairing ability occurs in both sequencesto yield the number of matched positions, dividing the number of matchedpositions by the total number of positions in the window of comparison(i.e., the window size), and multiplying the result by 100 to yield thepercentage of sequence identity. For the purposes of the presentinvention, “sequence identity” will be understood to mean the “matchpercentage” calculated by an appropriate method. For example, sequenceidentity analysis may be carried out using the DNASIS computer program(Version 2.5 for windows; available from Hitachi Software engineeringCo., Ltd., South San Francisco, Calif., USA) using standard defaults asused in the reference manual accompanying the software. Thus, oligomercompounds of the present invention, or a portion thereof, may have adefined percent identity to a reference sequence. As used herein, anoligomer nucleobase sequence is identical to a reference nucleobasesequence if it has the same nucleobase-pairing ability. For example, anoligomer that contains uracil in place of thymidine in a referencesequence would be considered identical as they both pair with adenine.Similarly, an oligomer containing a modified guanine nucleobase such as6-methyl guanine in place of guanine in the reference sequence would beconsidered identical as they both pair with cytosine. The identity maybe over the entire length of the oligomeric compound, or in a portion ofthe oligomer compound (e.g., nucleobases 1-20 of a 27-mer may becompared to a 20-mer to determine percent identity of the oligomericcompound to the reference sequence). Any non-identical bases may beadjacent to each other, dispersed through out the oligomer, or both. Forexample, a 16-mer having the same sequence as nucleobases 2-17 of a20-mer is 80% identical to the 20-mer. Alternatively, a 20-mercontaining four nucleobases not identical to the 20-mer is also 80%identical to the 20-mer. A 14-mer having the same sequence asnucleobases 1-14 of an 18-mer is 78% identical to the 18-mer. Suchcalculations are well within the ability of those skilled in the art.

Terms used to describe sequence relationships between two or morepolynucleotides or polypeptides include “reference sequence”,“comparison window”, “sequence identity”, “percentage of sequenceidentity” and “substantial identity”. A “reference sequence” is at least14 and up to 29 (e.g., 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29) nucleobases. Because two nucleic acids may each comprise(1) a sequence that is similar between the two nucleic acids, and (2) asequence that is divergent between the two nucleic acids, sequencecomparisons between two (or more) nucleic acids are typically performedby comparing sequences of the two nucleic acids over a “comparisonwindow” to identify and compare local regions of sequence similarity. A“comparison window” refers to a conceptual segment of at least 14 and upto 29 (e.g., 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29) contiguous nucleobase positions, in which a sequence is compared toa reference sequence of the same number of contiguous nucleobasepositions after the two sequences are optimally aligned. The comparisonwindow may comprise additions or deletions (i.e., gaps) of about 20% orless as compared to the reference sequence (which does not compriseadditions or deletions) for optimal alignment of the two sequences.Optimal alignment of sequences for aligning a comparison window may beconducted by computerized implementations of algorithms (GAP, BESTFIT,FASTA, and TFASTA in the Wisconsin Genetics Software Package Release7.0, Genetics Computer Group, 575 Science Drive Madison, Wis., USA) orby inspection and the best alignment (i.e., resulting in the highestpercentage homology over the comparison window) generated by any of thevarious methods selected. Reference also may be made to the BLAST familyof programs as for example disclosed by Altschul et al., 1997, Nucl.Acids Res. 25:3389. A detailed discussion of sequence analysis can befound in Unit 19.3 of Ausubel et al., “Current Protocols in MolecularBiology,” John Wiley & Sons Inc, 1994-1998, Chapter 15.

“Stringency” as used herein refers to the temperature and ionic strengthconditions, and presence or absence of certain organic solvents, duringhybridization. The higher the stringency, the higher will be theobserved degree of complementarity between sequences. “Stringentconditions” as used herein refers to temperature and ionic conditionsunder which only polynucleotides having a high proportion ofcomplementary nucleobases, preferably having exact complementarity, willhybridize. The stringency required is nucleotide sequence dependent anddepends upon the various components present during hybridization, and isgreatly changed when nucleotide analogues are used. Generally, stringentconditions are selected to be about 10° C. to 20° C. less than thethermal melting point for the specific sequence at a defined ionicstrength and pH. The Tm is the temperature (under defined ionic strengthand pH) at which 50% of a target sequence hybridizes to a complementaryprobe. It will be understood that a polynucleotide will hybridize to atarget sequence under at least low stringency conditions, preferablyunder at least medium stringency conditions and more preferably underhigh stringency conditions. Reference herein to low stringencyconditions include and encompass from at least about 1% v/v to at leastabout 15% v/v formamide and from at least about 1 M to at least about 2M salt for hybridization at 42° C., and at least about 1 M to at leastabout 2 M salt for washing at 42° C. Low stringency conditions also mayinclude 1% Bovine Serum Albumin (BSA), 1 mM EDTA, 0.5 M NaHPO4 (pH 7.2),7% SDS for hybridization at 65° C., and (i) 2×SSC, 0.1% SDS; or (ii)0.5% BSA, 1 mM EDTA, 40 mM NaHPO4 (pH 7.2), 5% SDS for washing at roomtemperature. Medium stringency conditions include and encompass from atleast about 16% v/v to at least about 30% v/v formamide and from atleast about 0.5 M to at least about 0.9 M salt for hybridization at 42°C., and at least about 0.5 M to at least about 0.9 M salt for washing at42° C. Medium stringency conditions also may include 1% Bovine SerumAlbumin (BSA), 1 mM EDTA, 0.5 M NaHPO4 (pH 7.2), 7% SDS forhybridization at 65° C., and (i) 2×SSC, 0.1% SDS; or (ii) 0.5% BSA, 1 mMEDTA, 40 mM NaHPO4 (pH 7.2), 5% SDS for washing at 42° C. Highstringency conditions include and encompass from at least about 31% v/vto at least about 50% v/v formamide and from at least about 0.01 M to atleast about 0.15 M salt for hybridization at 42° C., and at least about0.01 M to at least about 0.15 M salt for washing at 42° C. Highstringency conditions also may include 1% BSA, 1 mM EDTA, 0.5 M NaHPO4(pH 7.2), 7% SDS for hybridization at 65° C., and (i) 0.2×SSC, 0.1% SDS;or (ii) 0.5% BSA, 1 mM EDTA, 40 mM NaHPO4 (pH 7.2), 1% SDS for washingat a temperature in excess of 65° C. One embodiment of high stringencyconditions includes hybridizing in 6×SSC at about 45° C., followed byone or more washes in 0.2×SSC, 0.1% SDS at 65° C. One embodiment of veryhigh stringency conditions includes hybridizing 0.5 M sodium phosphate,7% SDS at 65° C., followed by one or more washes at 0.2×SSC, 1% SDS at65° C. Other stringent conditions are well known in the art. A skilledaddressee will recognize that various factors can be manipulated tooptimize the specificity of the hybridization. Optimization of thestringency of the final washes can serve to ensure a high degree ofhybridization. For detailed examples, see CURRENT PROTOCOLS IN MOLECULARBIOLOGY (supra) at pages 2.10.1 to 2.10.16 and MOLECULAR CLONING. ALABORATORY MANUAL (Sambrook, et al., eds.) (Cold Spring Harbor Press1989) at sections 1.101 to 1.104.

The terms “substituent” and “substituent group”, as used herein, aremeant to include groups that are typically added to other groups orparent compounds to enhance desired properties or give desired effects.Substituent groups can be protected or unprotected and can be added toone available site or to many available sites in a parent compound.Substituent groups may also be further substituted with othersubstituent groups and may be attached directly or via a linking groupsuch as an alkyl or hydrocarbyl group to the parent compound. Suchgroups include without limitation, halogen, hydroxyl, alkyl, alkenyl,alkynyl, acyl (—C(O)R_(a)), carboxyl (—C(O)O—R_(a)), aliphatic,alicyclic, alkoxy, substituted oxo (—O—R_(a)), aryl, aralkyl,heterocyclic, heteroaryl, heteroarylalkyl, amino (—NR_(b)R_(c)),imino(=NR_(b)), amido (—C(O)NR_(b)R_(c) or —N(R_(b))C(O)R_(a)), azido(—N₃), nitro (—NO₂), cyano (—CN), carbamido (—OC(O)NR_(b)R_(c) or—N(R_(b))C(O)OR_(a)), ureido (—N(R_(b))C(O) NR_(b)R_(c)), thioureido(—N(R_(b))C(S) NR_(b)R_(c)), guanidinyl (—N(R_(b))C(═NR_(b))NR_(b)R_(c)), amidinyl (—C(═NR_(b))NR_(b)R_(c) or—N(R_(b))C(NR_(b))R_(a)), thiol (—SR_(b)), sulfinyl (—S(O)R_(b)),sulfonyl (—S(O)₂R_(b)) and sulfonamidyl (—S(O)₂NR_(b)R_(c) or—N(_(b))S(O)₂R_(b)), wherein each R_(a), R_(b) and R_(c) is a furthersubstituent group with a preferred list including without limitationalkyl, alkenyl, alkynyl, aliphatic, alkoxy, acyl, aryl, aralkyl,heteroaryl, alicyclic, heterocyclic and heteroarylalkyl.

The terms “target nucleic acid sequence” and “target sequence” are usedinterchangeably herein to refer to a portion of a target RNA or targetDNA molecule against which the targeting sequence of an oligomercompound of the invention is directed, that is, the sequence to whichthe oligomer compound will hybridize by Watson-Crick base-pairing of acomplementary sequence.

The term “targeting sequence” as used herein refers to the sequence inan antisense oligomer compound of the present invention that issubstantially complementary to the target sequence in a target RNA ortarget DNA molecule. The entire sequence, or only a portion, of theoligomer compound may be substantially complementary to the targetsequence. For example, in an oligomer having 18 nucleobases, only 12-14may be targeting sequences. Typically, the targeting sequence is formedof at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28 or more contiguous bases in the oligomer compound, butmay alternatively be formed of non-contiguous sequences that when placedtogether, e.g., from opposite ends of the oligomer, constitute sequencethat spans the target sequence.

As used herein, the term “transcriptome” refers to the set of allmessenger RNA (mRNA) molecules, or “transcripts”, produced in one or apopulation of cells. The term can be applied to the total set oftranscripts in a given organism, or to the specific subset oftranscripts present in a particular cell type. Unlike the genome, whichis roughly fixed for a given cell line (excluding mutations), thetranscriptome can vary with external environmental conditions. Becauseit includes all mRNA transcripts in the cell (including pre-mRNA), thetranscriptome reflects the genes that are being actively expressed atany given time, with the exception of mRNA degradation phenomena such astranscriptional attenuation.

As used herein, the terms “treatment”, “treating”, and the like, referto obtaining a desired pharmacologic and/or physiologic effect. Theeffect may be therapeutic in terms of a partial or complete cure for adisease or condition (e.g., a hematologic malignancy) and/or adverseaffect attributable to the disease or condition. These terms also coverany treatment of a condition or disease in a mammal, particularly in ahuman, and include: (a) inhibiting the disease or condition, i.e.,arresting its development; or (b) relieving the disease or condition,i.e., causing regression of the disease or condition.

The term “tumor,” as used herein, refers to any neoplastic cell growthand proliferation, whether malignant or benign, and all pre-cancerousand cancerous cells and tissues. The terms “cancer” and “cancerous”refer to or describe the physiological condition in mammals that istypically characterized in part by unregulated cell growth. As usedherein, the term “cancer” refers to non-metastatic and metastaticcancers, including early stage and late stage cancers. The term“precancerous” refers to a condition or a growth that typically precedesor develops into a cancer. By “non-metastatic” is meant a cancer that isbenign or that remains at the primary site and has not penetrated intothe lymphatic or blood vessel system or to tissues other than theprimary site. Generally, a non-metastatic cancer is any cancer that is aStage 0, I, or II cancer, and occasionally a Stage III cancer. By “earlystage cancer” is meant a cancer that is not invasive or metastatic or isclassified as a Stage 0, I, or H cancer. The term “late stage cancer”generally refers to a Stage III or Stage IV cancer, but can also referto a Stage II cancer or a substage of a Stage II cancer. One skilled inthe art will appreciate that the classification of a Stage II cancer aseither an early stage cancer or a late stage cancer depends on theparticular type of cancer. Illustrative examples of cancer include, butare not limited to, breast cancer, prostate cancer, ovarian cancer,cervical cancer, pancreatic cancer, colorectal cancer, lung cancer,hepatocellular cancer, gastric cancer, liver cancer, bladder cancer,cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma,melanoma, brain cancer, non-small cell lung cancer, squamous cell cancerof the head and neck, endometrial cancer, multiple myeloma, rectalcancer, and esophageal cancer. In an exemplary embodiment, the cancer isselected from prostate, lung, pancreatic, breast, ovarian and bonecancer.

The term “tumor-modulating” refers to a substance that inhibits orprevents the function of tumor cells and/or causes destruction of tumorcells. The tumor-modulating activity may be cytotoxic or cytostatic.Cytotoxic agents are toxic to tumor cells and the toxic effect mayresult in death and/or lysis of the tumor cells. In certain instances,the toxic effect may be a sublethal destructive effect on the tumorcell, e.g., slowing or arresting cell growth. Cytostatic agents inhibitor stop growth and/or proliferation of tumor cells.

As used herein, underscoring or italicizing the name of a gene shallindicate the gene, in contrast to its protein product, which isindicated by the name of the gene in the absence of any underscoring oritalicizing. For example, “hSSB1” shall mean the hSSB1 gene, whereas“hSSB1” shall indicate the protein product or products generated fromtranscription and translation and alternative splicing of the “hSSB1”gene.

Each embodiment described herein is to be applied mutatis mutandis toeach and every embodiment unless specifically stated otherwise.

2. Abbreviations

The following abbreviations are used throughout the application:

-   -   nt=nucleotide    -   nts=nucleotides    -   Da=Dalton(s)    -   kDa=kiloDalton(s)    -   min=minute(s)    -   hr=hour(s)    -   wk=week(s)    -   PD=phosphodiester    -   PS=phosphorothioate    -   LSA=PS oligomer compound    -   ASO=antisense oligonucleotide    -   GC=guanosine/cytosine    -   Tm=melting temperature    -   SSB1=single stranded DNA-binding protein 1, also known as NABP2,        OBFC2B    -   SSB2=single stranded DNA-binding protein 2    -   hSSB1=human SSB1    -   hSSB2=human SSB2    -   mSSB1=mouse SSB1    -   THOC4=ALYREF, THO complex subunit 4    -   hTHOC4=human THOC4

3. Nucleic Acid Oligomeric Compounds for Targeting Tumor Cells

The present invention is predicated in part on the finding that nucleicacid oligomer compounds with a backbone comprising mostlyphosphorothioate internucleoside linkages and at least about half theoligomer nucleobases being purines bind to one or both of SSB1 andTHOC4, which are proteins involved, respectively, in DNA repair and innuclear export of RNA molecules to the protein synthesis machinery of acell. Unexpectedly, these oligomers have also been found tosignificantly inhibit proliferation or stimulate the death of tumorcells, regardless of whether or not they have substantialcomplementarity to the transcriptome, or whether or not that they havehomology to the genome.

The present inventors have further explored this finding by testing over300 oligomer sequences to determine features underlying theprotein-binding and tumor cell-modulating activities. Of thesesequences, 195 were found to bind with one or both of SSB1 and THOC4 andto inhibit proliferation, survival or viability of tumor cells. Thesequence and chemistry of these oligomer compounds are shown in TABLE 2.

TABLE 2 Oligomer Nucleobase Seq Sequence & Chemistry IdmC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC* 1 mU*mU*mG*mC*mC*mUmC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA* 2 mC*mG*mA*mC*mG*mGmG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC* 3 mG*mG*mA*mG*mU*mGmC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC* 5 mU*mU*mG*mC*mC*mUU*C*U*C*C*C*A*G*C*G*U*G*C*G*C*C*A*U 6U*A*C*C*G*C*G*U*G*C*G*A*C*C*C*U*C*U 7mU*mA*mC*mC*mG*mC*mG*mU*mG*mC*mG*mA*mC*mC* 10 mC*mU*mC*mUmG*mG*mU*mC*mG*mU*mA*mA*mU*mA*mC*mU*mU*mU* 12 mC*mA*mC*mU*mU*mAmU*mC*mA*mA*mG*mG*mA*mA*mG*mA*mU*mG*mG*mC* 14 mA*mU*mU*mU*mC*mUmC*mU*mG*mC*mC*mU*mA*mA*mG*mU*mA*mA*mA*mA* 15 mA*mG*mU*mG*mU*mA*mA*mA*mCmC*mC*mA*mU*mC*mU*mG*mU*mA*mA*mU*mU*mA*mC* 16 mA*mA*mA*mA*mU*mU*mA*mA*mAmG*mA*mG*mU*mA*mA*mA*mC*mA*mU*mU*mC*mU*mG* 17 mU*mG*mU*mG*mG*mA*mG*mU*mCmC*mA*mG*mC*mA*mG*mC*mA*mG*mA*mG*mU*mC*mU* 21 mU*mC*mA*mU*mC*mA*mUmU*mG*mU*mG*mC*mU*mA*mU*mU*mC*mU*mG*mU*mG* 22 mA*mA*mU*mUmU*mA*mA*mG*mC*mU*mG*mU*mU*mC*mU*mA*mU*mG* 23 mU*mG*mU*mUmG*mA*mG*mG*mA*mA*mC*TmC*mC*mG*mC*mC*mG*mC 24mU*mC*mU*mU*mA*mU*mG*mU*mU*mU*mC*mC*mG*mA* 25 mA*mC*mC*mG*mU*mUmG*mG*mC*mG*mA*mA*mU*mG*mA*mG*mA*mC*mU*mU* 27 mC*mU*mC*mU*mU*mAmU*mC*mC*mU*mG*mG*mA*mU*mC*mC*mU*mU*mC*mA* 28 mC*mC*mA*mA*mU*mGmU*mG*mU*mC*mA*mU*mA*mU*mU*mC*mC*mU*mG*mG* 29 mA*mU*mC*mC*mU*mUmC*mA*mG*mC*mA*mG*mC*mA*mG*mA*mG*mU*mA*mU* 31 mU*mU*mA*mU*mC*mA*mUmG*mC*mU*mC*mC*mA*mG*mC*mA*mU*mC*mU*mG*mC* 32 mU*mG*mC*mU*mU*mCmG*mC*mU*mC*mC*mA*mG*mC*mA*mU*mC*mU*mG*mC* 33 mU*mG*mC*mU*mU*mCmA*mC*mA*mU*mC*mG*mU*mU*mA*mC*mC*mA*mG*mA* 34 mC*mA*mG*mU*mG*mU*mU*mAmA*mC*mA*mU*mG*mG*mU*mU*mC*mC*mC*mC*mG*mA* 35 mC*mA*mG*mU*mG*mU*mU*mAmA*mG*mG*mC*mA*mA*mG*mU*mC*mC*mG*mG*mC*mU* 36 mC*mA*mC*mU*mG*mGmC*mG*mU*mG*mU*mC*mA*mU*mC*mC*mG*mC*mU*mC* 37 mU*mC*mG*mA*mC*mUmC*mC*mA*mG*mA*mC*mA*mG*mC*mU*mG*mG*mU*mG* 38 mU*mC*mG*mC*mC*mUmC*mC*mG*mG*mU*mG*mA*mG*mC*mG*mA*mC*mA*mC* 39 mU*mA*mG*mG*mC*mUmC*mC*mA*mG*mU*GAGCCGGACTmU*mG*mC*mC*mU 40mC*mC*mA*mG*mU*mG*mA*mG*mC*mU*mG*mG*mA*mC* 41 mU*mU*mG*mC*mC*mUmC*mC*mA*mGmUmGmAmGmCmCmGmGmAmCmUmUmG*mC* 44 mC*mUmC*mG*mC*mG*mU*mC*mA*mC*mU*mC*mG*mC*mA*mC* 45 mU*mC*mG*mC*mC*mUmU*mU*mG*mA*mC*mA*mG*mA*mU*mU*mA*mA*mG*mU* 51 mC*mC*mA*mU*mU*mCmG*mC*mC*mA*mC*mC*mC*mG*mU*mC*mG*mG*mU*mU* 52 mG*mC*mU*mA*mG*mAmG*mC*mG*mG*mG*mU*mC*mC*mU*mC*mU*mA*mC*mG* 53 mC*mA*mC*mU*mG*mAmG*mC*mC*mC*mG*mU*mC*mU*mG*mG*mC*mG*mC*mA* 54 mU*mA*mG*mC*mU*mAmG*mG*mG*mC*mC*mU*mC*mC*mC*mG*mC*mA*mC*mU* 55 mU*mG*mA*mG*mA*mUmG*mG*mC*mA*mC*mG*mU*mC*mC*mG*mC*mC*mA*mG* 56 mU*mC*mA*mU*mG*mUmC*mC*mU*mG*mU*mC*mA*mG*mC*mC*mG*mC*mA*mC* 59 mU*mU*mG*mC*mC*mUmC*mC*mA*mG*mU*mA*mA*mG*mC*mC*mA*mG*mA*mC* 61 mU*mU*mG*mC*mA*mUmC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mA*mA*mC* 62 mU*mU*mC*mU*mC*mUmC*mU*mA*mG*mU*mA*mA*mG*mU*mC*mG*mG*mA*mC* 63 mU*mU*mG*mC*mC*mUmC*mC*mA*mG*mG*mG*mA*mG*mC*mC*mG*mG*mA*mC* 64 mU*mU*mG*mG*mC*mGmG*mC*mG*mG*mU*mG*mA*mA*mC*mC*mG*mG*mA*mG* 66 mU*mU*mG*mG*mC*mUmC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC* 67 mU*mU*mG*mC*mCmC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC* 68 mU*mU*mG*mCmC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC* 69 mU*mU*mGmC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC* 70 mU*mUmC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU 71mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC 72mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA 73mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU* 79 mU*mG*mC*mC*mUmA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU* 80 mG*mC*mC*mUmG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG* 81 mC*mC*mUmU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC* 82 mC*mUmG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 83mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 84mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 85mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU* 91 mU*mG*mC*mCmA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU* 92 mG*mCmG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG 93mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU 94mC*mA*mG*mA*mG*GCAGCAGTACmG*mA*mC*mG*mG 98mC*mA*mG*mAmGmGmCmAmGmCmAmGmUmAmCmGmA*mC* 100 mG*mGmG*mU*mC*mU*mC*mC*mG*mU*mC*mG*mU*mC*mA*mU* 101 mG*mC*mU*mG*mC*mCC*C*A*G*U*G*A*G*C*C*G*G*A*C*U*U*G*C*C*U 103mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA* 104mC*mG*mA*mC*mG*mG*mC*mA*mG*mA*mG*mG*mC*mA* mG*mCmC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC 105mG*mG*mA*mG*mC*mC*mG*mG*mA*mC*mA*mA*mG*mG* 107 mG*TmC*mA*mC*mAmG*mG*mG*mA*mC*mC*mC*mA*mA*mG*mG*mA*mG*mC* 108 mG*TmA*mC*mG*mAmG*mA*mG*mC*mG*mA*mG*mA*mC*mG*mC*mG*mG*mA* 109 mG*mA*mC*mC*mAmG*mC*mG*mG*mA*mA*mC*mG*mG*mA*mC*mG*mG*mA* 110 mA*mG*mA*mC*mCmG*mC*TmG*mA*mC*mG*mG*mC*mA*mC*mG*mG*mC*mA* 111 mG*mA*mG*mA*mAmG*mG*mG*mC*mG*mG*mC*mA*mG*mU*mA*mG*mU*mC* 113 mC*mG*mA*mC*mA*mGmG*mA*mG*mA*mA*mG*mA*mA*mG*mC*mA*mG*mU*mA* 114 mC*mG*mA*mU*mG*mGmC*mA*mU*mA*mG*mU*mC*mA*mC*mC*mU*mG*mU*mA* 115 mC*mU*mA*mC*mC*mGmC*mA*mC*mU*mC*mG*mC*mU*mG*mC*mA*mU*mU*mU* 117 mC*mG*mC*mC*mG*mGmC*mU*mG*mU*mG*mC*mC*mA*mU*mC*mU*mG*mU*mA* 118 mC*mC*mA*mC*mG*mGmC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA* 119 mC*mG*mA*mC*mGmC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA* 120 mC*mG*mA*mCmC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA* 121 mC*mG*mAmC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA* 122 mC*mGmA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC* 131 mG*mA*mC*mG*mGmG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG* 132 mA*mC*mG*mGmA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA* 133 mC*mG*mGmG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC* 134 mG*mGmG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 135mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 137mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 138mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC* 143 mG*mA*mC*mGmG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG* 144 mA*mCmA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA 145mG*mU*mG*mCmAmUmGmGmAmAmUmCmAmCmGmGmA*mG*mU 152 *mGC*A*G*A*G*G*C*A*G*C*A*G*U*A*C*G*A*C*G*G 153mG*mA*mG*mU*mC*mC*mG*mG*mU*mG*mA*mG*mC*mG* 155 mU*mA*mG*mA*mU*mAmG*mC*mA*mU*mA*mG*mA*mC*mG*mU*mC*mG*mG*mA* 156 mG*mA*mG*mU*mG*mUmG*mU*mA*mG*mC*mA*mG*mG*mC*mU*mC*mG*mG*mU* 158 mA*mG*mA*mG*mA*mUmG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC* 159 mG*mG*mA*mG*mU*mGmG*mG*mU*mA*mG*mG*mA*mC*mG*mC*mG*mG*mA*mC* 160 mA*mG*mU*mU*mA*mUmG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mA*mC*mA*mC* 161 mG*mG*mU*mA*mU*mGmC*mA*mG*mC*mA*mU*mA*mG*mA*mA*mU*mC*mA*mC* 162 mG*mG*mA*mG*mU*mGmG*mU*mG*mC*mA*mG*mA*mG*mA*mA*mU*mC*mA*mC* 164 mU*mG*mA*mA*mG*mGmG*mU*mC*mC*mA*mU*mG*mU*mC*mU*mU*mC*mU*mC* 165 mG*mG*mA*mA*mU*mGmC*mU*mG*mC*mU*mU*mU*mG*mA*mA*mU*mC*mA*mC* 166 mG*mC*mA*mG*mU*mUmG*mU*mC*mC*mU*mU*mG*mU*mC*mA*mU*mC*mA*mC* 167 mG*mU*mU*mG*mU*mGmG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC* 168 mG*mG*mA*mG*mUmG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC* 169 mG*mG*mA*mGmG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC* 170 mG*mG*mAmG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC* 171 mG*mGmG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG 172mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC 173mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA 174mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC 175 mG*mU*mG*mC*mA*mU*mG*mG*mA*mA177 mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG* 180 mG*mA*mG*mU*mGmG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG* 181 mA*mG*mU*mGmC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA* 182 mG*mU*mGmA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG* 183 mU*mGmU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 184mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 185mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG* 191 mA*mGmC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA 192mC*mA*mC*mG*mU*mA*mC*mC*mU*mU*mA*mG*mU*mG* 196mC*mC*mU*mC*mA*mC*mC*mA*mC*mG*mU*mA*mC*mC* mU*mUmC*mA*mC*mG*mU*mA*mC*mC*mU*mU*mA*mG*mU*mG* 198 mC*mC*mU*mC*mA*mCG*U*G*C*A*U*G*G*A*A*U*C*A*C*G*G*A*G*U*G 203mG*mC*mG*mC*mU*mU*mA*mC*mC*mG*mU*mU*mC*mC* 206 mU*mC*mA*mA*mC*mAmG*mC*mA*mC*mG*mU*mC*mU*mC*mG*mC*mU*mC*mC* 207 mA*mA*mU*mC*mU*mAmC*mA*mC*mG*mU*mA*mC*mC*mU*mU*mA*mG*mA*mG* 209 mC*mU*mU*mC*mC*mCmC*mA*mG*mG*mA*mA*mC*mG*mU*mA*mA*mG*mU*mG* 210 mG*mG*mU*mC*mA*mCmC*mA*mC*mG*mU*mA*mG*mC*mA*mG*mA*mG*mU*mG* 211 mG*mG*mA*mC*mA*mCmG*mU*mG*mC*mC*mU*mG*mU*mU*mA*mU*mC*mA*mC* 223 mG*mC*mU*mC*mU*mGmC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mA*mU*mA* 224 mA*mG*mA*mA*mG*mGmC*mG*mU*mG*mA*mC*mG*mA*mA*mG*mG*mA*mG*mU* 225 mC*mG*mU*mC*mA*mC*mGmC*mU*mG*mU*mA*mC*mG*mC*mG*mC*mG*mA*mA*mC* 226 mG*mU*mA*mC*mA*mGmC*mU*mG*mU*mA*mC*mG*mA*mG*mG*mA*mG*mA*mC* 227 mG*mU*mA*mC*mA*mGmA*mG*mU*mC*mG*mC*mG*mC*mG*mG*mG*mA*mU*mG* 228 mA*mC*mG*mC*mG*mA*mC*mUmC*mG*mU*mG*mA*mC*mG*mA*mC*mU*mC*mC*mU*mU* 229 mC*mG*mU*mC*mA*mC*mGmC*mU*mG*mU*mA*mC*mG*mU*mU*mC*mG*mC*mG*mC* 230 mG*mU*mA*mC*mA*mGmC*mU*mG*mU*mA*mC*mG*mU*mC*mU*mC*mC*mU*mC* 231 mG*mU*mA*mC*mA*mGmA*mG*mU*mC*mG*mC*mG*mU*mC*mA*mU*mC*mC*mC* 232 mG*mC*mG*mC*mG*mA*mC*mUmG*mA*mA*mG*mC*mG*mU*mG*mA*mC*mG*mA*mA*mG* 233mG*mA*mG*mU*mC*mG*mU*mC*mA*mC*mGmG*mA*mA*mG*mC*mG*mU*mG*mA*mC*mG*mA*mC*mU* 234mC*mC*mU*mU*mC*mG*mU*mC*mA*mC*mGmC*mG*mU*mG*mA*mC*mG*mA*mA*mG*mG*mA*mG*mU* 235mC*mG*mU*mC*mA*mC*mG*mG*mA*mA*mGmC*mG*mU*mG*mA*mC*mG*mA*mC*mU*mC*mC*mU*mU* 236mC*mG*mU*mC*mA*mC*mG*mG*mA*mA*mGmA*mC*mC*mG*mA*mA*mC*mA*mA*mU*mA*mA*mA*mU* 237 mC*mC*mA*mC*mU*mAmU*mG*mU*mU*mG*mU*mA*mU*mG*mU*mC*mC*mG*mU* 238 mG*mC*mG*mA*mA*mAmC*mG*mG*mA*mC*mC*mG*mU*mG*mC*mU*mC*mC*mA* 239 mC*mG*mG*mU*mU*mCmG*mU*mU*mA*mG*mA*mC*mC*mG*mU*mA*mC*mU*mG* 240 mU*mG*mU*mA*mU*mUmA*mU*mU*mC*mG*mU*mA*mU*mG*mA*mG*mA*mA*mC* 244 mU*mA*mU*mC*mU*mGmA*mA*mU*mG*mC*mG*mG*mU*mC*mG*mG*mU*mC*mC* 245 mG*mC*mA*mU*mA*mUmU*mC*mG*mU*mG*mA*mU*mA*mU*mC*mU*mA*mA*mG* 247 mG*mU*mG*mC*mC*mCmU*mC*mC*mU*mU*mU*mU*mU*mA*mU*mU*mU*mU*mU* 248 mC*mG*mG*mG*mU*mGmA*mC*mU*mU*mG*mC*mA*mA*mG*mU*mG*mC*mU*mC* 249 mG*mA*mC*mG*mA*mGmG*mG*mG*mC*mG*mC*mU*mA*mC*mU*mA*mC*mG*mG* 250 mU*mC*mA*mU*mU*mCmC*mG*mC*mC*mU*mC*mU*mG*mG*mU*mU*mU*mA*mG* 251 mG*mC*mG*mU*mC*mAmU*mA*mU*mU*mG*mC*mC*mG*mA*mU*mU*mG*mG*mU* 252 mG*mG*mG*mU*mA*mGmG*mA*mC*mA*mG*mA*mC*mA*mG*mU*mA*mG*mG*mA* 253 mC*mU*mA*mU*mG*mGmU*mU*mC*mU*mG*mU*mC*mG*mA*mG*mU*mC*mA*mC* 256 mU*mU*mG*mU*mC*mAmU*mU*mC*mC*mG*mU*mC*mA*mG*mG*mC*mU*mC*mG* 258 mG*mG*mU*mU*mC*mGmU*mC*mG*mU*mU*mU*mG*mA*mG*mG*mC*mA*mA*mG* 259 mA*mU*mG*mC*mG*mUmU*mU*mG*mA*mU*mC*mU*mA*mU*mU*mC*mU*mU*mU* 261 mC*mG*mC*mA*mG*mGmA*mA*mG*mG*mA*mG*mU*mU*mU*mG*mU*mA*mG*mC* 263 mA*mC*mA*mC*mU*mCmC*mG*mC*mA*mU*mA*mU*mG*mA*mA*mA*mC*mU*mC* 264 mA*mU*mA*mC*mU*mGmU*mA*mU*mC*mA*mG*mC*mC*mC*mG*mU*mU*mG*mU* 265 mA*mC*mA*mG*mC*mAmA*mU*mG*mC*mU*mA*mG*mG*mA*mG*mC*mU*mC*mU* 269 mG*mC*mC*mG*mA*mAmC*mU*mG*mC*mA*mC*mC*mC*mG*mA*mC*mG*mA*mA* 270 mC*mU*mC*mU*mG*mUmC*mC*mG*mA*mC*mC*mA*mC*mG*mG*mC*mG*mG*mG* 271 mA*mA*mU*mU*mG*mUmU*mU*mU*mU*mA*mA*mG*mC*mG*mC*mA*mA*mA*mA* 272 mA*mA*mU*mA*mA*mGmC*mG*mC*mA*mC*mG*mG*mU*mA*mU*mG*mU*mU*mC* 274 mC*mU*mA*mG*mU*mUmC*mU*mC*mC*mU*mC*mC*mC*mU*mU*mA*mC*mG*mG* 277 mA*mC*mA*mC*mU*mCmC*mU*mC*mU*mU*mG*mG*mC*mU*mG*mA*mG*mC*mC* 278 mC*mA*mU*mC*mU*mCmG*mU*mC*mU*mC*mC*mG*mU*mC*mG*mU*mC*mA*mU* 279 mG*mC*mU*mG*mC*mCmC*mU*mC*mG*mG*mC*mA*mC*mC*mC*mC*mA*mC*mU* 280 mG*mG*mA*mU*mG*mGmG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC*mG*mA* 281 mU*mC*mG*mA*mU*mCmG*mA*mG*mC*mC*mG*mU*mG*mG*mG*mG*mU*mG*mA* 282 mC*mC*mU*mA*mC*mCmG*mA*mC*mU*mU*mC*mG*mC*mA*mU*mG*mG*mG*mA* 283 mA*mA*mC*mC*mA*mCmG*mG*mU*mC*mA*mC*mU*mC*mG*mG*mC*mC*mU*mG* 284 mA*mA*mC*mG*mG*mAmC*mG*mG*mC*mU*mG*mU*mC*mA*mU*mC*mU*mC*mC* 285 mG*mC*mG*mC*mG*mGmC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC* 286 mU*mU*mG*mC*mC*mUmC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC* 287 mU*mU*mG*mC*mC*mUmC*mU*mG*mA*mA*mG*mC*mG*mU*mA*mC*mC*mC*mU* 288 mU*mU*mG*mG*mU*mGmG*mA*mU*mG*mA*mC*mC*mU*mC*mC*mC*mC*mU*mG* 289 mC*mA*mG*mG*mU*mAmC*mU*mC*mG*mG*mG*mU*mG*mA*mU*mU*mA*mC*mG* 290 mA*mU*mC*mG*mC*mGmC*mA*mG*mC*mU*mC*mG*mU*mC*mC*mA*mU*mG*mC* 291 mC*mG*mA*mG*mA*mGmA*mC*mG*mA*mU*mA*mG*mU*mC*mC*mC*mU*mG*mC* 292 mC*mG*mC*mG*mA*mGmU*mA*mG*mU*mC*mC*mG*mC*mU*mU*mA*mC*mG*mC* 293 mC*mG*mA*mG*mA*mGmC*mU*mA*mC*mU*mG*mG*mA*mG*mG*mG*mG*mA*mC* 295 mG*mU*mC*mC*mA*mUmA*mG*mG*mC*mA*mA*mG*mT*mC*mC*mG*mG*mC*mT* 296 mC*mA*mC*mT*mG*mGmC*mU*mU*mG*mG*mG*mG*mG*mG*mU*mC*mU*mA*mG* 297 mA*mG*mG*mA*mA*mGmC*mG*mG*mA*mU*mG*mG*mA*mA*mA*mA*mG*mG*mG* 298 mU*mC*mC*mA*mG*mUmG*mA*mG*mG*mA*mG*mG*mG*mA*mA*mU*mG*mC*mC* 299 mU*mG*mU*mG*mA*mGmA*mC*mC*mG*mA*mA*mC*mG*mG*mA*mC*mA*mU*mU* 300 mU*mC*mG*mA*mA*mGmG*mC*mC*mG*mA*mC*mA*mG*mU*mA*mG*mA*mG*mG* 301 mC*mG*mC*mG*mC*mCmG*mA*mG*mA*mA*mC*mC*mG*mA*mC*mU*mC*mG*mG* 303 mG*mU*mA*mG*mA*mG

In TABLE 2, m represents a 2′OMe-modified nucleoside, and * represents aphosphorothioate (PS) internucleoside linkage.

Based on these findings, the present invention broadly relates tooligomer compounds that have the following features:

-   -   a) a backbone comprising at least about 70% phosphorothioate        internucleoside linkages;    -   b) (i) a purine content of at least about 50%, or (ii) a purine        content of at least about 45% with a guanosine-cytosine (GC)        content of at least about 50%;    -   c) a length of at least 14 nucleobases and no more than 29        nucleobases;    -   d) binding to one or both of THOC4 and SSB1 in an aqueous        solution comprising 10 mM Tris-HCl (pH8.0) and 100 mM NaCl at        37° C.; and    -   e) cause apoptosis or necrosis of tumor cells in vivo or in        vitro.

It has also been determined that in addition to SSB1, the oligomercompounds of the present invention also bind to SSB2 in an aqueoussolution comprising 10 mM Tris-HCl (pH8.0) and 100 mM NaCl at 37° C.Based on this determination, and the observation that SSB1 (includinghSSB1 and mSSB1) and SSB2 are each oligonucleotide/oligosaccharidebinding (OB)-fold proteins, it is proposed that the oligomer compoundsdisclosed herein bind OB-fold proteins generally.

The present inventors have also found that these oligomer compoundstypically have the following features:

-   -   f) a melting temperature (Tm) in the range of 45° C. to 80° C.;    -   g) preferential uptake by tumor cells;    -   h) inhibit translocation of mRNA from the nucleus to the        cytoplasm of tumor cells.

3.1 Oligomer Chemistry and Design

Oligomeric compounds of the present invention are generally singlestranded and are preferably at least 14 (e.g., 14, 15, 16, 17, 18, 19 ormore) nucleobases in length (i.e., at least 14, 15, 16, 17, 18, 19 ormore linked nucleosides/monomeric subunits) and no more than 29 (e.g.,29, 28, 27, 26, 25, 24, 23, 22, 21 or less) nucleobases in length (i.e.,no more than 29, 28, 27, 26, 25, 24, 23, 22, 21 or less or more linkednucleosides/monomeric subunits). In specific embodiments, the oligomersare between 14 and 28, 14 and 27, 14 and 26, 14 and 25, 14 and 24, 14and 23, 14 and 22, 14 and 21, 14 and 20, 15 and 29, 15 and 28, 15 and27, 15 and 26, 15 and 25, 15 and 24, 15 and 23, 15 and 22, 15 and 21, 15and 20, 16 and 29, 16 and 28, 16 and 27, 16 and 26, 16 and 25, 16 and24, 16 and 23, 16 and 22, 16 and 21, 16 and 20, 17 and 29, 17 and 28, 17and 27, 17 and 26, 17 and 25, 17 and 24, 17 and 23, 17 and 22, 17 and21, 17 and 20, 18 and 29, 18 and 28, 18 and 27, 18 and 26, 18 and 25, 18and 24, 18 and 23, 18 and 22, 18 and 21, 18 and 20, 19 and 29, 19 and28, 19 and 27, 19 and 26, 19 and 25, 19 and 24, 19 and 23, 19 and 22, 19and 21, or 19 and 20 nucleobases in length. One of ordinary skill in theart will appreciate that the invention thus embodies oligomericcompounds of 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28or 29 nucleobases in length.

3.2 Backbone Chemistry

3.2.1 Internucleoside Linkages

The oligomer backbone comprises at least about 70% phosphorothioateinternucleoside linkages. In this regard, not all the internucleosidelinkages need to comprise phosphorothioate internucleoside linkages andthe present invention thus encompasses oligomeric compounds with mixedbackbones that also comprise alternative internucleoside linkages suchas phosphodiester, phosphorodithioate, phosphonate, methyl phosphonate,alkyl phosphonate, 3′-alkylene phosphonate, 5′-alkylene phosphonate,chiral phosphonate, phosphonoacetate, thiophosphonoacetate, phosphinate,phosphoramidate, 3′-amino phosphoramidate, aminoalkylphosphoramidate,thionophosphoramidate, phosphorothioamidate, thionoalkylphosphonate,phosphotriester, thionoalkylphosphotriester, aminoalkylphosphotriester,thionoalkylphosphotriester selenophosphate, and/or boranophosphateinternucleoside linkages. In some embodiments, at least about 70%, 80%,90% or even 100% of the internucleoside linkages of the oligomerbackbone comprise phosphorothioate internucleoside linkages. Inpreferred embodiments, all internucleoside linkages of the oligomerbackbone comprise phosphorothioate internucleoside linkages.

Representative oligomer backbones with at least about 70%phosphorothioate internucleoside linkages (PIL) encompass at least 10PIL in a 14-nucleobase oligomer, at least 10 or 11 PIL in a15-nucleobase oligomer, at least 11 PIL in a 16-nucleobase oligomer, atleast 12 PIL in a 17-nucleobase oligomer, at least 12 or 13 PIL in a18-nucleobase oligomer, at least 13 PIL in a 19-nucleobase oligomer, atleast 14 PIL in a 20-nucleobase oligomer, at least 14 or 15 PIL in a21-nucleobase oligomer, at least 15 PIL in a 22-nucleobase oligomer, atleast 16 PIL in a 23-nucleobase oligomer, at least 17 PIL in a24-nucleobase oligomer, at least 17 or 18 PIL in a 25-nucleobaseoligomer, at least 18 PIL in a 26-nucleobase oligomer, at least 19 PILin a 27-nucleobase oligomer, at least 19 or 20 PIL in a 28-nucleobaseoligomer and at least 20 PIL in a 29-nucleobase oligomer.

Representative numbers of PIL as a function of oligomer length for 80%and 90% PIL can be calculated from TABLE 1 supra.

Any alternative internucleoside linkages (i.e., internucleoside linkagesother than PIL), may be at one or both ends of the oligomer, may be in acentral portion of the oligomer, may be adjacent to each other, and ormay be dispersed throughout the oligomer.

3.2.2 Modified Sugar Moieties

The backbone of the oligomer suitably comprises at least one 2′-O-alkylmodified sugar moiety, illustrative examples of which include2′-O-methyl, 2′-O-methoxyethyl and 2′-O-2-methoxyethyl modified sugarmoieties. (e.g., 2′-O-methyl sugar moiety). In specific examples, theoligomer comprises at least one 2′-O-methyl ribose moiety. Suitably, atleast about 50%, 60%, 70%, 80%, 90% or all of the sugar moieties of theoligomer are each a 2′-O-alkyl modified sugar moiety (e.g., 2′-O-methylmodified sugar moiety). In specific embodiments, all sugar moieties ofthe oligomer are each a 2′-O-alkyl modified sugar moiety (e.g.,2′-O-methyl modified sugar moiety).

Representative MSM contents of at least about 50% encompass at least 7MSM nucleobases in a 14-nucleobase oligomer, at least 7 or 8 MSMnucleobases in a 15-nucleobase oligomer, at least 8 MSM nucleobases in a16-nucleobase oligomer, at least 8 or 9 MSM nucleobases in a17-nucleobase oligomer, at least 9 MSM nucleobases in a 18-nucleobaseoligomer, at least 9 or 10 MSM nucleobases in a 19-nucleobase oligomer,at least 10 MSM nucleobases in a 20-nucleobase oligomer, at least 10 or11 MSM nucleobases in a 21-nucleobase oligomer, at least 11 MSMnucleobases in a 22-nucleobase oligomer, at least 11 or 12 MSMnucleobases in a 23-nucleobase oligomer, at least 12 MSM nucleobases ina 24-nucleobase oligomer, at least 12 or 13 MSM nucleobases in a25-nucleobase oligomer, at least 13 MSM nucleobases in a 26-nucleobaseoligomer, at least 13 or 14 MSM nucleobases in a 27-nucleobase oligomer,at least 14 MSM nucleobases in a 28-nucleobase oligomer and at least 14or 15 MSM nucleobases in a 29-nucleobase oligomer.

Representative numbers of MSM nucleobases as a function of oligomerlength for 60%, 70%, 80% or 90% MSM contents can be calculated fromTABLE 1 supra.

3.3 Nucleobase Sequences

Nucleobase sequences may be designed using any suitable technique toachieve a purine and/or GC content and/or Tm, as described for examplebelow. For non-targeting oligomers of the present invention, thenucleobase sequences can be generated using a random sequence generator(e.g., a random sequence generator tool located at the Swiss-Protwebsite: http://au.expasy.org/tools/randseq.html) or rational design andscreened by suitable sequence analysis means (e.g., BLAST) so that thenucleobase has the appropriate sequence identity to the selectedtranscriptome and/or genome. Alternatively, for antisense oligomers, anucleic acid sequence of interest can be analyzed using suitableanalysis means (e.g., OligoAnalyzer, Primer3, PrimerQuest, etc.) toidentify a target sequence with appropriate purine and/or GC contentand/or Tm.

3.3.1 PURINE CONTENT

The nucleobase sequence of the oligomers suitably has a purine contentof at least about 45% and no more than about 90%, e.g., a purine contentof about 45%, about 50%, about 55%, about 60%, about 65%, about 70%,about 75%, about 80%, about 85% or about 90%. In specific embodiments,the oligomers have a purine content of about 45-90%, about 45-85%, about45-80%, about 45-75%, about 45-70%, about 45-65%, about 45-60%, about45-55%, about 45-50%, about 50-90%, about 50-85%, about 50-80%, about50-75%, about 50-70%, about 50-65%, about 50-60%, about 50-55%, about55-90%, about 55-85%, about 55-80%, about 55-75%, about 55-70%, about55-65% or about 55-60%.

Representative purine contents of at least about 45% encompass at least6 purines in a 14-nucleobase oligomer, at least 6 or 7 purines in a15-nucleobase oligomer, at least 7 purines in a 16-nucleobase oligomer,at least 7 or 8 purines in a 17-nucleobase oligomer, at least 8 purinesin a 18-nucleobase oligomer, at least 8 or 9 purines in a 19-nucleobaseoligomer, at least 9 purines in a 20-nucleobase oligomer, at least 9 to10 purines in a 21-nucleobase oligomer, at least 10 purines in a22-nucleobase oligomer, at least 10 purines in a 23-nucleobase oligomer,at least 10 or 11 purines in a 24-nucleobase oligomer, at least 11purines in a 25-nucleobase oligomer, at least 11 or 12 purines in a26-nucleobase oligomer, at least 12 purines in a 27-nucleobase oligomer,at least 12 or 13 purines in a 28-nucleobase oligomer and at least 13purines in a 29-nucleobase oligomer.

Representative numbers of purine nucleobases as a function of oligomerlength for 50%, 60%, 70%, 80% or 90% purine contents can be calculatedfrom TABLE 1 supra.

3.3.2 GC Content

The nucleobase sequence of the oligomers may have a GC content of atleast about 50% and no more than about 90%, e.g., a GC content of about50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%,about 85% or about 90%. In specific embodiments, the oligomers have a GCcontent of 50-90%, 50-85%, 50-80%, 50-75%, 50-70%, 50-65%, 50-60%,50-55%, 55-90%, 55-85%, 55-80%, 55-75%, 55-70%, 55-65% or 55-60%.

Representative GC contents of at least about 50% encompass at least 7G/C in a 14-nucleobase oligomer, at least 7 or 8 G/C in a 15-nucleobaseoligomer, at least 8 G/C in a 16-nucleobase oligomer, at least 8 or 9G/C in a 17-nucleobase oligomer, at least 9 G/C in a 18-nucleobaseoligomer, at least 9 or 10 G/C in a 19-nucleobase oligomer, at least 10G/C in a 20-nucleobase oligomer, at least 10 or 11 G/C in a21-nucleobase oligomer, at least 11 G/C in a 22-nucleobase oligomer, atleast 11 or 12 G/C in a 23-nucleobase oligomer, at least 12 G/C in a24-nucleobase oligomer, at least 12 or 13 G/C in a 25-nucleobaseoligomer, at least 13 G/C in a 26-nucleobase oligomer, at least 13 or 14G/C in a 27-nucleobase oligomer, at least 14 G/C in a 28-nucleobaseoligomer and at least 14 or 15 G/C in a 29-nucleobase oligomer.

Representative numbers of G/C nucleobases as a function of oligomerlength for 60%, 70%, 80% or 90% GC contents can be calculated from TABLE1 supra.

3.3.3 Purine and GC Content Embodiments

In certain embodiments, the nucleobase sequence of the oligomers has apurine content of at least about 45% and no more than about 90% asdescribed above, and a GC content of at least about 50% and no more thanabout 90% as described above.

In other embodiments, the nucleobase sequence of the oligomers has apurine content of at least about 50% and no more than about 90%, and aGC content of less than about 50% and more than 10%, e.g., about 50%,about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about15% or about 10%. In illustrative examples of this type, the oligomershave a purine content of about 45-90%, about 45-85%, about 45-80%, about45-75%, about 45-70%, about 45-65%, about 45-60%, about 45-55% or about45-50% and a GC content of about 10-50%, about 15-50%, about 20-50%,about 25-50%, about 30-50%, about 35-50%, about 40-50%, about 45-50%,about 10-45%, about 15-45%, about 20-45%, about 25-45%, about 30-45%,about 35-45%, about 40-45%, about 10-40%, about 15-40%, about 20-40%,about 25-40%, about 30-40% or about 35-40%.

3.3.4 Melting Temperature

The oligomers suitably have a melting temperature (Tm) of at least about45° C. and generally no more than 80° C. (e.g., about 45, 46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 65, 70, 75 or 80° C.).In specific embodiments, the oligomers have a Tm of 45-80° C., 45-75°C., 45-70° C., 45-65° C., 45-60° C., 45-55° C., 45-50° C., 50-80° C.,50-75° C., 50-70° C., 50-65° C., 50-60° C. or 50-55°.

3.3.5 Non-Targeting Oligomers

Most of the oligomers presented in TABLE 2 significantly inhibitproliferation or stimulate the death of tumor cells, but lacksubstantial complementarity to the transcriptome, and/or homology to thegenome.

The oligomer nucleobase sequences of the present invention may lackperfect complementarity to the transcriptome of a target tumor cell andoften also lack perfect complementarity to the genome of a mammal fromwhich the target tumor cell is suitably derived. In some embodiments,the nucleobase sequence over the length of the oligomer lackssubstantially complementarity to the transcriptome. Suitably, no morethan about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%,35% 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of the nucleobases ofthe oligomer are able to engage in base-pairing with the transcriptome.In illustrative examples of this type, an oligomer of 14 to 29nucleobases with no more than 95% of its nucleobases able to engage inbase-pairing with the transcriptome has at least one non-complementarynucleobase that is unable to base-pair with a nucleobase of a referencenucleobase sequence of the transcriptome. In other illustrativeexamples, an oligomer an oligomer of 14 to 29 nucleobases with no morethan 90% of its nucleobases able to engage in base-pairing with thetranscriptome has at least two non-complementary nucleobases that areunable to base-pair with a nucleobase of a reference nucleobase sequenceof the transcriptome.

In some embodiments, the nucleobase sequence over the length of theoligomer lacks homology to the genome of a mammal from which the tumorcell is suitably derived. Suitably, the nucleobase sequence over thelength of the oligomer has no more than about 95%, 90%, 85%, 80%, 75%,70%, 65%, 60%, 55%, 50%, 45%, 40%, 35% 30%, 25%, 20%, 15%, 10%, 5%, 4%,3%, 2%, 1% sequence identity to any equal length of contiguousnucleobases defining a reference nucleobase sequence in the genome. Inillustrative examples of this type, an oligomer of 14 to 29 nucleobaseswith no more than 95% sequence identity to the reference nucleobasesequence in the genome has at least one nucleobase that is not identicalto, or does not have the same or equivalent nucleobase-pairing abilityas, a nucleobase at a matching position of the reference nucleobasesequence. In other illustrative examples, an oligomer of 14 to 29nucleobases with no more than 90% sequence identity to the referencenucleobase sequence in the genome has at least two nucleobases that arenot identical to, or do not have the same or equivalentnucleobase-pairing ability as, a nucleobase at a matching position ofthe reference nucleobase sequence.

Representative numbers of nucleobases as a function of oligomer lengthand percentage of nucleobases able to engage in base-pairing or havingsequence identity can be calculated from TABLE 1 supra.

In specific embodiments, the non-targeting oligomer nucleobase sequenceis selected from any one of SEQ ID NO: 1, 2, 3, 5, 7, 36, 37, 38, 39,40, 41, 44, 45, 51, 52, 53, 54, 55, 56, 59, 61, 62, 63, 64, 66, 67, 68,69, 70, 71, 72, 73, 79, 80, 81, 82, 83, 84, 85, 91, 92, 93, 94, 98, 100,103, 104, 105, 107, 108, 109, 110, 111, 113, 114, 115, 117, 118, 119,120, 121, 122, 131, 132, 133, 134, 135, 137, 138, 143, 144, 145, 152,153, 155, 156, 158, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169,170, 171, 172, 173, 174, 175, 177, 180, 181, 182, 183, 184, 185, 191,192, 196, 198, 203, 206, 207, 209, 210, 211, 223, 224, 225, 226, 227,228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 244,245, 247, 248, 249, 250, 251, 252, 253, 256, 258, 259, 261, 263, 264,265, 269, 270, 271, 272, 274, 277, 281, 282, 283, 286, 287, 290, 291,292, 293, 295, 296, 298, 300, 301 and 303.

3.3.6 Antisense Oligomers

It has also been found that antisense oligomers with specificity to aparticular target sequence can be adapted to bind SSB1 and/or THOC4 byincluding in the oligomer design the backbone chemistry and base contentdescribed above. These oligomers have also been found to cause apoptosisor necrosis of tumor cells in vivo or in vitro, regardless of the geneto which the antisense oligomer is targeted. Otherwise, the targetingsequence of an antisense oligomer can be designed using standardantisense design programs and analysis tools known in the art.

Thus, the nucleobase sequence of the subject antisense oligomers willtypically have substantial complementarity to an antisense strand of aselected gene. In these embodiments, the nucleobase sequence is suitablycomplementary to and capable of hybridizing to a target sequence of theselected gene or transcript thereof, including a pre-mRNA or mRNAmolecule encoded by the selected gene, under high stringency conditions.The antisense oligomers can be tested for efficacy using a variety oftechniques known in the art.

For example, an antisense oligomer can be tested for heteroduplexformation. The effectiveness of a given antisense oligomer in forming aheteroduplex with the target nucleic acid sequence may be determined byscreening methods known in the art. For example, the oligomer may beincubated in a cell culture containing an mRNA preferentially expressedin tumor cells, and the effect on the target mRNA is evaluated bymonitoring the presence or absence of (1) heteroduplex formation withthe target sequence and non-target sequences using procedures known tothose of skill in the art, (2) the amount of the target mRNA expressedby tumor cells, as determined by standard techniques such as RT-PCR orNorthern blot, (3) the amount of protein transcribed from the targetmRNA, as determined by standard techniques such as ELISA or Westernblotting. Alternatively, or in addition, the effectiveness of anantisense oligomer can be determined by measuring expression of atargeted gene in tumor cells treated with the antisense oligomer.

In specific embodiments, the antisense oligomer targets eIF-4E or SSB1.Illustrative antisense oligomer nucleobase sequences are suitablyselected from any one of SEQ ID NO: 6, 10, 12, 14, 15, 16, 17, 21, 22,23, 24, 25, 27, 28, 29, 31, 32, 33, 34, 35, 101, 278, 279, 280, 284,285, 288, 289, 297 and 299.

3.4 Oligomer Property Modifications

The present invention also contemplates modifications that can enhancethe properties of an oligomeric compound of the invention or can be usedto track the oligomeric compound or its metabolites, including theattachment of one or more moieties or conjugates. Properties that aretypically enhanced include without limitation activity, cellulardistribution and cellular uptake. In some embodiments, such modifiedoligomeric compounds are prepared by covalently attaching conjugategroups to functional groups available on an oligomeric compound such ashydroxyl or amino functional groups. Conjugate groups of the inventioninclude intercalators, reporter molecules, polyamines, polyamides,polyethylene glycols, polyethers, groups that enhance thepharmacodynamic properties of oligomers, and groups that enhance thepharmacokinetic properties of oligomers. Typical conjugate groupsinclude cholesterols, lipids, phospholipids, biotin, phenazine, folate,phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines,coumarins, and dyes. Groups that enhance the pharmacodynamic properties,in the context of this invention, include groups that improve propertiesincluding but not limited to oligomer uptake and/or enhance oligomerresistance to degradation. Groups that enhance the pharmacokineticproperties, in the context of this invention, include groups thatimprove properties including but not limited to oligomer uptake,distribution, metabolism and excretion. Representative conjugate groupsare disclosed in International Patent Application PCT/US92/09196.

Conjugate groups include but are not limited to lipid moieties such as acholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989,86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let.,1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharanet al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al.,Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol(Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphaticchain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al.,EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259,327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid,e.g., di-hexadecyl-rac-glycerol or triethylammonium1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.,Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res.,1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain(Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), oradamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36,3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta,1995, 1264, 229-237), or an octadecylamine orhexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol.Exp. Ther., 1996, 277, 923-937).

The oligomeric compounds of the present invention may also be conjugatedto active drug substances, for example, aspirin, warfarin,phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen,(S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoicacid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide,a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug,an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drugconjugates and their preparation are described in U.S. patentapplication Ser. No. 09/334,130, which is incorporated hereby byreference in its entirety.

Oligomeric compounds of the present invention can also be modified tohave one or more stabilizing groups that are generally attached to oneor both termini of oligomeric compounds to enhance properties such asfor example nuclease stability. Included in stabilizing groups are capstructures. These terminal modifications protect the oligomericcompounds having terminal nucleic acid moieties from exonucleasedegradation, and can help in delivery and/or localization within a cell.The cap can be present at the 5′-terminus (5′-cap) or at the 3′-terminus(3′-cap) or can be present on both termini. In non-limiting examples,the 5′-cap includes inverted abasic residue (moiety), 4′,5′-methylenenucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide,carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides;alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage;threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; acyclic3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide,3′-3′-inverted nucleotide moiety; 3′-3′-inverted abasic moiety;3′-2′-inverted nucleotide moiety; 3′-2′-inverted abasic moiety;1,4-butanediol phosphate; 3′-phosphoramidate; hexylphosphate; aminohexylphosphate; 3′-phosphate; 3′-phosphorothioate; phosphorodithioate; orbridging or non-bridging methylphosphonate moiety (for more details seeWincott et al., International PCT publication No. WO 97/26270,incorporated by reference herein).

Exemplary 3′-cap structures include, for example 4′,5′-methylenenucleotide; 1-(beta-D-erythrofuranosyl) nucleotide; 4′-thio nucleotide,carbocyclic nucleotide; 5′-amino-alkyl phosphate; 1,3-diamino-2-propylphosphate, 3-aminopropyl phosphate; 6-aminohexyl phosphate;1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitolnucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide;phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seconucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentylnucleotide, 5′-5′-inverted nucleotide moiety; 5′-5′-inverted abasicmoiety; 5′-phosphoramidate; 5′-phosphorothioate; 1,4-butanediolphosphate; 5′-amino; bridging and/or non-bridging 5′-phosphoramidate,phosphorothioate and/or phosphorodithioate, bridging or non bridgingmethylphosphonate and 5′-mercapto moieties (for more details seeBeaucage and Tyer, 1993, Tetrahedron 49, 1925 and Published U.S. PatentApplication Publication Number US 2005/0020525 published on Jan. 27,2005).

The oligomers of the present invention can be prepared using methodswell known to those skilled in the art, including literature proceduresfor DNA like compounds (Protocols for Oligonucleotides and Analogs, Ed.Agrawal (1993), Humana Press) and/or RNA like compounds (Scaringe,Methods, 2001, 23, 206-217. Gait et al., Applications of Chemicallysynthesized RNA in RNA:Protein Interactions, Ed. Smith (1998), 1-36.Gallo et al., Tetrahedron, 2001, 57, 5707-5713) synthesis asappropriate.

Alternatively, oligomeric compounds of the invention may be purchasedfrom various oligonucleotide synthesis companies such as, for example,Sigma-Aldrich Inc. (Castle Hill, NSW, Australia). Irrespective of theparticular protocol used, the subject oligomeric compounds may beconveniently and routinely made through the well-known technique ofsolid phase synthesis. Equipment for such synthesis is sold by severalvendors including, for example, Applied Biosystems (Foster City,Calif.). Any other means for such synthesis known in the art mayadditionally or alternatively be employed (including solution phasesynthesis). Methods of purification and analysis of oligomeric compoundsare known to those skilled in the art. Analysis methods includecapillary electrophoresis (CE) and electrospray-mass spectroscopy. Themethod of the invention is not limited by the method of oligomersynthesis or purification.

3.5 Oligomer Properties

The oligomer compounds may be taken up by tumor cells by facilitated oractive transport across the tumor cell membrane when administered infree (non-complexed) form, or by an endocytotic mechanism whenadministered in complexed form. The oligomer may be a substrate for amembrane transporter system (i.e., a membrane protein or proteins)capable of facilitating transport or actively transporting the oligomeracross the cell membrane. This feature may be determined by one of anumber of tests for oligomer interaction or cell uptake, as follows.

A first test assesses binding at cell surface receptors, by examiningthe ability of an oligomer compound to displace or be displaced by aselected charged oligomer on a cell surface. The cells are incubatedwith a given quantity of test oligomer, which is typically fluorescentlylabeled, at a final oligomer concentration of between about 10-300 nM.Shortly thereafter, e.g., 10-30 minutes (before significantinternalization of the test oligomer can occur), the displacing compoundis added, in incrementally increasing concentrations. If the testcompound is able to bind to a cell surface receptor, the displacingcompound will be observed to displace the test compound. If thedisplacing compound is shown to produce 50% displacement at aconcentration of 10× the test compound concentration or less, the testcompound is considered to bind at the same recognition site for the celltransport system as the displacing compound.

A second test measures cell transport, by examining the ability of thetest compound to transport a labeled reporter, e.g., a fluorescencereporter, into cells. The cells are incubated in the presence of labeledtest compound, added at a final concentration between about 10-300 nM.After incubation for 30-120 minutes, the cells are examined, e.g., bymicroscopy, for intracellular label. The presence of significantintracellular label is evidence that the test compound is transported byfacilitated or active transport.

The oligomer compound may also be administered in complexed form, wherethe complexing agent is typically a polymer, e.g., a cationic lipid,polypeptide, or non-biological cationic polymer, having an oppositecharge to any net charge on the oligomer. Methods of forming complexes,including bilayer complexes, between anionic oligonucleotides andcationic lipid or other polymer components, are well known. For example,the liposomal composition Lipofectin™ (Feigner et al. Proc Nati Acad SciUSA, 1987, 84(21): 7413-7417), containing the cationic lipid DOTMA(N-[1-(2,3-dioleyloxyl)propyl]-N,N,N-trimethylammonium chloride) and theneutral phospholipid DOPE (dioleyl phosphatidyl ethanolamine), is widelyused. After administration, the complex is taken up by cells through anendocytotic mechanism, typically involving particle encapsulation inendosomal bodies.

The oligomer compound may also be administered in conjugated form withan arginine-rich peptide linked covalently to the 5′ or 3′ end of theoligomer. The peptide is typically 8-16 amino acids and consists of amixture of arginine, and other amino acids including phenylalanine andcysteine. The use of arginine-rich peptide-PMO conjugates can be used toenhance cellular uptake of an oligomer (see, e.g., Moulton et al.,Bioconjug Chem, 2004, 15(2): 290-299; Nelson et al., Bioconjug Chem,2005, 16(4): 959-966).

In some instances, liposomes may be employed to facilitate uptake of theoligomers into cells (see, e.g., Williams, S. A., Leukemia 10(12):1980-1989, 1996; Lappalainen et al., Antiviral Res., 1994, 23:119;Uhlmann et al., Chemical Reviews, 1990, 90(4): 544-584). Hydrogels mayalso be used as vehicles for oligomer administration, for example, asdescribed in WO 93/01286. Alternatively, the oligomers may beadministered in microspheres or microparticles (see, e.g., Wu, G. Y. andWu, C. H., J. Biol. Chem. 1987, 262:4429-4432). Alternatively, the useof gas-filled microbubbles complexed with the antisense oligomers canenhance delivery to target tissues, as described in U.S. Pat. No.6,245,747.

In other examples, the requisite uptake properties of the oligomers ofthe present invention can be confirmed by a simple in vivo test, inwhich a labeled compound is administered to an animal (e.g., a mammal),and a body fluid sample, taken from the animal several hours after theoligomer is administered, is assayed, or the animal in whole or in partis imaged for the presence of the oligomer in a tumor cells of theanimal.

In specific embodiments, the subject oligomer compounds are taken uppreferentially by a tumor cell of a mammal than by a non-tumor or normalcell.

The oligomer compounds of the present invention suitably bind THOC4and/or SSB1. Candidate oligomers can be tested for binding to one orboth of the proteins using any suitable assay, including affinityassays. The assay can measure any one or more of dissociation rateconstant (k_(d)) or association rate constant (k_(a)) or equilibriumbinding constant (K_(D)) of an oligomer compound for THOC4 and/or SSB1.These constants are in some embodiments measured by a radiolabeled orfluorescently-labeled oligomer binding assay. This assay equilibrates atitration series of THOC4 or SSB1 with a minimal concentration oflabeled oligomer. Polyacrylamide gel electrophoresis is used todetermine the degree of binding to THOC4 or SSB1.

Affinity measurements can be determined by standard methodology fornucleic acid:protein interactions, for example, surface plasmonresonance (SPR) (Rich and Myszka Curr. Opin. Biotechnol, 2000, 11: 54;Englebienne Analyst. 1998, 123: 1599), isothermal titration calorimetry(ITC) or other kinetic interaction assays known in the art. In specificembodiments, the constants are measured by using surface plasmonresonance assays, e.g., using BIAcore surface plasmon resonance(BIAcore, Inc., Piscataway, N.J.) with immobilized THOC4 or SSB1 or aregion thereof. Exemplary SPR methods are described in U.S. Pat. No.7,229,619.

In specific embodiments, THOC4 binds the tumor-modulating oligomers witha K_(D) that is at least two fold lower than the K_(D) for the negativecontrol oligomer Neg_C under the same conditions (e.g., under aqueousconditions comprising 10 mM Tris-HCl (pH 8.0) and 100 mM NaCl at 37°C.). Exemplary conditions are described in Example 3. In representativeexamples, the oligomers bind THOC4, including hTHOC4, with a K_(D)≤about60 nM, ≤about 50 nM, ≤about 40 nM, ≤about 30 nM, ≤about 20 nM or ≤about10 nM.

In some embodiments, an OB-fold protein binds the tumor-modulatingoligomers with a K_(D) that is at least two fold lower than the K_(D)for the negative control oligomer Neg_C under the same conditions (e.g.,under aqueous conditions comprising 10 mM Tris-HCl (pH 8.0) and 100 mMNaCl at 37° C.). Exemplary conditions are described in Examples 3 and 7.In representative examples, the oligomers bind an OB-fold protein,including SSB1 and SSB2, with a K_(D)≤about 10 nM, ≤about 5 nM, ≤about 4nM, ≤about 3 nM or ≤about 2 nM. In illustrative examples of this type,SSB1 binds the tumor-modulating oligomers with a K_(D) that is at leasttwo fold lower than the K_(D) for the negative control oligomer Neg_Cunder the same conditions (e.g., under aqueous conditions comprising 10mM Tris-HCl (pH 8.0) and 100 mM NaCl at 37° C.). Exemplary conditionsare described in Example 3. In representative examples, the oligomersbind SSB1, including hSSB1 and mSSB1, with a K_(D)≤about 10 nM, ≤about 5nM, ≤about 4 nM, ≤about 3 nM or ≤about 2 nM. In other illustrativeexamples, SSB2 binds the tumor-modulating oligomers with a K_(D) that isat least two fold lower than the K_(D) for the negative control oligomerNeg_C under the same conditions (e.g., under aqueous conditionscomprising 10 mM Tris-HCl (pH 8.0) and 100 mM NaCl at 37° C.). Exemplaryconditions are described in Example 7. In representative examples, theoligomers bind SSB2, including hSSB2, with a K_(D)≤about 10 nM, ≤about 5nM, ≤about 4 nM, ≤about 3 nM or ≤about 2 nM. Alternatively, or inaddition, oligomer compounds of the present invention may be designedand/or identified using modeling in silico. For example, structuralmodels may be used, which provide a representation of an OB-foldprotein's three-dimensional secondary, tertiary, and/or quaternary aminoacid residue structure. A structural model encompasses X-Ray crystalstructures, NMR structures, theoretical protein structures, structurescreated from homology modeling, Protein Tomography models, and atomisticmodels built from electron microscopic studies. In specific embodiments,atomistic molecular dynamics (MD) simulations of OB-fold proteincomplexes with candidate oligomers can be used to identify compoundswith promising affinity for OB-fold proteins and anti-tumor activity, asdisclosed herein. Numerous MD simulations techniques are known in theart, representative examples of which are disclosed for example byAllison JR (2016, Curr Opin Struct Biol. 43:79-87), Ganesan et al.(2016, Drug Discov Today S1359-6446(16)30414-7) and Karplus et al.(2002, Nature Structural Biology 9: 646-652).

The oligomers of the present invention may block translocation of RNA,typically, mRNA from the nucleus to the cytoplasm of a tumor cell.Translocation of RNA to the nucleus can be measured, e.g., by nucleartranslocation assays in which the emission of two or morefluorescently-labeled species is detected simultaneously. For example,the cell nucleus can be labeled with a known fluorophore specific forDNA, such as Hoechst 33342. The RNA can be directly or indirectlylabeled, e.g., fluorescently-labeled antibody specific for RNA. Theamount of RNA that translocates to or from the nucleus can be determinedby determining the amount of a first fluorescently-labeled species,i.e., the nucleus, that is distributed in a correlated oranti-correlated manner with respect to a second fluorescently-labeledspecies, i.e., the RNA as described in U.S. Pat. No. 6,400,487, thecontents of which are hereby incorporated by reference.

Oligomeric compounds of the present invention can inhibit proliferationof a tumor cell and often cause apoptosis or necrosis of a tumor cell.Cell proliferation may be assayed by exposing cells to a fluoresceinlabeled anti-PCNA antibody (e.g., PC-10, Santa Cruz Biotechnology) whichbinds to proliferating cell nuclear antigen (PCNA). Selected oligomersmay be tested for an effect on proliferation on cell lines. From 2×10⁵to 2×10⁸ cells may be plated in each well of a 96 well plate. Mediumcontaining 1 μM to 10 μM of each oligomer may then be added to wells intriplicate. Minimally, a negative (no ligands) and a positive controlare also performed. After 2 hours, FITC anti-PCNA may be added to thewells, incubated with the cells for 15 minutes and, after 3 washingsteps, the level of fluorescence may be determined using a plate reader.The PCNA assay has already been used in cells and in tissues (Kulldorffet al. J. Clin Epidemiology, 2000, 53:875). Oligomeric compounds thatinhibit proliferation may be tested on fresh tumor biopsies from cancerpatients, including breast or prostate cancer patients. Small pieces oftumor biopsy may be plated in wells of a 96 well plate and the sameassay as above repeated with each sample in duplicate. After thefluorescence is read, the samples may be assessed under a fluorescencemicroscope to confirm that the cells whose proliferation indeed is beingaffected are the cancer cells.

Apoptosis may be assayed using a cell membrane phosphatidyl serinebinding dye (FITC Annexin V; alternative dyes such as Cy5.5 may also beused). Oligomeric compounds of the present invention may be tested foran effect on apoptosis on various cell lines. From 2×10⁵ to 2×10⁸ cellsmay be plated in each well of a 96 well plate and medium containing 1 μMto 10 μM of each oligomer is added to wells in triplicate. Minimally, anegative (no oligomer) and a positive (bcl2 reactive ligand) control arealso performed. After 1.5 hours, FITC Annexin is added to the wells,incubated with the cells for 15 minutes and, after 3 washing steps, thelevel of fluorescence is determined using a plate reader. The assays maybe demonstrated to be transferable from cells to tissues by using bcl-2expressing cells and tissues from bcl-2 transgenic mice (Charles River).Ligands which induce apoptosis may be tested on fresh tumor biopsiesfrom breast cancer patients. One advantage of using primary tissuebiopsy is that the assay may be performed within two hours of tissuecollection, i.e., before the tissue has begun showing the changesassociated with ischemia. Small pieces of tumor biopsy may be plated inwells of a 96 well plate and the same assay as above is repeated witheach sample in duplicate. After, the fluorescence is read, the samplesmay be stained with DAPI staining (Molecular Probes, Eugene Oreg.) andnuclear morphology may be assessed under a fluorescence microscope fornuclear condensation and fragmentation for confirmation. Alternatively,the classic TUNEL (terminal deoxynucleotidyl transferase mediatedbiotinylated deoxyuridine triphosphate nick end labeling) method tolabel DNA strand breaks may be used.

Techniques to detect necrosis include but are not limited to the classictechniques of DNA binding dyes such as propidium iodide or TOTO-3.Alternatively, a colorimetric methylthiazole tetrazolium (MTT) assay forthe mitochondrial enzyme release can also be used to determine cellviability. In specific embodiments, cell viability is determined usingthe DNA binding dyes propidium iodide and TOTO-3. Conducting theseassays in cell lines may enable one to distinguish between necrosis andapoptosis which will facilitate distinguishing oligomers have specificeffects from oligomers which are broadly cytotoxic. This distinction mayalso be facilitated by performing necrosis and apoptosis assays inparallel. Selected oligomers may be tested for an effect on necrosis ofthe cell lines. From 2×10⁵ to 2×10⁸ cells may be plated in each well ofa 96 well plate and medium containing 1 μM to 10 μM of each oligomer isadded to wells in triplicate. Minimally, a negative (no oligomer) and apositive control are also performed. After 8 hours, propidium iodide orTOTO 3 is added to the wells, incubated with the cells for 15 minutesand after 3 washing steps, the level of fluorescence is determined usinga fluorescent plate reader. Necrosis may be a difficult assay totransfer to tissue biopsies because it is generally assayed after atleast 8 hours and there is a lot of necrosis due to ischemia in tissuebiopsies after such an interval providing a high background. To overcomethis problem, human biopsy tissue may be transplanted into nude mice,thereby preventing ischemia induced necrosis during the 8 hour assayperiod. To insure that growth in the nude mouse does not alter thetumor, a tumor, grown in a nude mouse for 1 month, may be explanted andtested in the short term apoptosis and proliferation. The tumor may alsobe viewed histologically and compared with the fresh tumor explant toassess differences. The ligands which bind to the same target and inducenecrosis in 50% of the cases may be injected into the tumor in theanimal, collected after 8 hours, and stained with propidium iodide.Histological examination may reveal that the tumor cells are undergoingnecrosis while the other cells in the biopsy are not.

4. Oligomer Compositions and Applications

The oligomer compounds of the present invention function are useful asactives for inhibiting proliferation, survival or viability of a tumorcell, or for treating or preventing a cancer. The tumor cells can betreated in vivo or in vitro. Thus, the subject oligomers are useful,suitably in pharmaceutical compositions, for treating or preventingcancers. As such the present invention contemplates pharmaceuticalcompositions for treating, preventing and/or relieving the symptoms of acancer, wherein the compositions comprise an effective amount of anoligomer of the invention and a pharmaceutically acceptable carrier.

The oligomeric compounds of the invention encompass any pharmaceuticallyacceptable salts, esters, or salts of such esters, or any other compoundwhich, upon administration to an animal, typically a mammal including ahuman, is capable of providing (directly or indirectly) the biologicallyactive metabolite or residue thereof. Accordingly, for example, thedisclosure is also drawn to prodrugs and pharmaceutically acceptablesalts of the oligomeric compounds of the invention, pharmaceuticallyacceptable salts of such prodrugs, and other bioequivalents. For nucleicacid oligomers, examples of pharmaceutically acceptable salts and theiruses are further described in U.S. Pat. No. 6,287,860, which isincorporated herein in its entirety.

The compositions of the invention may also be admixed, encapsulated,conjugated or otherwise associated with other molecules, moleculestructures or mixtures of compounds, as for example, liposomes,receptor-targeted molecules, oral, rectal, topical or otherformulations, for assisting in uptake, distribution and/or absorption.Representative patent documents that teach the preparation of suchuptake, distribution and/or absorption-assisting formulations include,but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016;5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721;4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170;5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854;5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948;5,580,575; and 5,595,756, each of which is herein incorporated byreference.

The pharmaceutical compositions of the present invention may beadministered in a number of ways depending upon whether local orsystemic treatment is desired and upon the area to be treated.Administration may be topical (including ophthalmic and to mucousmembranes including vaginal and rectal delivery), pulmonary, e.g., byinhalation or insufflation of powders or aerosols, including bynebulizer; intratracheal, intranasal, epidermal and transdermal), oralor parenteral. Parenteral administration includes intravenous,intraarterial, subcutaneous, intraperitoneal or intramuscular injectionor infusion; or intracranial, e.g., intrathecal or intraventricular,administration. Oligomers with at least one 2′-O-methoxyethylmodification are believed to be particularly useful for oraladministration. Pharmaceutical compositions and formulations for topicaladministration may include transdermal patches, ointments, lotions,creams, gels, drops, suppositories, sprays, liquids and powders.Conventional pharmaceutical carriers, aqueous, powder or oily bases,thickeners and the like may be necessary or desirable. Coated condoms,gloves and the like may also be useful.

Pharmaceutical compositions of the present invention include, but arenot limited to, solutions, emulsions, foams and liposome-containingformulations. The pharmaceutical compositions of the present inventionmay comprise one or more penetration enhancers, carriers, excipients orother active or inactive ingredients.

One of skill in the art will recognize that pharmaceutical compositionsare routinely designed according to their intended use, i.e. route ofadministration.

For example, preferred formulations for topical administration includethose in which the oligonucleotides of the invention are in admixturewith a topical delivery agent such as lipids, liposomes, fatty acids,fatty acid esters, steroids, chelating agents and surfactants. Preferredlipids and liposomes include neutral (e.g., dioleoylphosphatidyl DOPEethanolamine, dimyristoylphosphatidyl choline DMPC,distearolyphosphatidyl choline) negative (e.g., dimyristoylphosphatidylglycerol DMPG) and cationic (e.g., dioleoyltetramethylaminopropyl DOTAPand dioleoylphosphatidyl ethanolamine DOTMA). Penetration enhancers andtheir uses are further described in U.S. Pat. No. 6,287,860, which isincorporated herein in its entirety. Surfactants and their uses arefurther described in U.S. Pat. No. 6,287,860, which is incorporatedherein in its entirety.

Compositions for oral administration include powders or granules,microparticulates, nanoparticulates, suspensions or solutions in wateror non-aqueous media, capsules, gel capsules, sachets, tablets orminitablets. Thickeners, flavoring agents, diluents, emulsifiers,dispersing aids or binders may be desirable. Preferred oral formulationsare those in which oligonucleotides of the invention are administered inconjunction with one or more penetration enhancers surfactants andchelators. Preferred surfactants include fatty acids and/or esters orsalts thereof, bile acids and/or salts thereof. Preferred bileacids/salts and fatty acids and their uses are further described in U.S.Pat. No. 6,287,860, which is incorporated herein in its entirety. Alsopreferred are combinations of penetration enhancers, for example, fattyacids/salts in combination with bile acids/salts. A particularlypreferred combination is the sodium salt of lauric acid, capric acid andUDCA. Further penetration enhancers include polyoxyethylene-9-laurylether, polyoxyethylene-20-cetyl ether. Oligomeric compounds of theinvention may be delivered orally, in granular form including sprayeddried particles, or complexed to form micro or nanoparticles. Nucleicacid oligomer complexing agents and their uses are further described inU.S. Pat. No. 6,287,860, which is incorporated herein in its entirety.Oral formulations for nucleic acid oligomers and their preparation aredescribed in detail in U.S. application Ser. No. 09/108,673 (filed Jul.1, 1998), Ser. No. 09/315,298 (filed May 20, 1999) and Ser. No.10/071,822, filed Feb. 8, 2002, each of which is incorporated herein byreference in their entirety.

In another related embodiment, therapeutically effective combinationtherapies may comprise the use of two or more compositions of theinvention wherein the multiple compositions are targeted to a single ormultiple nucleic acid targets. Numerous examples of antisense oligomericcompounds are known in the art. Two or more combined compounds may beused together or sequentially.

Any oligomeric compound can be used in the compositions and methods ofthe present invention, provided that the compound is pharmaceuticallyactive. A “pharmaceutically active” oligomer is in a form that resultsin a reduction, impairment, abrogation or prevention in the (i)formation; (ii) proliferation; (iii) survival; (iv) viability; or (v)maintenance of a tumor cell, and/or in the treatment and/or preventionof a cancer, including the prevention of incurring a symptom, holding incheck such symptoms or treating existing symptoms associated with thecancer, when administered to an individual in need thereof.

Modes of administration, amounts of oligomer administered, and oligomerformulations, for use in the methods of the present invention, areroutine and within the skill of practitioners in the art. Whether acancer has been treated is determined by measuring one or morediagnostic parameters indicative of the course of the disease, comparedto a suitable control. In the case of an animal experiment, a “suitablecontrol” is an animal not treated with the oligomer compound, or treatedwith the pharmaceutical composition without the oligomer compound. Inthe case of a human subject, a “suitable control” may be the individualbefore treatment, or may be a human (e.g., an age-matched or similarcontrol) treated with a placebo. In accordance with the presentinvention, the treatment of a cancer includes and encompasses withoutlimitation: (1) impairing, abrogating, reducing, preventing, orarresting the development of, the (i) formation; (ii) proliferation;(iii) survival; (iv) viability; or (v) maintenance of a tumor cell in apatient; (2) treating a cancer (e.g., a primary or metastatic cancer) ina subject; (3) preventing a cancer (e.g., a primary or metastaticcancer) in a subject that has a predisposition to the cancer but has notyet been diagnosed with the cancer and, accordingly, the treatmentconstitutes prophylactic treatment of the cancer; or (iii) causingregression of a cancer (e.g., a primary or metastatic cancer).

The compositions and methods of the present invention are thus suitablefor treating an individual who has been diagnosed with a cancer, who issuspected of having a cancer, who is known to be susceptible and who isconsidered likely to develop a cancer, or who is considered likely todevelop a recurrence of a previously treated cancer. The cancer may behormone receptor positive or hormone receptor negative. In someembodiments, the cancer is hormone receptor negative and is thusresistant to hormone or endocrine therapy. In some embodiments in whichthe cancer is breast cancer, the breast cancer (e.g., the non-breast CMCtumor cells) is hormone receptor negative (e.g., estrogen receptor (ER)negative and/or progesterone receptor (PR) negative).

The present invention also contemplates administering the oligomercompounds concurrently with at least one cancer therapy that inhibitsthe proliferation, survival or viability of tumor cells. The oligomermay be used therapeutically after the cancer therapy or may be usedbefore the therapy is administered or together with the therapy.Accordingly, the present invention contemplates combination therapies,which employ an oligomer of the present invention and concurrentadministration of an cancer therapy, non-limiting examples of whichinclude radiotherapy, surgery, chemotherapy, hormone ablation therapy,pro-apoptosis therapy and immunotherapy.

4.1 Radiotherapy

Radiotherapies include radiation and waves that induce DNA damage forexample, γ-irradiation, X-rays, UV irradiation, microwaves, electronicemissions, radioisotopes, and the like. Therapy may be achieved byirradiating the localized tumor site with the above described forms ofradiations. It is most likely that all of these factors effect a broadrange of damage DNA, on the precursors of DNA, the replication andrepair of DNA, and the assembly and maintenance of chromosomes.

Dosage ranges for X-rays range from daily doses of 50 to 200 roentgensfor prolonged periods of time (3 to 4 weeks), to single doses of 2000 to6000 roentgens. Dosage ranges for radioisotopes vary widely, and dependon the half life of the isotope, the strength and type of radiationemitted, and the uptake by the neoplastic cells.

Non-limiting examples of radiotherapies include conformal external beamradiotherapy (50-100 Grey given as fractions over 4-8 weeks), eithersingle shot or fractionated, high dose rate brachytherapy, permanentinterstitial brachytherapy, systemic radio-isotopes (e.g., Strontium89). In some embodiments the radiotherapy may be administered incombination with a radiosensitizing agent. Illustrative examples ofradiosensitizing agents include but are not limited to efaproxiral,etanidazole, fluosol, misonidazole, nimorazole, temoporfin andtirapazamine.

4.2 Chemotherapy

Chemotherapeutic agents may be selected from any one or more of thefollowing categories:

(i) antiproliferative/antineoplastic drugs and combinations thereof, asused in medical oncology, such as alkylating agents (for examplecis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan,chlorambucil, busulphan and nitrosoureas); antimetabolites (for exampleantifolates such as fluoropyridines like 5-fluorouracil and tegafur,raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea;anti-tumor antibiotics (for example anthracyclines like adriamycin,bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C,dactinomycin and mithramycin); antimitotic agents (for example vincaalkaloids like vincristine, vinblastine, vindesine and vinorelbine andtaxoids like paclitaxel and docetaxel; and topoisomerase inhibitors (forexample epipodophyllotoxins like etoposide and teniposide, amsacrine,topotecan and camptothecin);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen,toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptordown regulators (for example fulvestrant), antiandrogens (for examplebicalutamide, flutamide, nilutamide and cyproterone acetate), UHantagonists or LHRH agonists (for example goserelin, leuprorelin andbuserelin), progestogens (for example megestrol acetate), aromataseinhibitors (for example as anastrozole, letrozole, vorazole andexemestane) and inhibitors of 5α-reductase such as finasteride;

(iii) agents which inhibit cancer cell invasion (for examplemetalloproteinase inhibitors like marimastat and inhibitors of urokinaseplasminogen activator receptor function);

(iv) inhibitors of growth factor function, for example such inhibitorsinclude growth factor antibodies, growth factor receptor antibodies (forexample the anti-erbb2 antibody trastuzumab [Herceptin™] and theanti-erbb1 antibody cetuximab [C225]), farnesyl transferase inhibitors,MEK inhibitors, tyrosine kinase inhibitors and serine/threonine kinaseinhibitors, for example other inhibitors of the epidermal growth factorfamily (for example other EGFR family tyrosine kinase inhibitors such asN-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine(gefitinib, AZD1839),N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine(erlotinib, OSI-774) and6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazoll-n-4-amine(CI 1033)), for example inhibitors of the platelet-derived growth factorfamily and for example inhibitors of the hepatocyte growth factorfamily;

(v) anti-angiogenic agents such as those which inhibit the effects ofvascular endothelial growth factor, (for example the anti-vascularendothelial cell growth factor antibody bevacizumab [Avastin™],compounds such as those disclosed in International Patent ApplicationsWO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compoundsthat work by other mechanisms (for example linomide, inhibitors ofintegrin αvβ3 function and angiostatin);

(vi) vascular damaging agents such as Combretastatin A4 and compoundsdisclosed in International Patent Applications WO 99/02166, WO00/40529,WO 00/41669, WO01/92224, WO02/04434 and WO02/08213;

(vii) antisense therapies, for example those which are directed to thetargets listed above, such as ISIS 2503, an anti-ras antisense; and

(viii) gene therapy approaches, including for example approaches toreplace aberrant genes such as aberrant p53 or aberrant GDEPT(gene-directed enzyme pro-drug therapy) approaches such as those usingcytosine deaminase, thymidine kinase or a bacterial nitroreductaseenzyme and approaches to increase patient tolerance to chemotherapy orradiotherapy such as multi-drug resistance gene therapy.

4.3 Immunotherapy

Immunotherapy approaches, include for example ex-vivo and in-vivoapproaches to increase the immunogenicity of patient tumor cells, suchas transfection with cytokines such as interleukin 2, interleukin 4 orgranulocyte-macrophage colony stimulating factor, approaches to decreaseT-cell anergy, approaches using transfected immune cells such ascytokine-transfected dendritic cells, approaches usingcytokine-transfected tumor cell lines and approaches usinganti-idiotypic antibodies. These approaches generally rely on the use ofimmune effector cells and molecules to target and destroy cancer cells.The immune effector may be, for example, an antibody specific for somemarker on the surface of a malignant cell. The antibody alone may serveas an effector of therapy or it may recruit other cells to actuallyfacilitate cell killing. The antibody also may be conjugated to a drugor toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin,pertussis toxin, etc.) and serve merely as a targeting agent.

Alternatively, the effector may be a lymphocyte carrying a surfacemolecule that interacts, either directly or indirectly, with a malignantcell target. Various effector cells include cytotoxic T cells and NKcells.

4.4 Other Therapies

Examples of other cancer therapies include phototherapy, cryotherapy,toxin therapy or pro-apoptosis therapy. One of skill in the art wouldknow that this list is not exhaustive of the types of treatmentmodalities available for cancer and other hyperplastic lesions.

It is well known that chemotherapy and radiation therapy target rapidlydividing cells and/or disrupt the cell cycle or cell division. Thesetreatments are offered as part of the treating several forms of cancer,aiming either at slowing their progression or reversing the symptoms ofdisease by means of a curative treatment. However, these cancertreatments may lead to an immunocompromised state and ensuing pathogenicinfections and thus the present invention also extends to combinationtherapies, which employ both an oligomeric compound of the invention, acancer therapy and an anti-infective agent that is effective against aninfection that develops or that has an increased risk of developing froman immunocompromised condition resulting from the cancer therapy. Theanti-infective drug is suitably selected from antimicrobials, whichinclude without limitation compounds that kill or inhibit the growth ofmicroorganisms such as viruses, bacteria, yeast, fungi, protozoa, etc.and thus include antibiotics, amebicides, antifungals, antiprotozoals,antimalarials, antituberculotics and antivirals. Anti-infective drugsalso include within their scope anthelmintics and nematocides.Illustrative antibiotics include quinolones (e.g., amifloxacin,cinoxacin, ciprofloxacin, enoxacin, fleroxacin, flumequine,lomefloxacin, nalidixic acid, norfloxacin, ofloxacin, levofloxacin,lomefloxacin, oxolinic acid, pefloxacin, rosoxacin, temafloxacin,tosufloxacin, sparfloxacin, clinafloxacin, gatifloxacin, moxifloxacin;gemifloxacin; and garenoxacin), tetracyclines, glycylcyclines andoxazolidinones (e.g., chlortetracycline, demeclocycline, doxycycline,lymecycline, methacycline, minocycline, oxytetracycline, tetracycline,tigecycline; linezolide, eperozolid), glycopeptides, aminoglycosides(e.g., amikacin, arbekacin, butirosin, dibekacin, fortimicins,gentamicin, kanamycin, meomycin, netilmicin, ribostamycin, sisomicin,spectinomycin, streptomycin, tobramycin), □-lactams (e.g., imipenem,meropenem, biapenem, cefaclor, cefadroxil, cefamandole, cefatrizine,cefazedone, cefazolin, cefixime, cefmenoxime, cefodizime, cefonicid,cefoperazone, ceforanide, cefotaxime, cefotiam, cefpimizole,cefpiramide, cefpodoxime, cefsulodin, ceftazidime, cefteram, ceftezole,ceftibuten, ceftizoxime, ceftriaxone, cefuroxime, cefuzonam,cephaacetrile, cephalexin, cephaloglycin, cephaloridine, cephalothin,cephapirin, cephradine, cefinetazole, cefoxitin, cefotetan, azthreonam,carumonam, flomoxef, moxalactam, amidinocillin, amoxicillin, ampicillin,azlocillin, carbenicillin, benzylpenicillin, carfecillin, cloxacillin,dicloxacillin, methicillin, mezlocillin, nafcillin, oxacillin,penicillin G, piperacillin, sulbenicillin, temocillin, ticarcillin,cefditoren, SC004, KY-020, cefdinir, ceftibuten, FK-312, S-1090,CP-0467, BK-218, FK-037, DQ-2556, FK-518, cefozopran, ME1228, KP-736,CP-6232, Ro 09-1227, OPC-20000, LY206763), rifamycins, macrolides (e.g.,azithromycin, clarithromycin, erythromycin, oleandomycin, rokitamycin,rosaramicin, roxithromycin, troleandomycin), ketolides (e.g.,telithromycin, cethromycin), coumermycins, lincosamides (e.g.,clindamycin, lincomycin) and chloramphenicol.

Illustrative antivirals include abacavir sulfate, acyclovir sodium,amantadine hydrochloride, amprenavir, cidofovir, delavirdine mesylate,didanosine, efavirenz, famciclovir, fomivirsen sodium, foscarnet sodium,ganciclovir, indinavir sulfate, lamivudine, lamivudine/zidovudine,nelfinavir mesylate, nevirapine, oseltamivir phosphate, ribavirin,rimantadine hydrochloride, ritonavir, saquinavir, saquinavir mesylate,stavudine, valacyclovir hydrochloride, zalcitabine, zanamivir, andzidovudine.

Non-limiting examples of amebicides or antiprotozoals includeatovaquone, chloroquine hydrochloride, chloroquine phosphate,metronidazole, metronidazole hydrochloride, and pentamidine isethionate.Anthelmintics can be at least one selected from mebendazole, pyrantelpamoate, albendazole, ivermectin and thiabendazole. Illustrativeantifungals can be selected from amphotericin B, amphotericin Bcholesteryl sulfate complex, amphotericin B lipid complex, amphotericinB liposomal, fluconazole, flucytosine, griseofulvin microsize,griseofulvin ultramicrosize, itraconazole, ketoconazole, nystatin, andterbinafine hydrochloride. Non-limiting examples of antimalarialsinclude chloroquine hydrochloride, chloroquine phosphate, doxycycline,hydroxychloroquine sulfate, mefloquine hydrochloride, primaquinephosphate, pyrimethamine, and pyrimethamine with sulfadoxine.Antituberculotics include but are not restricted to clofazimine,cycloserine, dapsone, ethambutol hydrochloride, isoniazid, pyrazinamide,rifabutin, rifampin, rifapentine, and streptomycin sulfate.

As noted above, the present invention encompasses co-administration ofan oligomer compound in concert with an additional agent. It will beunderstood that, in embodiments comprising administration of theoligomer with other agents, the dosages of the actives in thecombination may on their own comprise an effective amount and theadditional agent(s) may further augment the therapeutic or prophylacticbenefit to the patient. Alternatively, the oligomer and the additionalagent(s) may together comprise an effective amount for preventing ortreating the cancer. It will also be understood that effective amountsmay be defined in the context of particular treatment regimens,including, e.g., timing and number of administrations, modes ofadministrations, formulations, etc. In some embodiments, the oligomericcompound and optionally the cancer therapy are administered on a routineschedule. Alternatively, the cancer therapy may be administered assymptoms arise. A “routine schedule” as used herein, refers to apredetermined designated period of time. The routine schedule mayencompass periods of time which are identical or which differ in length,as long as the schedule is predetermined. For instance, the routineschedule may involve administration of the oligomer on a daily basis,every two days, every three days, every four days, every five days,every six days, a weekly basis, a monthly basis or any set number ofdays or weeks there-between, every two months, three months, fourmonths, five months, six months, seven months, eight months, ninemonths, ten months, eleven months, twelve months, etc. Alternatively,the predetermined routine schedule may involve concurrent administrationof the oligomer compound and the cancer therapy on a daily basis for thefirst week, followed by a monthly basis for several months, and thenevery three months after that. Any particular combination would becovered by the routine schedule as long as it is determined ahead oftime that the appropriate schedule involves administration on a certainday.

For any compound used in the treatment methods of the invention, thetherapeutically effective dose can be estimated initially from cellculture assays. For example, a dose can be formulated in animal modelsto achieve a circulating concentration range that includes the IC50 asdetermined in cell culture (e.g., the concentration of an active agent,which achieves a half-maximal inhibition in proliferation of a tumorcell). Such information can be used to more accurately determine usefuldoses in humans.

Dosing is dependent on severity and responsiveness of the disease stateto be treated, with the course of treatment lasting from several days toseveral months, or until a cure is effected or a diminution of thedisease state is achieved. Optimal dosing schedules can be calculatedfrom measurements of drug accumulation in the body of the patient.Persons of ordinary skill can easily determine optimum dosages, dosingmethodologies and repetition rates. Optimum dosages may vary dependingon the relative potency of individual oligomer compounds, and cangenerally be estimated based on EC_(50s) found to be effective in invitro and in vivo animal models. In general, dosage is from 0.01 μg to100 g per kg of body weight, and may be given once or more daily,weekly, monthly or yearly. Persons of ordinary skill in the art caneasily estimate repetition rates for dosing based on measured residencetimes and concentrations of the drug in bodily fluids or tissues.Following successful treatment, it may be desirable to have the patientundergo maintenance therapy to prevent the recurrence of the diseasestate, wherein the oligonucleotide is administered in maintenance doses,ranging from 0.01 μg to 100 g per kg of body weight, once or more daily,weekly, monthly, or yearly. For double-stranded compounds, the dose mustbe calculated to account for the increased nucleic acid load of thesecond strand (as with compounds comprising two separate strands) or theadditional nucleic acid length (as with self complementary singlestrands having double-stranded regions).

In some embodiments, and dependent on the intended mode ofadministration, the oligomer-containing compositions will generallycontain about 0.000001% to 90%, about 0.0001% to 50%, or about 0.01% toabout 25%, by weight of oligomer, the remainder being suitablepharmaceutical carriers or diluents etc. The dosage of the oligomer candepend on a variety of factors, such as mode of administration, thespecies of the affected subject, age, sex, weight and general healthcondition, and can be easily determined by a person of skill in the artusing standard protocols. The dosages will also take into considerationthe binding affinity of the oligomer to its target molecule (e.g., THOC4or SSB1), its bioavailability and its in vivo and pharmacokineticproperties. In this regard, precise amounts of the agents foradministration can also depend on the judgment of the practitioner. Indetermining the effective amount of the agents to be administered in thetreatment or prevention of a cancer, the physician or veterinarian mayevaluate the progression of the disease or condition over time. In anyevent, those of skill in the art may readily determine suitable dosagesof the oligomer compound without undue experimentation. The dosage ofthe actives administered to a patient should be sufficient to effect abeneficial response in the patient over time such as impairment,abrogation or prevention in the formation, proliferation, survival,viability or maintenance of tumor cells, and/or in the treatment and/orprevention of a cancer. The dosages may be administered at suitableintervals to ameliorating the symptoms of the cancer. Such intervals canbe ascertained using routine procedures known to persons of skill in theart and can vary depending on the type of active agent employed and itsformulation. For example, the interval may be daily, every other day,weekly, fortnightly, monthly, bimonthly, quarterly, half-yearly oryearly.

Dosage amount and interval may be adjusted individually to provideplasma levels of the active agent, which are sufficient to maintainoligomer effects. Usual patient dosages for systemic administrationrange from 1-2000 mg/day, commonly from 1-250 mg/day, and typically from10-150 mg/day. Stated in terms of patient body weight, usual dosagesrange from 0.02-25 mg/kg/day, commonly from 0.02-3 mg/kg/day, typicallyfrom 0.2-1.5 mg/kg/day. Stated in terms of patient body surface areas,usual dosages range from 0.5-1200 mg/m²/day, commonly from 0.5-150mg/m²/day, typically from 5-100 mg/m²/day.

Toxicity and therapeutic efficacy of the oligomer drugs can bedetermined by standard pharmaceutical procedures in cell cultures orexperimental animals, e.g., for determining the LD50 (the dose lethal to50% of the population) and the ED50 (the dose therapeutically effectivein 50% of the population). The dose ratio between toxic and therapeuticeffects is the therapeutic index and it can be expressed as the ratioLD50/ED50. Compounds that exhibit large therapeutic indices arepreferred. The data obtained from these cell culture assays and animalstudies can be used in formulating a range of dosage for use in human.The dosage of such compounds lies preferably within a range ofcirculating concentrations that include the ED50 with little or notoxicity. The dosage may vary within this range depending upon thedosage form employed and the route of administration utilized. The exactformulation, route of administration and dosage can be chosen by theindividual physician in view of the patient's condition. (See forexample Fingl et al., 1975, in “The Pharmacological Basis ofTherapeutics”, Ch. 1 p 1).

Alternately, one may administer the oligomer compound in a local ratherthan systemic manner, for example, via injection of the compounddirectly into a tissue, which is preferably subcutaneous or omentaltissue, often in a depot or sustained release formulation.

Furthermore, one may administer the oligomer compound in a targeted drugdelivery system, for example, in a liposome coated with tissue-specificantibody. The liposomes will be targeted to and taken up selectively bythe tissue.

In cases of local administration or selective uptake, the effectivelocal concentration of the oligomer compound may not be related toplasma concentration.

In order that the invention may be readily understood and put intopractical effect, particular preferred embodiments will now be describedby way of the following non-limiting example.

EXAMPLES Example 1 Tumor-Modulating Effects of Non-Targeting OligomerCompounds

Modified RNA oligomer compounds were designed, which are not consideredto target the transcriptome of tumor cells. The modifications include aphosphorothioate backbone (*) and a 2-O′-methyl modification (m), asindicated in TABLE 3, and are designated with the prefix ‘LSA’. Allsequences were ordered from Sigma-Aldrich (Castle Hill, NSW, Australia).

The oligomer compounds were transfected into the cancer cell lines HeLa,U205, LNCAP, MCF7, A549 and H460 at 100 nM or 50 nM final concentrationusing Lipofectamine 2000. This treatment resulted in the death of mostcells by 20-36 hours, as shown by lower cell confluence and adherence ofcells treated with the LSA compounds, as compared to cells treated withcontrol compound (see, FIG. 1).

Immunoblot analysis revealed a 40-50% reduction in hSSB1 polypeptideproduction of treated cells as well as PARP1 cleavage and increased H2AXphosphorylation (FIG. 2). PARP1 is cleaved during apoptosis and yH2AXspecifically marks DNA breaks within the genome, confirming the presenceof apoptosis and DNA damage, respectively, in cells treated with thenon-targeting oligomers.

TABLE 3 SEQ ID OLIGO CONSOLIDATED OLIGOMER SEQUENCE NO NAME OLIGO ID(5′-3′) 282 LSA_In2E2 DKLS636117 mG*mA*mG*mC*mC*mG* mU*mG*mG*mG*mU*mG*mA*mC*mC*mU*mA*mC* mC*mC   2 LSA_ATG DKLS230778 mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG* mU*mA*mC*mG*mA*mC* mG*mG   5 LSA_In3E3 DKLS394649mC*mC*mA*mG*mU*mG* mA*mG*mC*mC*mG*mG* mA*mC*mU*mU*mG*mC* mC*mU 283LSA_E3E4 DKLS612200 mG*mA*mC*mU*mU*mC* mG*mC*mA*mU*mG*mG*mG*mA*mA*mA*mC*mC* mA*mC 281 CTRL DKLS329687 mG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC* mG*mA*mU*mC*mG*mA* mU*mC Sequence designations are asfollows: m = 2′OMe-modified nucleoside, * = phosphorothioate (PS)internucleoside linkage. The oligomer names for the experimentsdescribed in Example 1 are shown (OLIGO NAME), together with theircorresponding consolidated OLIGO ID and SEQ ID NO listed in TABLE 8.

Example 2 Comparison of Non-Targeting Oligomer Compounds and AntisenseCompounds for Toxicity on Tumor Cells

The non-targeting oligomers described in Example 1 were compared toantisense oligomers for tumor cell toxicity. The antisense oligomerswere designed with the same backbone chemistry as the non-targetingoligomers and with specificity for targeting hSSB1 sequences. Thesequences of the oligomers used for this study are shown in TABLE 4 inwhich non-targeting compounds are designated with the prefix ‘LSA’ andantisense compounds are designated with the prefix ‘ASO’. All sequenceswere ordered from Sigma-Aldrich (Castle Hill, NSW, Australia).

As shown by PARP cleavage and H2AX induction, both non-targetingoligomers (LSAs) and antisense oligomers (ASOs) induced cell toxicity(FIG. 3). Notably, hSSB1 protein levels were also reduced in cellstransfected with non-targeting oligomers and antisense oligomers.

Additional non-targeting oligomers and antisense oligomer compounds weredesigned and screened for toxicity in a panel of cancer cell lines usingthe IncuCyte kinetic live cell imaging system. These oligomers are shownin TABLE 5.

Briefly, cells were seeded in microwell plates and 24 hr latertransfected with LSA or ASO oligos (100 nM) and immediately loaded to anIncuCyte ZOOM system. Images were collected every 1-2 hr viaphase-contrast microscopy for a period of 72 hrs. Data was analysedusing IncuCyte ZOOM software. Cell proliferation was measured bymonitoring the percentage cell confluence over time, as shown forrepresentative oligonucleotides in FIG. 4. The 41 oligomer compoundslisted in TABLE 5 were scored as 3=highly toxic, 2=moderately toxic,1=slightly toxic and 0=non-toxic and this did not seem to depend on LSAor ASO orientation.

TABLE 4 SEQ ID CONSOLIDATED NO OLIGO NAME OLIGO IDOLIGOMER SEQUENCE (5′-3′) 282 LSA_In2E2 DKLS636117mG*mA*mG*mC*mC*mG*mU*mG*mG*mG*mU*mG*mA*mC*mC*mU*mA*mC*mC*mC   2 LSA_ATGDKLS230778 mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG  5 LSA_In3E3 DKLS394649mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 283 LSA_E3E4DKLS612200 mG*mA*mC*mU*mU*mC*mG*mC*mA*mU*mG*mG*mG*mA*mA*mA*mC*mC*mA*mC281 CTRL DKLS329687mG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC 280ASO_In2E2 DKLS364918mC*mU*mC*mG*mG*mC*mA*mC*mC*mC*mC*mA*mC*mU*mG*mG*mA*mU*mG*mG 284ASO_In3E3 DKLS860834mG*mG*mU*mC*mA*mC*mU*mC*mG*mG*mC*mC*mU*mG*mA*mA*mC*mG*mG*mA 288 ASO_E3E4DKLS409068 mC*mU*mG*mA*mA*mG*mC*mG*mU*mA*mC*mC*mC*mU*mU*mU*mG*mG*mU*mG101 ASO_ATG DKLS421748mG*mU*mC*mU*mC*mC*mG*mU*mC*mG*mU*mC*mA*mU*mG*mC*mU*mG*mC*mC 295 ASO_GFPDKLS827917 mC*mA*mG*mC*mU*mC*mG*mU*mC*mC*mA*mU*mG*mC*mC*mG*mA*mG*mA*mGSequence designations are as follows: m = 2′OMe-modified nucleoside, *= phosphorothioate (PS) internucleoside linkage. The oligomer names forthe experiments described in Example 2 are shown (OLIGO NAME), togetherwith their corresponding consolidated OLIGO ID and SEQ ID NO listed inTABLE 8.

TABLE 5 SEQ ID CONSOLIDATED Base GC AG NO OLIGO NAME OLIGO IDOLIGOMER SEQUENCE (5′-3′) Type # (%) Tm (%)   4 Neg_C DKLS525146mC*mU*mC*mA*mU*mU*mC*mC*mU*mA*mC*mC*mG*mA*mC*mA*mC*mC*mC*mC* LSA 20 6064.5 25%  42 NEG_C_GAP DKLS848880mC*mU*mC*mA*mU*TCCTACCGACmA*mC*mC*mC*mC LSA 20 60 35.5 25% 294ASO_GFP_CT-5 DKLS675388mC*mU*mG*mC*mU*mC*mC*mU*mC*mC*mU*mU*mC*mC*mC*mG*mU*mA*mA*mG ASO 20 6064.6 25% 302 cdca3_L_In4E4-1 DKLS649218mG*mA*mA*mC*mC*mC*mC*mC*mC*mA*mG*mA*mU*mC*mU*mC*mC*mU*mU*mC LSA 20 6064.9 30% 304 FK-Aso_E2In2_3 DKLS789189mG*mC*mC*mU*mA*mC*mC*mU*mU*mU*mU*mC*mC*mC*mA*mG*mG*mU*mC*mA ASO 20 5564.3 30% 305 ASO_GFP_CT-6 DKLS651753mC*mA*mC*mC*mU*mA*mG*mU*mC*mC*mC*mU*mU*mC*mC*mU*mC*mG*mA*mG ASO 20 60 6430%  37 LSA_In3E3_CT4 DKLS727270mC*mG*mU*mG*mU*mC*mA*mU*mC*mC*mG*mC*mU*mC*mU*mC*mG*mA*mC*mU LSA 20 6063.5 30%  45 LSA_In3E3_CT5 DKLS786970mC*mG*mC*mG*mU*mC*mA*mC*mU*mC*mG*mC*mA*mC*mU*mC*mG*mC*mC*mU LSA 20 7069.2 30% 198 open_L_1 DKLS659460mC*mA*mC*mG*mU*mA*mC*mC*mU*mU*mA*mG*mU*mG*mC*mC*mU*mC*mA*mC LSA 20 5561.9 35% 277 cdca3_L_In2E2-2 DKLS832163mC*mU*mC*mC*mU*mC*mC*mC*mU*mU*mA*mC*mG*mG*mA*mC*mA*mC*mU*mC LSA 20 6064.1 25% 278 cdca3_A_ATG-3 DKLS696616mC*mU*mC*mU*mU*mG*mG*mC*mU*mG*mA*mG*mC*mC*mC*mA*mU*mC*mU*mC ASO 20 6064.6 30% 279 ASO_ATG DKLS370480mG*mU*mC*mU*mC*mC*mG*mU*mC*mG*mU*mC*mA*mU*mG*mC*mU*mG*mC*mC ASO 20 6568.9 30% 280 ASO_In2 DKLS364918mC*mU*mC*mG*mG*mC*mA*mC*mC*mC*mC*mA*mC*mU*mG*mG*mA*mU*mG*mG ASO 20 7068.5 45%  40 In3LSA_GAP DKLS316231mC*mC*mA*mG*mU*mG*A*G*C*C*G*G*A*C*T*mU*mG*mC*mC*mU LSA 20 65 42.2 45%281 Ctrl DKLS329687mG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC LSA 20 5055.5 50% 282 LSA_In2E2 DKLS636117mG*mA*mG*mC*mC*mG*mU*mG*mG*mG*mG*mU*mG*mA*mC*mC*mU*mA*mC*mC LSA 20 70 6850% 283 LSA_E3E4 DKLS612200mG*mA*mC*mU*mU*mC*mG*mC*mA*mU*mG*mG*mG*mA*mA*mA*mC*mC*mA*mC LSA 20 5562.1 55% 284 ASO_In3 DKLS860834mG*mG*mU*mC*mA*mC*mU*mC*mG*mG*mC*mC*mU*mG*mA*mA*mC*mG*mG*mA ASO 20 6566.6 55% 285 FK-Aso_ATG_1 DKLS331584mC*mG*mG*mC*mU*mG*mU*mC*mA*mU*mC*mU*mC*mC*mG*mC*mG*mC*mG*mG ASO 20 7570.8 40% 286 In3LSA_biotin DKLS645702mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU LSA 20 6568.6 45% 287 In3LSA_FAM DKLS645702mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU LSA 20 6568.6 45%  38 In3LSA_scr3_5 DKLS748531mC*mC*mA*mG*mA*mC*mA*mG*mC*mU*mG*mG*mU*mG*mU*mC*mG*mC*mC*mU LSA 20 6568.2 45%   5 LSA_In3E3 DKLS394649mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU LSA 20 6568.6 45% 288 ASO_E3E4 DKLS409068mC*mU*mG*mA*mA*mG*mC*mG*mU*mA*mC*mC*mC*mU*mU*mU*mG*mG*mU*mG ASO 20 5567.8 45% 289 FK-Aso_In2E3 DKLS684387mG*mA*mU*mG*mA*mC*mC*mU*mC*mC*mC*mC*mU*mG*mC*mA*mG*mG*mU*mA ASO 20 6066.4 45% 290 LACZ_2224 DKLS484655mC*mU*mC*mG*mG*mG*mU*mG*mA*mU*mU*mA*mC*mG*mA*mU*mC*mG*mC*mG LSA 20 6062.3 50% 291 ASO_GFP DKLS771111mC*mA*mG*mC*mU*mC*mG*mU*mC*mC*mA*mU*mG*mC*mC*mG*mA*mG*mA*mG ASO 20 6566.9 50% 292 ASO_GFP_scr5 DKLS820087mA*mC*mG*mA*mU*mA*mG*mU*mC*mC*mC*mU*mG*mC*mC*mG*mC*mG*mA*mG ASO 20 6567.7 50% 293 ASO_GFP_scr6 DKLS817322mU*mA*mG*mU*mC*mC*mG*mC*mU*mU*mA*mC*mG*mC*mC*mG*mA*mG*mA*mG ASO 20 60 6550% 295 FK-Lsa_In2E3 DKLS827917mC*mU*mA*mC*mU*mG*mG*mA*mG*mG*mG*mG*mA*mC*mG*mU*mC*mC*mA*mU LSA 20 6065.8 55% 296 RevIn3LSA DKLS843537mA*mG*mG*mC*mA*mA*mG*mT*mC*mC*mG*mG*mC*mT*mC*mA*mC*mT*mG*mG LSA 20 6555% 297 cdca3_A_In4E4-1 DKLS859480mC*mU*mU*mG*mG*mG*mG*mG*mG*mU*mC*mU*mA*mG*mA*mG*mG*mA*mA*mG ASO 20 6065.2 70% 298 FK-Lsa_E2In2_3 DKLS371273mC*mG*mG*mA*mU*mG*mG*mA*mA*mA*mA*mG*mG*mG*mU*mC*mC*mA*mG*mU LSA 20 5563.1 70% 299 cdca3_A_In2E2-2 DKLS658030mG*mA*mG*mG*mA*mG*mG*mG*mA*mA*mU*mG*mC*mC*mU*mG*mU*mG*mA*mG ASO 20 6064.6 75%  41 In3LSA_CU DKLS629290mC*mC*mA*mG*mU*mG*mA*mG*mC*mU*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU LSA 20 6066.2 45%  39 In3LSA_scr3_4 DKLS357796mC*mC*mG*mG*mU*mG*mA*mG*mC*mG*mA*mC*mA*mC*mU*mA*mG*mG*mC*mU LSA 20 6568.3 55% 300 Luc_2243 DKLS506891mA*mC*mC*mG*mA*mA*mC*mG*mG*mA*mC*mA*mU*mU*mU*mC*mG*mA*mA*mG ILSA 20 5058.3 60% 301 FK-Lsa_ATG-1 DKLS665920mG*mC*mC*mG*mA*mC*mA*mG*mU*mA*mG*mA*mG*mG*mC*mG*mC*mG*mC*mC LSA 20 7572.4 60%   3 open_A_1 DKLS170415mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG LSA 20 55 6165%   2 LSA_ATG DKLS230778mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG LSA 20 6566.4 70% 303 cdca3_L_ATG-3 DKLS991101mG*mA*mG*mA*mA*mC*mC*mG*mA*mC*mU*mC*mG*mG*mG*mU*mA*mG*mA*mG LSA 20 6063.3 70% Sequence designations are as follows: m = 2′OMe-modifiednucleoside, * = phosphorothioate (PS) internucleoside linkage. The typeof an individual oligomer (e.g., LSA or ASO) is shown, as well as itslength (Base #), percentage guanosine-cytosine (GC) content, meltingtemperature (Tm) and percentage purine content (AG). Any detectablelabels or reporter groups (e.g., biotin FAM) are indicated the OLIGONAME. The oligomer names for the experiments described in Example 2 areshown (OLIGO NAME), together with their corresponding consolidated OLIGOID and SEQ ID NO listed in TABLE 8.

Example 3 Oligomer Compounds Bind to SSB1 and THOC4

Biotinylated non-targeting compound, LSA-IN3E3, and a negative controloligomer compound, NEGC, were incubated with cellular lysates.Interacting proteins were extracted using streptavidin beads, which bindto the biotinylated compounds. The beads were washed and interactingproteins were separated by SDS-PAGE, stained with Coomassie R250 andbands were excised for mass spectrometry identification oftrypsin-digested fragments. Among the proteins identified in the massspectrometry analysis were the single strand DNA repair protein hSSB1,and the mRNA transport protein THOC4. THOC4 is a 32-kDa proteincomponent of the TREX complex, the complex which couples mRNAtranscription, processing and nuclear export. THOC4 contains an RNARecognition Motif (RRM), a single-stranded RNA binding domain, whichcould potentially mediate the binding to the oligomer compoundsdescribed herein.

To confirm this interaction electromobility shift assays (EMSA) wereperformed using oligomer compounds that were effective at causing celldeath (LSA_In3E3, Open_A_1, cdca3_L_ATG-3 and ASO E3E4) and oligomercompounds that were relatively non-toxic in cells (Neg_C, LSA_In3E3CT5=a mutated version of In3LSA, Open L_1 and cdca3_A_ATG-3). Theoligomeric compounds were labeled with FAM or Cy5, incubated withvarying amounts of hSSB1 or THOC4, and bound and free oligomers wereseparated by native gel electrophoresis. Notably, both hSSB1 and THOC4retarded the migration of the tumor-modulating oligomers withsignificantly higher affinity than the non-toxic oligomers, suggestingthese two proteins may be involved in the observed phenotype (see, FIG.5). The dissociation constants (K_(D)) for THOC4 are shown in TABLE 6,and those for hSSB1 are shown in TABLE 7 (K_(D) values determined usingnon-linear regression in GraphPad Prism). Purified hSSB1 or THOC4protein was incubated with 10 nmol of labeled oligo for 15 min at 37° C.in a buffer consisting of 10 mM Tris-HCl (pH8.0), 100 mM NaCl, 0.01%IGEPAL, 1 mM EDTA and 100 ng/μL BSA. Samples were separated byelectrophoresis on a 10% PAGE gel in

TBE buffer for 60 min at 80V at 4° C.

TABLE 6 Oligomer Label Cell Death KD (nM) LSA_In3E3 Fam 3 81 Neg_C Fam 0150 LSA_In3E3_CT5 Fam 0 125 Open_A_1 Fam 3 52 Open_L_1 Fam 0 104cdca3_A_ATG-3 Fam 0 134 cdca3_ L_ATG-3 Cy5 3 58 ASO_E3E4 Cy5 2 70

TABLE 6 summarizes the results of triplicate EMSA experiments performedwith THOC4 and eight different oligomer compounds. Dissociationconstants for individual THOC4:oligomer interactions are shown (K_(D),concentration of protein at which 50% of oligonucleotide is bound to theprotein at equilibrium). As can be seen, THOC4 binds to tumor-modulatingoligomers with a K_(D) of about 50 to 80 nM, and to a negative controloligomer with a K_(D)of 150 nM. K_(D) values were determined byelectrophoretic mobility shift assay (EMSA). Purified THOC4 protein wasincubated with 10 nmol of labeled oligomer for 15 min at 37° C. in abuffer consisting of 10 mM Tris-HCl (pH8.0), 100 mM NaCl, 0.0% IGEPAL, 1mM EDTA and 100 ng/μL BSA. Samples were separated by electrophoresis ona 10% PAGE gel in TBE buffer for 60 min at 80V at 4° C. K_(D) valueswere determined using non-linear regression in GraphPad Prism byplotting the amount of free unbound oligo against protein concentration.

In a separate experiment, a GST-THOC4 derivative with improvedsolubility was found to THOC4 bind tumor-modulating oligomers with aK_(D) of about 11 nM under the same conditions.

TABLE 7 Oligomer Label Cell Death K_(D) (nM) LSA_In3E3 Fam 3 3 Neg_C Fam0 9

TABLE 7 summarizes the results of triplicate EMSA experiments performedwith hSSB1 and two different oligomer compounds. Dissociation constantsfor individual THOC4:oligomer interactions are shown (K_(D),concentration of protein at which 50% of oligonucleotide is bound to theprotein at equilibrium). As can be seen, hSSB1 binds to tumor-modulatingoligomers with a K_(D) of about 3 nM, and to a negative control oligomerwith a K_(D) of 9 nM. K_(D) values were determined by electrophoreticmobility shift assay (EMSA). Purified hSSB1 protein was incubated with10 nmol of labeled oligomer for 15 min at 37° C. in a buffer consistingof 10 mM Tris-HCl (pH 8.0), 100 mM NaCl, 0.0% IGEPAL, 1 mM EDTA and 100ng/μL BSA. Samples were separated by electrophoresis on a 10% PAGE gelin TBE buffer for 60 min at 80V at 4° C. K_(D) values were determinedusing non-linear regression in GraphPad Prism by plotting the amount offree unbound oligo against protein concentration.

Example 4 Oligomer Compounds Inhibit Cell Gene Expression and mRNATranslocation

Based on the involvement of THOC4 in transcription and mRNA export, aGFP reporter expression assay was performed in which apoptosis resistantHeLa-BCL2 cells were transfected (to avoid the bias of apoptosis) with100 nM ASOs/LSAs using Lipofectamine 3000 (Life Technologies). Fivehours later, the cells were transfected with the GFP reporter plasmidusing Fugene 9 (Roche) and 20 hr post GFP transfection the fluorescencesignal was analyzed using the high throughput Cytell cell imagingsystem. GFP plasmid only transfected cells were used as comparison(GFP). As shown in FIG. 6, non-targeting oligomers (LSAs) and antisenseoligomers (ASOs) that are known to induce cell death also showed adramatically reduced GFP fluorescence while non-toxic ASOs/LSAs did notaffect GFP expression. This result suggests that the ASOs/LSAs thatinduce cell death do so by depleting components of the TREX complexleading to interference with global transcription. This in turn leads toDNA damage and cell death.

Global mRNA export was investigated in cells transfected with IN3LSA orNEGC by mRNA fluorescent in situ hybridization (FISH) experiments. Theresults show that nuclear export of polyA mRNA (stained in red), wasinhibited in cells transfected with In3LSA but not NEGC (see, FIG. 7).This confirms that the TREX complex is inhibited by the In3LSA oligomer.

Example 5 High Content Screen of Candidate Oligomers for IdentifyingEssential Features

A high content screen was performed to identify the minimum length,chemistry, pyrimidine/purine content required for potency oftumor-modulating oligomer sequences of the present invention and forbinding to THOC4 and/or hSSB1. A total of 305 different oligomers werescreened using an Incell 2200 platform in HeLa and U2OS cells, using aLive-Dead protocol that combines the fluorescent stains Hoescht 33342(cell permeable, stains live and dead cells) and Propidium Iodide (PI,cell impermeable, stains late apoptotic and dead cells). Cells wereanalyzed for: total cell count, apoptotic nuclei and propidium iodide(PI) staining, with results reported as the percentage of apoptotic(fragmented) nuclei and PI-positive cells (late-apoptotic or dead)measured at 24 hrs following treatment with oligomer compounds.

Binding of Oligomers to THOC4 or hSSB1 was performed using surfaceplasmon resonance (SPR), in which purified recombinant THOC4 or hSSB1protein was coupled to the surface of the SPR chip, and oligomers werepassed over the surface at a concentrations ranging from 2 nM to 16 μMin a buffer consisting of 20 mM Tris-HCl (pH 8.0), 100 mM NaCl and 0.01%IGEPAL.

The results from this high content screen are summarized in TABLE 8.

TABLE 8Summary data from the 305 oligomer screen, including oligomer sequence and chemistry, length, melting temperature (Tm) purineand GC content, death score based on a high content screen (HCS) and the oligomer-Thoc4 and -hSSB1 results from SPR binding assays.A high-content screen (HCS) was performed in which the percentage of apoptotic and dead cells was measured and used to assign a death scoreto each oligomer. Death Scores assigned were: 0 = non toxic, 1 = slightly toxic, 2 = moderately toxic, 3 = highly toxic. (SPR was used tomeasure binding between oligos and either THOC4 or hSSB1 protein. Scores were calculated by normalizing the Rmax (maximum binding response)for each oligo to the Rnnax for the positive and negative control oligos, LSA_In3E3 and Neg_C. Sequence designations are as follows:m = 2′OMe-modified nucleoside, * = phosphorothioate (PS)  SEQ Base % %Death SPR- SPR- ID NAME SEQUENCE AND CHEMISTRY # Tm GC AG Score Thoc4hSSB1 1 DKLS47mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 20 68.6 65%45% 3 1.00 1.00 8030 2 DKLS23mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 20 62.26 65%70% 3 0.96 1.10 0778 3 DKLS17mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 20 55.4 55%65% 3 0.74 1.05 0415 4 DKLS52mC*mU*mC*mA*mU*mU*mC*mC*mU*mA*mC*mC*mG*mA*mC*mA*mC*mC*mC*mC 20 64.5 60%25% 0 0.18 0.39 5146 5 DKLS39mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 20 68.6 65%45% 3 1.00 1.00 4649 6 DKLS50 U*C*U*C*C*C*A*G*C*G*U*G*C*G*C*C*A*U 1856.81 67% 33% 2 0.44 1.14 6891 7 DKLS37U*A*C*C*G*C*G*U*G*C*G*A*C*C*C*U*C*U 18 57.57 67% 33% 1 0.81 1.05 1273 8DKLS65 U*C*U*C*C*C*A*G*C*A*U*G*U*G*C*C*A*U 18 52.83 56% 33% 0 0.52 0.518030 9 DKLS69 mU*mC*mU*mC*mC*mC*mA*mG*mC*mG*mU*mG*mC*mG*mC*mC*mA*mU 1856.81 67% 33% 0 1.12 0.79 6616 10 DKLS78mU*mA*mC*mC*mG*mC*mG*mU*mG*mC*mG*mA*mC*mC*mC*mU*mC*mU 18 57.57 67% 33% 20.49 0.69 4557 11 DKLS83mU*mC*mU*mC*mC*mC*mA*mG*mC*mA*mU*mG*mU*mG*mC*mC*mA*mU 18 52.83 56% 33% 00.33 0.31 2163 12 DKLS62mG*mG*mU*mC*mG*mU*mA*mA*mU*mA*mC*mU*mU*mU*mC*mA*mC*mU*mU*mA 20 37.75 35%40% 2 0.47 0.97 9224 13 DKLS78 ZEN/CUCAUUCCUACCGACACCCC/ZEN 20 54.3 60%25% 0 0.03 0.09 9189 14 DKLS68mU*mC*mA*mA*mG*mG*mA*mA*mG*mA*mU*mG*mG*mC*mA*mU*mU*mU*mC*mU 20 48.05 40%55% 3 0.55 1.12 7764 15 DKLS68mC*mU*mG*mC*mC*mU*mA*mA*mG*mU*mA*mA*mA*mA*mA*mG*mU*mG*mU*mA*mA*m 2349.33 35% 61% 2 0.51 1.21 7118 A*mC 16 DKLS76mC*mC*mA*mU*mC*mU*mG*mU*mA*mA*mU*mU*mA*mC*mA*mA*mA*mA*mU*mU*mA*m 2337.83 22% 52% 3 0.97 1.93 5774 A*mA 17 DKLS96mG*mA*mG*mU*mA*mA*mA*mC*mA*mU*mU*mC*mU*mG*mU*mG*mU*mG*mG*mA*mG* 23 50.6243% 57% 3 0.64 1.35 5031 mU*mC 18 DKLS93mC*mU*mG*mC*mC*TAAGTAAAAAGTGmU*mA*mA*mA*mC 23 49.71 35% 61% 0 0.00 -0.144835 19 DKLS65 mC*mC*mA*mU*mC*TGTAATTACAAAAmU*mU*mA*mA*mA 23 40.25 22%52% 0 0.01 -0.03 6574 20 DKLS79mG*mA*mG*mU*mA*AACATTCTGTGTGmG*mA*mG*mU*mC 23 53.56 43% 57% 0 0.02 0.129151 21 DKLS35mC*mA*mG*mC*mA*mG*mC*mA*mG*mA*mG*mU*mC*mU*mU*mC*mA*mU*mC*mA*mU 21 49.6148% 48% 2 0.37 0.91 4527 22 DKLS48mU*mG*mU*mG*mC*mU*mA*mU*mU*mC*mU*mG*mU*mG*mA*mA*mU*mU 18 37.22 33% 39% 20.22 0.43 4655 23 DKLS46mU*mA*mA*mG*mC*mU*mG*mU*mU*mC*mU*mA*mU*mG*mU*mG*mU*mU 18 36.59 33% 39% 20.32 0.74 3500 24 DKLS47 mG*mA*mG*mG*mA*mA*mC*TmC*mC*mG*mC*mC*mG*mC 1558.73 73% 53% 2 0.14 0.23 4224 25 DKLS37mU*mC*mU*mU*mA*mU*mG*mU*mU*mU*mC*mC*mG*mA*mA*mC*mC*mG*mU*mU 20 38.69 40%30% 2 0.34 0.69 0480 26 DKLS33mU*mG*mC*mU*mA*mU*mC*mU*mU*mA*mU*mC*mA*mC*mC*mU*mU*mU*mA*mG 20 38.53 35%30% 0 0.15 0.48 1584 27 DKLS69mG*mG*mC*mG*mA*mA*mU*mG*mA*mG*mA*mC*mU*mU*mC*mU*mC*mU*mU*mA 20 47.45 45%50% 1 0.89 1.64 3540 28 DKLS68mU*mC*mC*mU*mG*mG*mA*mU*mC*mC*mU*mU*mC*mA*mC*mC*mA*mA*mU*mG 20 50.52 50%35% 2 0.76 1.08 7192 29 DKLS68mU*mG*mU*mC*mA*mU*mA*mU*mU*mC*mC*mU*mG*mG*mA*mU*mC*mC*mU*mU 20 42.92 40%30% 1 0.87 1.38 4387 30 DKLS95mG*mG*mG*mA*mC*mG*mC*mG*mG*mC*mG*mC*mU*mC*mG*mG*mU*mC*mA*mU 20 64.09 75%55% 0 1.35 2.13 1212 31 DKLS48mC*mA*mG*mC*mA*mG*mC*mA*mG*mA*mG*mU*mA*mU*mU*mU*mA*mU*mC*mA*mU 21 44.0238% 52% 3 0.46 1.10 1254 32 DKLS49mG*mC*mU*mC*mC*mA*mG*mC*mA*mU*mC*mU*mG*mC*mU*mG*mC*mU*mU*mC 20 56.03 60%30% 2 0.26 0.65 1049 33 DKLS46mG*mC*mU*mC*mC*mA*mG*mC*mA*mU*mC*mU*mG*mC*mU*mG*mC*mU*mU*mC 20 57.41 55%65% 1 0.98 2.62 6380 34 DKLS68mA*mC*mA*mU*mC*mG*mU*mU*mA*mC*mC*mA*mG*mA*mC*mA*mG*mU*mG*mU*mU*m 2246.82 41% 50% 3 0.75 1.47 7764 A 35 DKLS68mA*mC*mA*mU*mG*mG*mU*mU*mC*mC*mC*mC*mG*mA*mC*mA*mG*mU*mG*mU*mU*m 2251.67 50% 45% 3 0.72 1.70 7118 A 36 DKLS48mA*mG*mG*mC*mA*mA*mG*mU*mC*mC*mG*mG*mC*mU*mC*mA*mC*mU*mG*mG 20 63.22 65%55% 3 0.76 0.82 1254 37 DKLS72mC*mG*mU*mG*mU*mC*mA*mU*mC*mC*mG*mC*mU*mC*mU*mC*mG*mA*mC*mU 20 50.65 60%30% 1 0.21 0.80 7270 38 DKLS74mC*mC*mA*mG*mA*mC*mA*mG*mC*mU*mG*mG*mU*mG*mU*mC*mG*mC*mC*mU 20 60.77 65%45% 3 0.43 0.75 8531 39 DKLS35mC*mC*mG*mG*mU*mG*mA*mG*mC*mG*mA*mC*mA*mC*mU*mA*mG*mG*mC*mU 20 62.99 65%55% 3 0.66 0.77 7796 40 DKLS31 mC*mC*mA*mG*mU*GAGCCGGACTmU*mG*mC*mC*mU20 58.27 65% 45% 1 -0.10 0.55 6231 41 DKLS62mC*mC*mA*mG*mU*mG*mA*mG*mC*mU*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 20 59.66 60%45% 2 0.54 0.97 9290 42 DKLS84 mC*mU*mC*mA*mU*TCCTACCGACmA*mC*mC*mC*mC20 53.93 60% 25% 0 -0.10 0.56 8880 43 DKLS64mCmCmAmGmUmGmAmGmCmCmGmGmAmCmUmUmGmCmCmU 20 60.82 65% 45% 0 -0.14 0.034620 44 DKLS62 mC*mC*mA*mGmUmGmAmGmCmCmGmGmAmCmUmUmG*mC*mC*mU 20 60.8265% 45% 2 -0.13 0.12 1499 45 DKLS78mC*mG*mC*mG*mU*mC*mA*mC*mU*mC*mG*mC*mA*mC*mU*mC*mG*mC*mC*mU 20 57.23 70%30% 1 0.03 0.46 6970 46 DKLS41 mC*mG*mC*mG*mU*CACTCGCACTmC*mG*mC*mC*mU20 57.6 70% 30% 0 -0.16 0.05 5889 47 DKLS99 ZEN/CCAGUGAGCCGGACUUGCCU/ZEN20 60.8 65% 45% 0 -0.13 0.17 1101 48 DKLS64 ZEN/CAGAGGCAGCAGUACGACGG/ZEN20 62.3 65% 70% 0 -0.09 0.15 9218 49 DKLS65 ZEN/GUGCAUGGAAUCACGGAGUG/ZEN20 55.4 55% 65% 0 -0.12 0.07 1753 50 DKLS66 ZEN/CACGUACCUUAGUGCCUCAC/ZEN20 51.6 55% 35% 0 -0.15 0.07 5920 51 DKLS67mU*mU*mG*mA*mC*mA*mG*mA*mU*mU*mA*mA*mG*mU*mC*mC*mA*mU*mU*mC 20 40.22 35%45% 1 0.15 0.89 5388 52 DKLS65mG*mC*mC*mA*mC*mC*mC*mG*mU*mC*mG*mG*mU*mU*mG*mC*mU*mA*mG*mA 20 57.41 65%45% 3 0.89 1.65 9460 53 DKLS64mG*mC*mG*mG*mG*mU*mC*mC*mU*mC*mU*mA*mC*mG*mC*mA*mC*mU*mG*mA 20 60.62 65%45% 2 0.85 1.55 9547 54 DKLS64mG*mC*mC*mC*mG*mU*mC*mU*mG*mG*mC*mG*mC*mA*mU*mA*mG*mC*mU*mA 20 59.55 65%45% 2 0.85 0.98 6683 55 DKLS67mG*mG*mG*mC*mC*mU*mC*mC*mC*mG*mC*mA*mC*mU*mU*mG*mA*mG*mA*mU 20 61.91 65%45% 1 0.37 0.85 9059 56 DKLS65mG*mG*mC*mA*mC*mG*mU*mC*mC*mG*mC*mC*mA*mG*mU*mC*mA*mU*mG*mU 20 57.42 65%45% 3 0.23 0.73 6105 57 DKLS42mC*mC*mU*mC*mU*mC*mU*mG*mC*mC*mG*mC*mU*mC*mU*mU*mG*mC*mC*mU 20 56.14 65%15% 0 0.03 0.48 0640 58 DKLS37mC*mC*mU*mG*mU*mG*mU*mG*mC*mC*mC*mC*mU*mC*mU*mU*mC*mC*mC*mU 20 55.81 65%15% 0 0.12 0.68 4580 59 DKLS46mC*mC*mU*mG*mU*mC*mA*mG*mC*mC*mG*mC*mA*mC*mU*mU*mG*mC*mC*mU 20 58 65%30% 2 0.39 0.95 3357 60 DKLS45mC*mC*mA*mC*mU*mG*mA*mG*mC*mC*mC*mG*mA*mC*mU*mU*mC*mC*mC*mU 20 59.67 65%30% 0 0.03 0.63 9520 61 DKLS39mC*mC*mA*mG*mU*mA*mA*mG*mC*mC*mA*mG*mA*mC*mU*mU*mG*mC*mA*mU 20 52.81 50%50% 2 0.30 0.64 9970 62 DKLS45mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mA*mA*mC*mU*mU*mC*mU*mC*mU 20 52.66 55%40% 1 0.26 0.55 9014 63 DKLS44mC*mU*mA*mG*mU*mA*mA*mG*mU*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 20 50.39 50%45% 2 1.22 1.22 7399 64 DKLS71mC*mC*mA*mG*mG*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mG*mC*mG 20 66.19 75%60% 2 0.51 0.70 2428 65 DKLS44mG*mG*mA*mG*mG*mG*mA*mG*mU*mC*mG*mG*mA*mC*mU*mU*mG*mU*mC*mU 20 59.03 60%60% 0 1.78 1.58 4294  66 DKLS43mG*mC*mG*mG*mU*mG*mA*mA*mC*mC*mG*mG*mA*mG*mU*mU*mG*mG*mC*mU 20 61.26 65%60% 2 1.11 1.03 8994 67 DKLS43mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC 19 60.94 68%47% 3 0.90 0.68 7053 68 DKLS39mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC 18 58.46 67% 50% 30.87 0.67 8126 69 DKLS43mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG 17 53.94 65% 53% 30.69 0.59 5532 70 DKLS42 mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU16 52.31 63% 50% 3 0.38 0.40 8543 71 DKLS42mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU 15 55.02 67% 53% 3 -0.090.36 6690 72 DKLS42 mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC 14 54.8571% 57% 2 0.08 0.35 6564 73 DKLS42mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA 13 50.01 69% 62% 2 0.08 0.53 174874 DKLS39 mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG 12 47.78 75% 58% 0 0.000.24 7701 75 DKLS79 mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG 11 40.65 73% 55% 0-0.03 0.15 1575 76 DKLS37 mC*mC*mA*mG*mU*mG*mA*mG*mC*mC 10 36.94 70% 50%0 -0.01 0.11 8257 77 DKLS18 mC*mC*mA*mG*mU*mG*mA*mG*mC 9 28.8 67% 56% 0-0.06 0.09 7090 78 DKLS35 mC*mC*mA*mG*mU*mG*mA*mG 8 16 63% 63% 0 -0.050.09 4527 79 DKLS50mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 19 58.45 63%47% 3 0.87 0.92 3590 80 DKLS47mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 18 58.56 61% 50% 30.84 0.84 2247 81 DKLS55mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 17 56.82 65% 47% 30.23 0.83 9250 82 DKLS93 mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU16 55.96 63% 44% 3 0.24 0.48 1438 83 DKLS67mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 15 54.8 67% 47% 3 0.45 0.408949 84 DKLS47 mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 14 52.41 64%43% 2 0.09 0.30 9801 85 DKLS35 mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 1349.76 69% 38% 1 0.01 0.22 6102 86 DKLS30mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 12 42.91 67% 33% 0 0.07 0.13 8827 87DKLS41 mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 11 37.39 64% 36% 0 0.01 0.094890 88 DKLS64 mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 10 33.12 60% 40% 0 -0.010.07 2581 89 DKLS62 mG*mA*mC*mU*mU*mG*mC*mC*mU 9 21.1 56% 33% 0 -0.020877 90 DKLS45 mA*mC*mU*mU*mG*mC*mC*mU 8 14.2 50% 25% 0 -0.02 9520 91DKLS74 mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC 18 58.4667% 50% 3 0.96 0.91 8531 92 DKLS71mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC 16 55.59 63% 56% 3 0.680.71 2428 93 DKLS31 mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG 14 47.6964% 57% 3 0.48 0.45 6231 94 DKLS39 mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU12 43.03 58% 50% 1 0.08 0.20 9970 95 DKLS30mG*mA*mG*mC*mC*mG*mG*mA*mC*mU 10 42.27 70% 60% 0 -0.04 0.13 8266 96DKLS30 mA*mG*mC*mC*mG*mG*mA*mC 8 35.6 75% 63% 0 -0.07 0.07 7561 97DKLS30 CCAGUGAGCCGGACUUGCCU 20 62.3 65% 45% 0 -0.05 0.03 0878 98 DKLS29mC*mA*mG*mA*mG*GCAGCAGTACmG*mA*mC*mG*mG 20 59.84 65% 70% 2 0.00 0.202688 99 DKLS45 mCmAmGmAmGmGmCmAmGmCmAmGmUmAmCmGmAmCmGmG 20 62.26 65% 70%0 -0.02 0.10 9014 100 DKLS28mC*mA*mG*mAmGmGmCmAmGmCmAmGmUmAmCmGmA*mC*mG*mG 20 62.26 65% 70% 3 -0.020.17 6198 101 DKLS42mG*mU*mC*mU*mC*mC*mG*mU*mC*mG*mU*mC*mA*mU*mG*mC*mU*mG*mC*mC 20 53.78 65%30% 1 0.33 0.64 1748 102 DKLS42 mG*mU*mC*mU*mC*CGTCGTCATGmC*mU*mG*mC*mC20 59.67 65% 30% 0 -0.03 0.16 6564 103 DKLS42C*C*A*G*U*G*A*G*C*C*G*G*A*C*U*U*G*C*C*U 20 62.3 65% 45% 3 1.06 0.99 6690104 DKLS42mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG*mC* 30 74.7467% 70% 2 1.21 1.89 8543 mA*mG*mA*mG*mG*mC*mA*mG*mC 105 DKLS43mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC 15 53.33 60% 67% 1 0.250.36 5532 106 DKLS39 mC*mA*mG*mA*mG*mG*mC*mA*mG*mC 10 42.41 70% 70% 00.11 0.17 8126 107 DKLS43mG*mG*mA*mG*mC*mC*mG*mG*mA*mC*mA*mA*mG*mG*mG*TmC*mA*mC*mA 20 66 65% 70%2 0.78 0.99 7053 108 DKLS39mG*mG*mG*mA*mC*mC*mC*mA*mA*mG*mG*mA*mG*mC*mG*TmA*mC*mG*mA 20 65.27 65%70% 1 1.64 1.60 4649 109 DKLS89mG*mA*mG*mC*mG*mA*mG*mA*mC*mG*mC*mG*mG*mA*mG*mA*mC*mC*mA 19 65.1 68% 74%3 0.68 0.84 1943 110 DKLS89mG*mC*mG*mG*mA*mA*mC*mG*mG*mA*mC*mG*mG*mA*mA*mG*mA*mC*mC 19 66.4 68% 74%3 0.59 0.66 4584 111 DKLS62mG*mC*TmG*mA*mC*mG*mG*mC*mA*mC*mG*mG*mC*mA*mG*mA*mG*mA*mA 20 66.54 65%70% 3 0.67 0.93 9290 112 DKLS62mU*mG*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mA*mA*mC*mU*mG 20 61.5 55%65% 0 1.10 1.11 1499 113 DKLS76mG*mG*mG*mC*mG*mG*mC*mA*mG*mU*mA*mG*mU*mC*mC*mG*mA*mC*mA*mG 20 63.45 70%65% 2 0.52 0.53 5774 114 DKLS65mG*mA*mG*mA*mA*mG*mA*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mU*mG*mG 20 56.32 50%80% 3 0.79 0.82 6574 115 DKLS85mC*mA*mU*mA*mG*mU*mC*mA*mC*mC*mU*mG*mU*mA*mC*mU*mA*mC*mC*mG 20 48.91 50%40% 1 0.39 0.47 9346 116 DKLS81mC*mA*mC*mC*mG*mU*mC*mA*mU*mC*mA*mC*mU*mA*mC*mC*mA*mC*mG*mG 20 54.35 60%40% 0 0.51 0.41 2894 117 DKLS81mC*mA*mC*mU*mC*mG*mC*mU*mG*mC*mA*mU*mU*mU*mC*mG*mC*mC*mG*mG 20 52.54 65%35% 2 0.49 0.56 7119 118 DKLS33mC*mU*mG*mU*mG*mC*mC*mA*mU*mC*mU*mG*mU*mA*mC*mC*mA*mC*mG*mG 20 55.09 60%40% 2 0.51 0.55 3877 119 DKLS35mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG 19 59.1 63% 68%3 0.92 0.78 7796  120 DKLS42mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC 18 59.29 61% 67% 20.71 0.64 0640 121 DKLS46mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA 17 55.55 59% 71% 21.46 1.19 3357 122 DKLS37mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG 16 53.89 63% 69% 2 0.530.46 4580 123 DKLS84 mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC 1553.33 60% 67% 0 0.21 0.39 0764 124 DKLS86mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA 14 48.49 57% 71% 0 0.46 0.610782 125 DKLS83 mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU 13 48.94 62% 69%0 -0.01 0.27 4767 126 DKLS80 mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG 1247.75 67% 75% 0 0.10 0.26 5605 127 DKLS41mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA 11 43.28 64% 73% 0 0.15 0.35 5889 128DKLS78 mC*mA*mG*mA*mG*mG*mC*mA*mG*mC 10 42.41 70% 70% 0 -0.04 0.20 6970129 DKLS86 mC*mA*mG*mA*mG*mG*mC*mA*mG 9 32.2 67% 78% 0 0.10 0.12 0509130 DKLS77 mC*mA*mG*mA*mG*mG*mC*mA 8 24.2 63% 75% 0 0.07 0.14 1223 131DKLS33 mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 19 62.5963% 74% 3 1.10 1.02 4259 132 DKLS95mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 18 61.23 67% 72% 21.06 0.77 8923 133 DKLS88mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 17 59.54 65% 71% 30.80 0.68 9313 134 DKLS71mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 16 57.88 69% 69% 3 0.490.64 7876 135 DKLS75 mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 1553.53 67% 67% 3 0.31 0.46 7016 136 DKLS73mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 14 47.91 64% 64% 0 0.26 0.374654 137 DKLS76 mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 13 47.13 62% 69%1 0.24 0.37 2544 138 DKLS72 mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 12 43.9467% 67% 1 0.24 0.26 7270 139 DKLS94 mC*mA*mG*mU*mA*mC*mG*mA*mC*mG*mG 1136.4 64% 64% 0 0.07 0.18 7541 140 DKLS44 mA*mG*mU*mA*mC*mG*mA*mC*mG*mG10 34.23 60% 70% 0 -0.02 0.14 7399 141 DKLS52 mG*mU*mA*mC*mG*mA*mC*mG*mG9 28.9 67% 67% 0 -0.05 0.07 5146 142 DKLS84 mU*mA*mC*mG*mA*mC*mG*mG 824.4 63% 63% 0 -0.06 0.03 8880 143 DKLS86mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC*mG 18 59.25 61% 72% 30.81 0.96 8095 144 DKLS77mG*mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA*mC 16 57.53 63% 69% 2 0.440.67 6802 145 DKLS87 mA*mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG*mA 14 50.6557% 71% 2 1.02 1.05 3408 146 DKLS92 mG*mG*mC*mA*mG*mC*mA*mG*mU*mA*mC*mG12 45.32 67% 67% 0 0.11 0.26 9958 147 DKLS87mG*mC*mA*mG*mC*mA*mG*mU*mA*mC 10 33.28 60% 60% 0 -0.03 0.15 0416 148DKLS90 mC*mA*mG*mC*mA*mG*mU*mA 8 11.4 50% 63% 0 -0.07 0.05 4311 149DKLS85 CAGAGGCAGCAGUACGACGG 20 60.2 65% 70% 0 0.04 0.03 8330 150 DKLS18mG*mU*mG*mC*mA*TGGAATCACGmG*mA*mG*mU*mG 20 54.67 55% 65% 0 0.04 -0.064327 151 DKLS93 mGmUmGmCmAmUmGmGmAmAmUmCmAmCmGmGmAmGmUmG 20 55.4 55% 65%0 0.00 -0.03 4835 152 DKLS94mG*mU*mG*mCmAmUmGmGmAmAmUmCmAmCmGmGmA*mG*mU*mG 20 55.4 55% 65% 1 -0.030.04 5812 153 DKLS57 C*A*G*A*G*G*C*A*G*C*A*G*U*A*C*G*A*C*G*G 20 60.2 65%70% 3 1.03 1.44 7569 154 DKLS72mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG*mG* 30 65.0353% 67% 0 1.53 4.08 2361 mU*mG*mC*mA*mU*mG*mG*mA*mA 155 DKLS72mG*mA*mG*mU*mC*mC*mG*mG*mU*mG*mA*mG*mC*mG*mU*mA*mG*mA*mU*mA 20 53.88 55%65% 3 1.39 2.66 1579 156 DKLS74mG*mC*mA*mU*mA*mG*mA*mC*mG*mU*mC*mG*mG*mA*mG*mA*mG*mU*mG*mU 20 54.9 55%65% 2 1.79 2.37 6864 157 DKLS74mG*mG*mU*mA*mG*mG*mA*mC*mG*mC*mU*mG*mG*mG*mU*mA*mC*mA*mA*mU 20 59.53 55%65% 0 1.55 5.71 4278 158 DKLS42mG*mU*mA*mG*mC*mA*mG*mG*mC*mU*mC*mG*mG*mU*mA*mG*mA*mG*mA*mU 20 57.52 55%65% 3 0.55 0.59 1479 159 DKLS95mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 20 55.4 55%65% 3 0.79 0.95 8321 160 DKLS71mG*mG*mU*mA*mG*mG*mA*mC*mG*mC*mG*mG*mA*mC*mA*mG*mU*mU*mA*mU 20 55.81 55%65% 2 1.37 1.63 0955 161 DKLS70mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mA*mC*mA*mC*mG*mG*mU*mA*mU*mG 20 53.57 50%65% 3 0.56 0.82 1719 162 DKLS65mC*mA*mG*mC*mA*mU*mA*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 20 52.16 50%65% 2 0.49 0.88 3496 163 DKLS37mG*mU*mG*mC*mA*mG*mA*mG*mU*mG*mU*mU*mA*mC*mG*mG*mA*mG*mG*mG 20 57.88 60%70% 0 1.19 2.32 7200 164 DKLS64mG*mU*mG*mC*mA*mG*mA*mG*mA*mA*mU*mC*mA*mC*mU*mG*mA*mA*mG*mG 20 55.97 50%70% 3 0.57 0.83 4620 165 DKLS68mG*mU*mC*mC*mA*mU*mG*mU*mC*mU*mU*mC*mU*mC*mG*mG*mA*mA*mU*mG 20 45.8 50%40% 2 0.40 0.70 3540 166 DKLS96mC*mU*mG*mC*mU*mU*mU*mG*mA*mA*mU*mC*mA*mC*mG*mC*mA*mG*mU*mU 20 44.01 45%40% 1 0.35 0.62 8463 167 DKLS75mG*mU*mC*mC*mU*mU*mG*mU*mC*mA*mU*mC*mA*mC*mG*mU*mU*mG*mU*mG 20 42.64 50%35% 2 0.35 0.74 3270 168 DKLS75mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU 19 54.15 53%63% 3 0.47 1.24 4387 169 DKLS62mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG 18 53.62 56% 67% 30.39 1.03 8743 170 DKLS81mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA 17 51.27 53% 65% 21.00 2.06 2155 171 DKLS82mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG 16 49.53 56% 63% 3 0.290.66 0015 172 DKLS67 mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG 1544.53 53% 60% 2 0.16 0.57 2961 173 DKLS88mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC 14 42.64 50% 57% 1 0.17 0.452074 174 DKLS34 mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA 13 37.19 46% 62%1 0.25 0.72 2515 175 DKLS97 mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC 12 35.950% 58% 1 0.17 0.42 0986 176 DKLS41 mG*mU*mG*mC*mA*mU*mG*mG*mA*mA*mU 1131.59 45% 64% 0 0.04 0.28 4293 177 DKLS36 mG*mU*mG*mC*mA*mU*mG*mG*mA*mA10 29.46 50% 70% 1 0.30 0.61 9957 178 DKLS33 mG*mU*mG*mC*mA*mU*mG*mG*mA9 26.3 56% 67% 0 0.06 0.15 0818 179 DKLS88 mG*mU*mG*mC*mA*mU*mG*mG 821.3 63% 63% 0 -0.05 -0.01 1730 180 DKLS40mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 19 54.65 53%63% 2 0.56 2.32 3667 181 DKLS47mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 18 53.62 56% 67% 30.50 1.00 4224 182 DKLS95mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 17 48.98 53% 65% 30.37 0.77 9154 183 DKLS48mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 16 48.43 50% 69% 1 0.060.78 5681 184 DKLS46 mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 1548.14 53% 67% 1 0.11 0.66 3625 185 DKLS79mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 14 46.3 57% 71% 1 0.16 0.479151 186 DKLS96 mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 13 40.02 54% 69%0 0.08 0.25 5031 187 DKLS53 mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 12 36.650% 67% 0 0.05 0.30 0510 188 DKLS88 mA*mU*mC*mA*mC*mG*mG*mA*mG*mU*mG 1134.73 55% 64% 0 0.04 0.26 1554 189 DKLS90 mU*mC*mA*mC*mG*mG*mA*mG*mU*mG10 33.05 60% 60% 0 0.08 0.25 9932 190 DKLS83mU*mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG*mU 18 53.27 50% 61% 00.55 2.74 5077 191 DKLS67mG*mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA*mG 16 51.36 56% 69% 2 0.180.56 0217 192 DKLS50 mC*mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG*mA 14 42.6250% 64% 2 0.56 0.80 2504 193 DKLS47 mA*mU*mG*mG*mA*mA*mU*mC*mA*mC*mG*mG12 38.7 50% 67% 0 0.03 0.26 2198 194 DKLS47mU*mG*mG*mA*mA*mU*mC*mA*mC*mG 10 28.73 50% 60% 0 0.06 0.22 5358 195DKLS53 mG*mG*mA*mA*mU*mC*mA*mC 8 14.6 50% 63% 0 0.10 0.01 4320 196DKLS63 mC*mA*mC*mG*mU*mA*mC*mC*mU*mU*mA*mG*mU*mG*mC*mC*mU*mC*mA*mC*mC*m30 58.86 53% 33% 1 0.63 2.24 6275 A*mC*mG*mU*mA*mC*mC*mU*mU 197 DKLS61mC*mA*mC*mG*mG*mA*mG*mU*mG 9 28.7 67% 67% 0 0.04 0.14 5979 198 DKLS65mC*mA*mC*mG*mU*mA*mC*mC*mU*mU*mA*mG*mU*mG*mC*mC*mU*mC*mA*mC 20 51.56 55%35% 1 0.32 0.80 9460 199 DKLS64 mC*mA*mC*mG*mU*ACCTTAGTGCmC*mU*mC*mA*mC20 50.96 55% 35% 0 0.05 0.20 6683 200 DKLS96mCmAmCmGmUmAmCmCmUmUmAmGmUmGmCmCmUmCmAmC 20 51.56 55% 35% 0 0.04 0.016527 201 DKLS33 mC*mA*mC*mGmUmAmCmCmUmUmAmGmUmGmCmCmU*mC*mA*mC 20 51.5655% 35% 0 0.02 0.08 3772 202 DKLS98 mA*mC*mG*mG*mA*mG*mU*mG 8 24.9 63%75% 0 0.04 0.29 1407 203 DKLS66 G*U*G*C*A*U*G*G*A*A*U*C*A*C*G*G*A*G*U*G20 56.3 55% 65% 3 0.76 1.30 9778 204 DKLS40mC*mA*mC*mG*mU*mA*mC*mC*mU*mU*mA*mG*mU*mG*mC 15 41.13 53% 40% 0 0.120.73 4613 205 DKLS64 mC*mA*mC*mG*mU*mA*mC*mC*mU*mU 10 20.92 50% 30% 0-0.14 0.17 9547 206 DKLS43mG*mC*mG*mC*mU*mU*mA*mC*mC*mG*mU*mU*mC*mC*mU*mC*mA*mA*mC*mA 20 49.41 55%35% 1 0.71 2.07 8994 207 DKLS49mG*mC*mA*mC*mG*mU*mC*mU*mC*mG*mC*mU*mC*mC*mA*mA*mU*mC*mU*mA 20 50.7 55%35% 1 0.46 1.67 1049 208 DKLS46mG*mA*mC*mG*mU*mA*mC*mC*mU*mU*mA*mG*mU*mA*mC*mC*mC*mC*mA*mC 20 53.99 55%40% 0 0.23 1.03 6380 209 DKLS40mC*mA*mC*mG*mU*mA*mC*mC*mU*mU*mA*mG*mA*mG*mC*mU*mU*mC*mC*mC 20 50.63 55%35% 1 0.30 1.18 4663 210 DKLS64mC*mA*mG*mG*mA*mA*mC*mG*mU*mA*mA*mG*mU*mG*mG*mG*mU*mC*mA*mC 20 56.46 55%65% 1 1.46 6.75 5944 211 DKLS62mC*mA*mC*mG*mU*mA*mG*mC*mA*mG*mA*mG*mU*mG*mG*mG*mA*mC*mA*mC 20 61.23 60%65% 1 1.73 16.20 7907 212 DKLS34mCmUmCmAmUmUmCmCmUmAmCmCmGmAmCmAmCmCmCmC 20 54.34 60% 25% 0 0.08 0.371370 213 DKLS77mA*mG*mG*mA*mA*mG*mA*mG*mA*mG*mG*mG*mA*mA*mA*mG*mA*mG*mA*mG 20 64.39 50%100% 0 2.02 13.19 6792 214 DKLS40mA*mG*mG*mG*mA*mG*mA*mG*mA*mA*mG*mA*mA*mG*mA*mG*mG*mA*mG*mA 20 65.82 50%100% 0 2.61 2835 215 DKLS44 mA*mG*mG*mA*mA*mG*mA*mG*mA*mG*mG*mG*mA*mA*mA15 54.64 47% 100% 0 2.39 4294 216 DKLS65mA*mG*mG*mG*mA*mG*mA*mG*mA*mA*mG*mA*mA*mG*mA 15 54.04 47% 100% 0 1.006105 217 DKLS49 mA*mG*mG*mA*mA*mG*mA*mG*mA*mG 10 34.61 50% 100% 0 -0.062769 218 DKLS46 GUGCAUGGAAUCACGGAGUG 20 56.3 55% 65% 0 -0.05 -0.01 6440219 DKLS69 mU*mC*mC*mU*mU*mC*mU*mC*mU*mC*mC*mC*mU*mU*mU*mC*mU*mC*mU*mC20 42.5 50% 0% 0 0.08 3540 220 DKLS40mC*mU*mU*mU*mC*mU*mC*mC*mU*mC*mC*mU*mC*mU*mC*mC*mU*mU*mU*mC 20 39.66 50%0% 0 0.06 3215 221 DKLS95 mU*mC*mC*mU*mU*mC*mU*mC*mU*mC*mC*mC*mU*mU*mU15 32.98 47% 0% 0 -0.08 1212 222 DKLS67mC*mU*mU*mU*mC*mU*mC*mC*mU*mC*mC*mU*mC*mU*mC 15 33.99 53% 0% 0 0.05 9059223 DKLS80 mG*mU*mG*mC*mC*mU*mG*mU*mU*mA*mU*mC*mA*mC*mG*mC*mU*mC*mU*mG20 49.62 55% 35% 1 0.15 2578 224 DKLS41mC*mA*mG*mA*mG*mG*mC*mA*mG*mC*mA*mA*mU*mA*mA*mG*mA*mA*mG*mG 20 57.81 50%80% 2 0.59 0263 225 DKLS55mC*mG*mU*mG*mA*mC*mG*mA*mA*mG*mG*mA*mG*mU*mC*mG*mU*mC*mA*mC*mG 21 54.8762% 62% 2 0.43 1191 226 DKLS54mC*mU*mG*mU*mA*mC*mG*mC*mG*mC*mG*mA*mA*mC*mG*mU*mA*mC*mA*mG 20 53.77 60%55% 2 0.84 0345 227 DKLS88mC*mU*mG*mU*mA*mC*mG*mA*mG*mG*mA*mG*mA*mC*mG*mU*mA*mC*mA*mG 20 55.09 55%65% 2 0.38 5676 228 DKLS62mA*mG*mU*mC*mG*mC*mG*mC*mG*mG*mG*mA*mU*mG*mA*mC*mG*mC*mG*mA*mC* 22 64.268% 59% 1 0.73 9224 mU 229 DKLS48mC*mG*mU*mG*mA*mC*mG*mA*mC*mU*mC*mC*mU*mU*mC*mG*mU*mC*mA*mC*mG 21 51.1762% 38% 2 0.25 2695 230 DKLS54mC*mU*mG*mU*mA*mC*mG*mU*mU*mC*mG*mC*mG*mC*mG*mU*mA*mC*mA*mG 20 49.28 60%45% 2 0.47 6051 231 DKLS57mC*mU*mG*mU*mA*mC*mG*mU*mC*mU*mC*mC*mU*mC*mG*mU*mA*mC*mA*mG 20 48.02 55%35% 1 0.18 4356 232 DKLS58mA*mG*mU*mC*mG*mC*mG*mU*mC*mA*mU*mC*mC*mC*mG*mC*mG*mC*mG*mA*mC*m 2259.15 68% 41% 1 0.55 0658 U 233 DKLS38mG*mA*mA*mG*mC*mG*mU*mG*mA*mC*mG*mA*mA*mG*mG*mA*mG*mU*mC*mG*mU* 25 60.6460% 68% 2 1.14 9392 mC*mA*mC*mG 234 DKLS37mG*mA*mA*mG*mC*mG*mU*mG*mA*mC*mG*mA*mC*mU*mC*mC*mU*mU*mC*mG*mU* 25 57.4260% 48% 2 0.77 9914 mC*mA*mC*mG 235 DKLS87mC*mG*mU*mG*mA*mC*mG*mA*mA*mG*mG*mA*mG*mU*mC*mG*mU*mC*mA*mC*mG* 25 60.0860% 68% 2 0.77 2305 mG*mA*mA*mG 236 DKLS36mC*mG*mU*mG*mA*mC*mG*mA*mC*mU*mC*mC*mU*mU*mC*mG*mU*mC*mA*mC*mG*m 2556.93 60% 48% 2 0.60 1530 G*mA*mA*mG 237 DKLS32mA*mC*mC*mG*mA*mA*mC*mA*mA*mU*mA*mA*mA*mU*mC*mC*mA*mC*mU*mA 20 47.12 35%55% 1 0.48 3181 238 DKLS56mU*mG*mU*mU*mG*mU*mA*mU*mG*mU*mC*mC*mG*mU*mG*mC*mG*mA*mA*mA 20 45.44 45%50% 2 0.98 8543 239 DKLS56mC*mG*mG*mA*mC*mC*mG*mU*mG*mC*mU*mC*mC*mA*mC*mG*mG*mU*mU*mC 20 57.66 70%40% 2 0.52 5265 240 DKLS60mG*mU*mU*mA*mG*mA*mC*mC*mG*mU*mA*mC*mU*mG*mU*mG*mU*mA*mU*mU 20 41.74 40%45% 2 0.59 8727 241 DKLS60mG*mG*mA*mG*mC*mA*mA*mC*mG*mU*mU*mC*mG*mG*mG*mU*mC*mA*mC*mG 20 56.72 65%60% 0 0.87 7664 242 DKLS60mC*mU*mC*mG*mC*mU*mG*mG*mA*mG*mC*mC*mA*mU*mC*mU*mU*mA*mC*mG 20 53.28 60%40% 0 0.19 3765 243 DKLS55mA*mA*mC*mU*mA*mA*mG*mU*mC*mG*mC*mC*mA*mC*mC*mG*mC*mA*mU*mC 20 55.14 55%45% 0 0.25 7745 244 DKLS60mA*mU*mU*mC*mG*mU*mA*mU*mG*mA*mG*mA*mA*mC*mU*mA*mU*mC*mU*mG 20 41.33 35%50% 1 0.17 1882 245 DKLS59mA*mA*mU*mG*mC*mG*mG*mU*mC*mG*mG*mU*mC*mC*mG*mC*mA*mU*mA*mU 20 52.97 55%50% 2 1.20 6033 246 DKLS59mC*mA*mG*mA*mG*mG*mG*mC*mA*mU*mC*mG*mC*mU*mU*mA*mG*mU*mU*mG 20 51.28 55%55% 0 2.10 5384 247 DKLS59mU*mC*mG*mU*mG*mA*mU*mA*mU*mC*mU*mA*mA*mG*mG*mU*mG*mC*mC*mC 20 51.8 50%45% 2 1.05 0665 248 DKLS59mU*mC*mC*mU*mU*mU*mU*mU*mA*mU*mU*mU*mU*mU*mC*mG*mG*mG*mU*mG 20 32.86 35%25% 1 0.39 0552 249 DKLS59mA*mC*mU*mU*mG*mC*mA*mA*mG*mU*mG*mC*mU*mC*mG*mA*mC*mG*mA*mG 20 54.47 55%55% 1 1.52 0093 250 DKLS58mG*mG*mG*mC*mG*mC*mU*mA*mC*mU*mA*mC*mG*mG*mU*mC*mA*mU*mU*mC 20 55.9 60%45% 1 0.83 7566 251 DKLS58mC*mG*mC*mC*mU*mC*mU*mG*mG*mU*mU*mU*mA*mG*mG*mC*mG*mU*mC*mA 20 51.27 60%40% 2 0.55 6797 252 DKLS58mU*mA*mU*mU*mG*mC*mC*mG*mA*mU*mU*mG*mG*mU*mG*mG*mG*mU*mA*mG 20 50.37 50%55% 2 0.69 2677 253 DKLS54mG*mA*mC*mA*mG*mA*mC*mA*mG*mU*mA*mG*mG*mA*mC*mU*mA*mU*mG*mG 20 57.67 50%70% 3 0.89 6680 254 DKLS53mC*mC*mG*mC*mC*mC*mU*mU*mU*mU*mU*mA*mU*mC*mC*mA*mA*mC*mC*mA 20 43.92 50%25% 0 0.23 0372 255 DKLS51mC*mC*mG*mC*mU*mG*mC*mC*mG*mC*mC*mC*mC*mU*mC*mA*mA*mC*mU*mA 20 61.69 70%30% 0 0.31 9203 256 DKLS71mU*mU*mC*mU*mG*mU*mC*mG*mA*mG*mU*mC*mA*mC*mU*mU*mG*mU*mC*mA 20 42.75 45%35% 1 0.83 1434 257 DKLS52mG*mA*mC*mG*mG*mG*mC*mC*mC*mA*mA*mG*mG*mU*mU*mC*mU*mC*mC*mA 20 60.36 65%50% 0 1.33 0505 258 DKLS82mU*mU*mC*mC*mG*mU*mC*mA*mG*mG*mC*mU*mC*mG*mG*mG*mU*mU*mC*mG 20 52.67 65%40% 2 0.52 7594 259 DKLS77mU*mC*mG*mU*mU*mU*mG*mA*mG*mG*mC*mA*mA*mG*mA*mU*mG*mC*mG*mU 20 49.89 50%55% 2 0.22 5409 260 DKLS86mG*mU*mG*mU*mG*mU*mA*mU*mU*mC*mG*mU*mG*mG*mG*mC*mU*mA*mG*mG 20 51.32 55%55% 0 0.90 5397 261 DKLS52mU*mU*mG*mA*mU*mC*mU*mA*mU*mU*mC*mU*mU*mU*mC*mG*mC*mA*mG*mG 20 39.52 40%35% 2 0.36 0022 262 DKLS46mU*mA*mG*mC*mC*mA*mC*mC*mC*mA*mU*mA*mA*mA*mU*mC*mA*mC*mG*mC 20 54.53 50%45% 0 0.16 3500 263 DKLS78mA*mA*mG*mG*mA*mG*mU*mU*mU*mG*mU*mA*mG*mC*mA*mC*mA*mC*mU*mC 20 50.1 45%55% 2 0.79 4557 264 DKLS48mC*mG*mC*mA*mU*mA*mU*mG*mA*mA*mA*mC*mU*mC*mA*mU*mA*mC*mU*mG 20 45.35 40%50% 2 0.24 4519 265 DKLS83mU*mA*mU*mC*mA*mG*mC*mC*mC*mG*mU*mU*mG*mU*mA*mC*mA*mG*mC*mA 20 50.45 50%45% 1 1.16 1379 266 DKLS93mG*mC*mA*mA*mA*mA*mC*mG*mU*mC*mG*mG*mG*mG*mU*mU*mA*mU*mU*mU 20 45.91 45%55% 0 3.73 6805 267 DKLS83mC*mC*mU*mU*mU*mU*mG*mC*mC*mC*mU*mC*mG*mU*mG*mA*mU*mG*mA*mA 20 45.43 50%35% 0 0.75 4800 268 DKLS80mU*mU*mG*mC*mC*mG*mU*mC*mC*mG*mU*mC*mU*mC*mA*mC*mC*mC*mU*mU 20 50.67 60%20% 0 0.06 7309 269 DKLS17mA*mU*mG*mC*mU*mA*mG*mG*mA*mG*mC*mU*mC*mU*mG*mC*mC*mG*mA*mA 20 59.49 55%55% 2 1.30 8323 270 DKLS62mC*mU*mG*mC*mA*mC*mC*mC*mG*mA*mC*mG*mA*mA*mC*mU*mC*mU*mG*mU 20 57.53 60%40% 1 0.19 9418 271 DKLS68mC*mC*mG*mA*mC*mC*mA*mC*mG*mG*mC*mG*mG*mG*mA*mA*mU*mU*mG*mU 20 59.03 65%55% 2 0.75 7192 272 DKLS70mU*mU*mU*mU*mA*mA*mG*mC*mG*mC*mA*mA*mA*mA*mA*mA*mU*mA*mA*mG 20 37.88 25%65% 3 0.52 6542 273 DKLS70mC*mG*mC*mU*mG*mG*mU*mG*mG*mG*mC*mG*mC*mG*mG*mC*mG*mG*mA*mG 20 69.23 85%65% 0 1.17 0850 274 DKLS79mC*mG*mC*mA*mC*mG*mG*mU*mA*mU*mG*mU*mU*mC*mC*mU*mA*mG*mU*mU 20 45.68 50%40% 2 0.29 2825 275 DKLS79mU*mG*mC*mC*mG*mG*mG*mA*mC*mC*mG*mA*mU*mU*mA*mU*mG*mG*mG*mC 20 62.55 65%55% 0 1.19 2598 276 DKLS82mG*mU*mU*mG*mG*mG*mU*mC*mC*mG*mU*mG*mU*mG*mG*mA*mU*mA*mU*mC 20 50.98 55%50% 0 0.61 1415 277 DKLS83mC*mU*mC*mC*mU*mC*mC*mC*mU*mU*mA*mC*mG*mG*mA*mC*mA*mC*mU*mC 20 64.1 64%25% 1 0.70 0.68 2163 278 DKLS69mC*mU*mC*mU*mU*mG*mG*mC*mU*mG*mA*mG*mC*mC*mC*mA*mU*mC*mU*mC 20 64.6 65%30% 1 0.85 1.30 6616 279 DKLS37mG*mU*mC*mU*mC*mC*mG*mU*mC*mG*mU*mC*mA*mU*mG*mC*mU*mG*mC*mC 20 68.9 69%30% 1 0.68 0480 280 DKLS36mC*mU*mC*mG*mG*mC*mA*mC*mC*mC*mC*mA*mC*mU*mG*mG*mA*mU*mG*mG 20 68.5 69%45% 1 0.93 4918 281 DKLS32mG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC*mG*mA*mU*mC 20 55.5 56%50% 1 9687 282 DKLS63mG*mA*mG*mC*mC*mG*mU*mG*mG*mG*mG*mU*mG*mA*mC*mC*mU*mA*mC*mC 20 68 68%50% 1 1.28 6117 283 DKLS61mG*mA*mC*mU*mU*mC*mG*mC*mA*mU*mG*mG*mG*mA*mA*mA*mC*mC*mA*mC 20 62.1 62%55% 1 0.81 2200 284 DKLS86mG*mG*mU*mC*mA*mC*mU*mC*mG*mG*mC*mC*mU*mG*mA*mA*mC*mG*mG*mA 20 66.6 67%55% 1 0834 285 DKL4533mC*mG*mG*mC*mU*mG*mU*mC*mA*mU*mC*mU*mC*mC*mG*mC*mG*mC*mG*mG 20 70.8 71%40% 2 1.95 2.14 158 286 DKLS64mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 20 68.6 69%45% 2 5702 287 DKLS62mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*mU 20 68.6 69%45% 2 1.53 1.56 3338 288 DKLS40mC*mU*mG*mA*mA*mG*mC*mG*mU*mA*mC*mC*mC*mU*mU*mU*mG*mG*mU*mG 20 67.8 68%45% 2 0.98 0.75 9068 289 DKLS68mG*mA*mU*mG*mA*mC*mC*mU*mC*mC*mC*mC*mU*mG*mC*mA*mG*mG*mU*mA 20 66.4 66%45% 2 1.25 1.36 4387 290 DKLS48mC*mU*mC*mG*mG*mG*mU*mG*mA*mU*mU*mA*mC*mG*mA*mU*mC*mG*mC*mG 20 62.3 62%50% 2 1.29 1.11 4655 291 DKLS77mC*mA*mG*mC*mU*mC*mG*mU*mC*mC*mA*mU*mG*mC*mC*mG*mA*mG*mA*mG 20 66.9 67%50% 2 1111 292 DKLS82mA*mC*mG*mA*mU*mA*mG*mU*mC*mC*mC*mU*mG*mC*mC*mG*mC*mG*mA*mG 20 67.7 68%50% 2 1.02 0.42 0087 293 DKLS81mU*mA*mG*mU*mC*mC*mG*mC*mU*mU*mA*mC*mG*mC*mC*mG*mA*mG*mA*mG 20 65 65%50% 2 0.72 7322 294 DKLS67mC*mU*mG*mC*mU*mC*mC*mU*mC*mC*mU*mU*mC*mC*mC*mG*mU*mA*mA*mG 20 64.6 65%25% 0 0.50 5388 295 DKLS82mC*mU*mA*mC*mU*mG*mG*mA*mG*mG*mG*mG*mA*mC*mG*mU*mC*mC*mA*mU 20 65.8 66%55% 2 1.14 1.43 7917 296 DKLS84mA*mG*mG*mC*mA*mA*mG*mT*mC*mC*mG*mG*mC*mT*mC*mA*mC*mT*mG*mG 20 63.2 63%55% 2 3537 297 DKLS85mC*mU*mU*mG*mG*mG*mG*mG*mG*mU*mC*mU*mA*mG*mA*mG*mG*mA*mA*mG 20 65.2 65%70% 2 3.04 9480 298 DKLS37mC*mG*mG*mA*mU*mG*mG*mA*mA*mA*mA*mG*mG*mG*mU*mC*mC*mA*mG*mU 20 63.1 63%70% 2 2.60 1.65 1273 299 DKLS65mG*mA*mG*mG*mA*mG*mG*mG*mA*mA*mU*mG*mC*mC*mU*mG*mU*mG*mA*mG 20 64.6 65%75% 2 2.46 8030 300 DKLS50mA*mC*mC*mG*mA*mA*mC*mG*mG*mA*mC*mA*mU*mU*mU*mC*mG*mA*mA*mG 20 58.3 58%60% 3 0.91 0.68 6891 301 DKLS66mG*mC*mC*mG*mA*mC*mA*mG*mU*mA*mG*mA*mG*mG*mC*mG*mC*mG*mC*mC 20 72.4 72%60% 3 1.51 0.88 5920 302 DKLS64mG*mA*mA*mC*mC*mC*mC*mC*mC*mA*mG*mA*mU*mC*mU*mC*mC*mU*mU*mC 20 64.9 65%30% 0 1.90 0.49 9218 303 DKLS99mG*mA*mG*mA*mA*mC*mC*mG*mA*mC*mU*mC*mG*mG*mG*mU*mA*mG*mA*mG 20 63.3 63%70% 3 1.15 1.09 1101 304 DKLS78mG*mC*mC*mU*mA*mC*mC*mU*mU*mU*mU*mC*mC*mC*mA*mG*mG*mU*mC*mA 20 64.3 64%30% 0 0.67 0.88 9189 305 DKLS65mC*mA*mC*mC*mU*mA*mG*mU*mC*mC*mC*mU*mU*mC*mC*mU*mC*mG*mA*mG 20 64 64%30% 0 0.78 1753

Oligomer Length

Increasing the size of a potent tumor-modulating oligomer (e.g., open_Aand ATG_LSA) from 20 nucleobases to 30 nucleobases, reduced orcompletely abrogated the tumor-modulating phenotype. Decreasing the sizeto 15 or 10 nucleobases also reduced or abrogated the phenotype. Whenthe size was reduced incrementally, by removing one nucleobase fromeither the 5′ or 3′ end, potency was maintained for the first 4-5nucleobases removed from either end, followed by a gradual decrease inpotency for the removal of the subsequent nucleobases (see, TABLE 8).Similarly, when one nucleobase was simultaneously removed from each end,potency was lost after removal of 6 nucleobases. The results exploringthe influence of oligomer length on tumor-modulating activity aresummarized in FIG. 8. These findings suggest that the minimum sizerequired for maintained potency of LSA oligomer compounds is 14-16nucleobases and the maximum size is 28-29 nucleobases.

Chemistry

Oligomeric compounds were synthesized using ZEN chemistry (proprietaryto IDT), which comprises a fully 2′-O-methyl modified sugar nucleobasebackbone with two internal ZEN™ modifications at or near the ends of theoligomer. The 2′-O-methyl residues confer resistance to endonucleasedegradation and increases binding affinity to RNA targets, while the ZENmodification blocks exonuclease degradation and further increasesbinding affinity. These compounds are referred to herein as ZENoligomers. All ZEN oligomers corresponding to cell death-inducing LSAoligomer sequences completely lost cell death inducing potency. Also aphosphodiester (PD) backbone with no other modification of thenucleobases, or a PD backbone with full 2′-O-methyl modified sugarnucleobases completely abrogated the killing effect. Maintaining full2′-O-methyl modifications but only three phosphorothioate (PS) residueson each end of the oligomer weakened the killing effect, as did gapmerswith non-modified DNA in the middle section of the oligomers. It wasconcluded that oligomeric compounds which preferably have a full PSbackbone and optionally no other modifications, was the preferredchemistry required for maintained and even increased killing effect ofthe oligomers, as well as binding to one or both of THOC4 and hSSB1(see, TABLE 8).

Pyrimidine/Purine Content

The results from the screen revealed that oligomer compounds required aminimum purine content of 50% for tumor-modulating activity, or a aminimum purine content of 45% with a minimum GC content of 50% fortumor-modulating activity and that there is a positive correlationbetween tumor-modulating activity and increased purine content. However,purine content alone is not sufficient to predict activity, as someoligomer compounds with high purine content are not effective. Oligomersdesigned to contain only purines (A and G) or pyrimidines (C and U) werealso ineffective, suggesting a mix of nucleobases is required foractivity (see, TABLE 8). The results exploring the influence of purinecontent on tumor-modulating activity are summarized in FIG. 9.

A number of antisense oligomeric compounds from the literature, some ofwhich are currently in clinical trials for various conditions includingcancer (BCL2 Oblimersen, SMN2-N1, dystrophin, clusterin, survivin,EIF4EASO4, Hsp27, Stat3), were modified to match the oligomer chemistrydescribed herein and screened for activity. Specifically, these modifiedliterature oligomers were designed to have a full PS backbone and full2′-O-methyl modified nucleobases and these oligomers were compared tosome of the most potent LSA oligomers tested, IN3LSA, ATG_LSA or Open A.Among the modified literature oligomeric compounds tested, only oneoligomer, dystrophin and one control oligomer HSP27 mm scored thehighest death score of 3 compared to oligomers IN3 LSA, ATG_LSA orOpen_A disclosed herein, with the majority of modified literatureoligomers showing weaker cell death-inducing capacity (scores of 2 or1), as compared to IN3 LSA, ATG_LSA or Open_A (see, TABLE 8).

Example 6 Oligomer Compounds Inhibit Tumor Cells Growth In Vivo

In vivo study

Non-targeting oligomers were tested in vivo in a prostate xenograftmodel. Specifically, 6-wk old SCID males were injected subcutaneouslywith C42B prostate cancer cells. Once the tumors reached a volume of 50mm³, the mice were treated with two of tumor-modulating non-targetingoligomers, In3LSA and ATGLSA, alongside a non effective control sequenceand PBS. Oligomer drugs were administered by intravenous injection twiceweekly at a dose of 80 mg/kg for four weeks. Tumor growth was monitoredby caliper measurements during the time of treatment. A statisticallysignificant retardation of tumor growth was observed (see, FIG. 10) forthe IN3LSA (In3) and ATGLSA (ATG) treated mice, as compared to control(ctrl) and PBS treated mice (FIG. 11), which demonstrate that thesenon-targeting oligomers had no significant toxicity on treated mice.

During the time of treatment, mice weight was monitored but nosignificant difference of weight loss was observed between IN3LSA (In3)and ATGLSA (ATG) treated mice, as compared to control (ctrl) and PBStreated mice. Notably, no weight loss was observed for mice with themost reduced tumors for IN3LSA and ATGLSA treated groups (FIG. 12),showing that the weight loss observed in FIG. 11 was most likely due totumor burden.

Example 7 Oligomer Compounds are Taken Up by Tumor Cells In Vivo

Uptake of oligomer compounds in the tumor site was investigatedfollowing intraperitoneal and intravenous delivery, by injecting afluorescently labeled IN3LSA oligomer and monitoring the mice for 7days. As shown in FIG. 13, the fluorescence signal was not detectedfollowing i.p. injections. However, the signal following i.v. injectionswas several log scales higher at the tumor site and importantly, thesignal persisted for seven days post injection, suggesting that the LSAoligomer selectively accumulates at the tumor site. These results areconsistent with whole mouse imaging analysis shown in FIG. 14.

Example 8 Oligomer Compounds Act Through theOligonucleotide/Oligosaccharide-Binding (OB) Fold-Containing Family ofProteins

FAM-labeled non-targeting PS compound, LSA_In3E3, PD compounds,DNA_In3E3 and RNA_In3E3, and a negative control oligomer compound, NEGC,were incubated separately with purified mouse SSB1 (mSSB1), hSSB1 andhuman SSB2 (hSSB2) proteins. Bound and free oligomers were separated bynative gel electrophoresis and as shown in FIGS. 15 and 16 and TABLES9-10, the OB-fold proteins, mSSB1, hSSB1 and hSSB2, retarded themigration of the tumor-modulating oligomer (LSA_In3E3) at a much greaterlevel than the non-toxic oligomers (DNA_In3E3, RNA_In3E3 and NEGC),indicating that tumor-modulating oligomer has significantly higheraffinity to the OB-fold proteins than the non-toxic oligomers.

TABLE 9 KD (nM) mSSB1 LSA_In3E3 DNA_In3E3 NegC 4.133 13.12 15.4

TABLE 9 summarizes the results of triplicate EMSA experiments performedwith mSSB1 and three different oligomer compounds, as set out below.Dissociation constants for individual mSSB1:oligomer interactions areshown (K_(D), concentration of protein at which 50% of oligonucleotideis bound to the protein at equilibrium).

Oligomer compounds used for TABLE 9 were as follows:

a) LSA_IN3E3 = [SEQ ID NO: 5]mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*Mu wherein m represents a 2′-Omethyl modified base, and * represents a PS inter- nucleoside linkage;b) DNA_In3E3 = [SEQ ID NO: 306]dCdCdAdGdUdGdAdGdCdCdGdGdAdCdUdUdGdCdCdU,wherein d represents a deoxyribonucleoside, and the oligomer comprises a PD internucleoside  linkage; and c) NEGC =[SEQ ID NO: 4] mC*mU*mC*mA*mU*mU*mC*mC*mU*mA*mC*mC*mG*mA*mC*mA*mC*mC*mC*mC, wherein m represents a 2′-Omethyl modified base, and * represents a PS inter- nucleoside linkage.

TABLE 10 KD (nM) hSSB1 LSA_IN3E3 DNA_In3E3 RNA_In3E3 NegC (PS) 3.29113.49 136.8 10.02

TABLE 10 summarizes the results of triplicate EMSA experiments performedwith hSSB1 and four different oligomer compounds, as set out below.Dissociation constants for individual mSSB1:oligomer interactions areshown (K_(D), concentration of protein at which 50% of oligonucleotideis bound to the protein at equilibrium).

Oligomer compounds used for TABLE 10 were as follows:

a) LSA_IN3E3 = [SEQ ID NO: 5]mC*mC*mA*mG*mU*mG*mA*mG*mC*mC*mG*mG*mA*mC*mU*mU*mG*mC*mC*Mu wherein m represents a 2′-Omethyl modified base, and * represents a PS inter- nucleoside linkage;b) DNA_In3E3 = [SEQ ID NO: 306]dCdCdAdGdUdGdAdGdCdCdGdGdAdCdUdUdGdCdCdU,wherein d represents a deoxyribonucleoside, and the oligomer comprises a PD internucleoside  linkage; and c) RNA_In3E3 =[SEQ ID NO: 307] rCrCrArGrUrGrArGrCrCrGrGrArCrUrUrGrCrCrU,wherein r represents a ribonucleoside, and theoligomer comprises a PD internucleoside linkage; c) NEGC =[SEQ ID NO: 4] mC*mU*mC*mA*mU*mU*mC*mC*mU*mA*mC*mC*mG*mA*mC*mA*mC*mC*mC*mC, wherein m represents a 2′-Omethyl modified base, and * represents a PS inter- nucleoside linkage.

Example 9 Molecular Simulation to Screen for Oligomers with GreaterhSSB1 Binding Affinity

Oligomer compounds with greater binding affinity to hSSB1 may also bedetermined using Atomistic Molecular Dynamics (AMD) simulations withsoftware such as OpenMM by Symbios. Simulations of hundreds of querysequences can be performed and free energy of binding determined foreach. FIG. 17 demonstrates that ATGLSA (killing sequence) binds hSSB1with a lower free energy of binding than the NegC (non killing sequence)to hSSB1 providing insight about the difference in lethality between thesequences and demonstrating the application of AMD simulations forfurther drug development. Such simulation software can be used to screenfor oligomer compounds with a lower free energy of binding and thus agreater binding affinity for hSSB1, providing a shortlist of improveddrug sequences which may have increased lethality and decreased offtarget effects.

FIGS. 17A and B show that human hSSB1 demonstrates a greater affinityfor the phosphorothioate backbone of the NEGC oligo than for thenucleotides themselves, this leaves the bases solvent exposed. hSSB1 hasa more favorable interaction with ATGLSA which leaves less of thenucleotides solvent exposed. When exposed to solvent these nucleotideswill interact with water, and this leaves the binding groove open tosolvent which will weaken the interaction with the oligomer. FIGS. 17Cand D shows that it takes less energy for ATGLSA to maintain itsinteraction with the binding groove of SSB1, demonstrating a bindingenergy 521 KJ/mol lower than NEGC. How this binding energy changes overthe simulation can be seen in FIG. 17D, which demonstrates aconsistently lower binding energy for ATGLSA than its nucleotidesequence, while NEGC has a binding energy that almost matches itsunmodified sequence.

Example 10 Oligomer Compounds Inhibit Tumor Cell Growth In Vivo in aLung Cancer Xenograft Model

Non-targeting oligomers were tested in vivo in a lung cancer xenograftmodel using the H460 lung cancer cell line. Specifically, 6-wk old SCIDmale mice (Animal Resources Centre—ARC, Canning Vale, Wash.) wereinjected sub-cutaneously in the flank with 2 millionLuciferase-expressing H460 lung cancer cells. Mice were subsequentlymonitored for tumor growth by palpation, caliper measurements andmeasure of the tumor bioluminescence signal with the IVIS scanningsystem. When the tumor volume reached an average of 50 mm³, mice wererandomly incorporated into either the PBS (vehicle control) group or thetumor-modulating non-targeting oligomer ATGLSA group (n=8 mice/treatmentgroup). Oligomer ATGLSA was diluted in PBS (Life Technologies) andadministered at the dose of 80 mg/kg via intravenous (i.v.) injectiontwice weekly for four weeks (for a total of 8 injections). During thecourse of the treatment, mice were monitored for weight and tumor growthby caliper measurements (volume calculated from the formula V=A/2×B2,with A=length >B=width in mm) and IVIS scan for bioluminescence signal.A statistically significant retardation of tumor growth was observed(see, FIG. 18) for the ATGLSA (ATG) treated mice, as compared to PBStreated mice, which demonstrate that these non-targeting oligomers hadchemostatic effect in a lung cancer xenograft model.

This difference in the tumor volume was confirmed by luciferase activityof the tumors. IVIS scans at day 14 of the treatment shows a lowerbioluminescence signal for the ATGLSA treated group compared to thecontrol PBS group (FIG. 19).

During the course of treatment, mice weight was monitored twice weekly.No significant weight loss, or loss of condition was observed in theanimals treated with PBS or ATGLSA, demonstrating that thesenon-targeting oligomers had no significant toxicity in treated mice(see, FIG. 20).

Example 11 Oligomer Compounds Inhibit Tumor Cell Growth inCisplatin-Resistant Lung Cancer In Vitro

The cisplatin-sensitive H460 lung cancer cell line was exposed toescalating doses of cisplatin over a three-month period to create acisplatin-resistant cell line. When tested in vitro, by measuring cellproliferation over 48 hours post addition of the non-targeting oligomerATGLSA (100 nM) using the Incucyte zoom system, ATGLSA was moreefficient at killing the cisplatin-resistant H460 cell line than theparental H460 cell line (FIG. 21).

Example 12 Oligomer Compounds Inhibit Tumor Cell Growth inCisplatin-Resistant Lung Cancer In Vivo

Non-targeting oligomers were tested in vivo in a lung cancer xenograftmodel using the cisplatin-resistant H460 lung cancer cell line.Specifically, 6-wk old SCID male mice (Animal Resources Centre—ARC,Canning Vale, Wash.) were injected sub-cutaneously in the flank with 2million Luciferase-expressing cisplatin-resistant H460 lung cancercells. Mice were subsequently monitored for tumor growth by palpation,caliper measurements and measure of the tumor bioluminescence signalwith the IVIS scanning system. When the tumor volume reached an averageof 50 mm³, mice were randomly incorporated into either the PBS (vehiclecontrol) group or the tumor-modulating non-targeting oligomer ATGLSAgroup (n=8 mice/treatment group). Oligonucleotide ATGLSA was diluted inPBS (Life Technologies) and administered at the dose of 80 mg/kg viaintravenous (i.v.) injection twice weekly for four weeks (for a total of8 injections). During the course of the treatment, mice were monitoredfor weight and tumor growth by caliper measurements (volume calculatedfrom the formula V=A/2×B², with A=length >B=width in mm) and IVIS scanfor bioluminescence signal. A statistically significant retardation oftumor growth was observed (see, FIG. 22) for the ATGLSA (ATG) treatedmice, as compared to PBS treated mice, which demonstrate that thesenon-targeting oligomers have chemostatic effect in a cisplatin-resistantlung cancer xenograft model.

The tumor volume difference was also validated by the luciferaseactivity of the tumor cells, as measured by the bioluminescence signalfor each tumor with IVIS scan (FIG. 23).

The present inventors did not observe any weight loss in the ATGLSAtreated cohort over the treatment time, nor did they discern anydifference in behavior or condition between the animals treated with PBSor ATGLSA. These results are in line with the parental H460 xenograftexperiment (FIG. 24).

Example 13 Long Term Effect of ATGLSA in Cisplatin-Sensitive andCisplatin-Resistant Lung Cancer Models In Vivo

To evaluate the long term effect of the ATGLSA treatment, tumor growthand mice weight were monitored post cessation of the 4-week treatment,until the tumors reached a final volume of 1000 mm³ and generated aKaplan-Meier graph. In the cisplatin-sensitive H460 model, the four-weekATGLSA treatment resulted in a statistically significant 41% (14 days)increase of the mice median survival in the ATGLSA treated group, ascompared to control group (FIG. 25 and Table 11).

TABLE 11 MEDIAN SURVIVAL OF SCID MALES WITH CISPLATIN- SENSITIVE H460AND CISPLATIN-RESISTANT LUNG H460 TUMOURS TREATED WITH CONTROL PBS VSATGLSA Cancer model PBS ATGLSA Lung H460 Cisplatin- Median survival(days) 35 49.5 sensitive P-value (Rank-Log test) 0.0051 Lung H460Cisplatin- Median survival (days) 48 66 resistant P-value (Rank-Logtest) 0.2032

In the cisplatin-resistant H460 model, a 37.5% (18 days) increasedmedian survival in the ATGLSA treated cohort was observed (FIG. 26),however, the difference between ATGLSA and the PBS control group was notstatistically significant in a Rank-Log test (Table 11).

Example 14 Atglsa Combination with Cisplatin Treatment in an In VivoLung Cancer Xenograft Model

Non-targeting oligomers were tested in vivo in a lung cancer xenograftmodel using the cisplatin-sensitive H460 lung cancer cell line.Specifically, 6-wk old SCID male mice (Animal Resources Centre—ARC,Canning Vale, Wash.) were injected sub-cutaneously in the flank with 2million Luciferase-expressing cisplatin-resistant H460 lung cancercells. Mice were subsequently monitored for tumor growth by palpation,caliper measurements and measure of the tumor bioluminescence signalwith the IVIS scanning system. When the tumor volume reached an averageof 50 mm³ (92% tumor intake), mice were randomly incorporated intoeither PBS control group, ATGLSA group, cisplatin group, or thecombination ATGLSA+Cisplatin group. Oligonucleotide ATGLSA was dilutedin PBS (Life Technologies) and administered at the dose of 80 mg/kg viaintravenous (i.v.) injection twice weekly. Cisplatin (in salinesuspension at 1 mg/kg, Hospira) was injected once a week byintra-peritoneal injection (4 mg/kg). Combination treatment groupreceived 2×ATGLSA (80 mg/kg) i.v injections and one cisplatin (4 mg/kg)i.p injection per week. Following 3 weeks of treatment all treatedcohorts has a significantly lower tumor growth compared to PBS however,there was no significant difference in tumor growth between the ATGLSA(ATG), cisplatin, and combination ATGLSA+Cisplatin (Combo) treatedcohorts (FIG. 27). At 3 weeks post treatment, the present inventorsswitched treatment between the groups (FIG. 28, dashed line): ATGLSAtreated mice were switched to Cisplatin (4 mg/kg, once a week, i.p),Cisplatin treated mice were switched to ATGLSA (80 mg/kg, i.v, twice aweek), and Combination ATGLSA+Cisplatin mice (Combo) became a controlPBS group (150 μL PBS, i.v, twice a week). We observed a significanttumor growth retardation in the ‘Cisplatin first/ATGLSA second’ treatedmice, with no tumor growth for the first days of treatment.

The weight of each animal was also monitored to check if the treatmentcould induce any acute toxicity in vivo. It was observed that while theATGLSA (ATG) compound had no significant impact on mouse weight loss at3 weeks of treatment as compared to PBS, a significant loss of weightwas observed in the cisplatin treated mice. This suggests that ATGLSA,while slowing tumor growth at the same rate as cisplatin, did not causeobvious adverse toxicity to the animal. Moreover, when switchingcisplatin treatment to ATGLSA, a statistically significant increase inmice weight was observed straight after the switch. This increaseremained stable for the rest of the treatment. Overall, the data showthat ATGLSA has chemostatic effect on lung cancer tumors and lung cancertumors that have developed resistance to cisplatin. The data also showthat a sequential treatment with ATGLSA post cisplatin is more efficientthan both drugs administered at the same time.

The disclosure of every patent, patent application, and publicationcited herein is hereby incorporated herein by reference in its entirety.

The citation of any reference herein should not be construed as anadmission that such reference is available as “Prior Art” to the instantapplication.

Throughout the specification the aim has been to describe the preferredembodiments of the invention without limiting the invention to any oneembodiment or specific collection of features. Those of skill in the artwill therefore appreciate that, in light of the instant disclosure,various modifications and changes can be made in the particularembodiments exemplified without departing from the scope of the presentinvention. All such modifications and changes are intended to beincluded within the scope of the appended claims.

What is claimed is:
 1. A method for inhibiting proliferation, survivalor viability of a tumor cell, the method comprising introducing into thetumor cell a nucleic acid oligomer that is characterized by: a) abackbone comprising phosphorothioate internucleoside linkages; b) (i) apurine content of at least about 50%, or (ii) a purine content of atleast about 45% with a guanosine-cytosine (GC) content of at least about50%; and c) a length of at least 14 nucleobases and no more than 29nucleobases, wherein the oligomer binds to one or both of a THO complexsubunit 4 (THOC4) protein and a single-stranded DNA-binding protein 1(SSB1).
 2. A method for inhibiting proliferation, survival or viabilityof a tumor cell, the method consisting essentially of introducing intothe tumor cell a nucleic acid oligomer that is characterized by: a) abackbone comprising phosphorothioate internucleoside linkages; b) (i) apurine content of at least about 50%, or (ii) a purine content of atleast about 45% with a guanosine-cytosine (GC) content of at least about50%; and c) a length of at least 14 nucleobases and no more than 29nucleobases, wherein the oligomer binds to one or both of a THO complexsubunit 4 (THOC4) protein and a single-stranded DNA-binding protein 1(SSB1).
 3. A method for inhibiting proliferation, survival or viabilityof a tumor cell, the method consisting of introducing into the tumorcell a nucleic acid oligomer that is characterized by: a) a backbonecomprising phosphorothioate internucleoside linkages; b) (i) a purinecontent of at least about 50%, or (ii) a purine content of at leastabout 45% with a guanosine-cytosine (GC) content of at least about 50%;and c) a length of at least 14 nucleobases and no more than 29nucleobases, wherein the oligomer binds to one or both of a THO complexsubunit 4 (THOC4) protein and a single-stranded DNA-binding protein 1(SSB1).
 4. The method of any one of claims 1 to 3, wherein the oligomerhas a length of 14 nucleobases.
 5. The method of claim 4, wherein theoligomer consists of 7 purines.
 6. The method of claim 4, wherein theoligomer consists of 6 purines and 7 G/C.
 7. The method of claim 4,wherein the oligomer consists of 8 purines.
 8. The method of claim 4,wherein the oligomer consists of 9 purines.
 9. The method of claim 4,wherein the oligomer consists of 10 purines.
 10. The method of claim 4,wherein the oligomer consists of 11 purines.
 11. The method of claim 4,wherein the oligomer consists of 12 purines.
 12. The method of claim 4,wherein the oligomer consists of 13 purines.
 13. The method of any oneof claims 1 to 3, wherein the oligomer has a length of 15 nucleobases.14. The method of claim 13, wherein the oligomer consists of 8 purines.15. The method of claim 13, wherein the oligomer consists of 7 purinesand 8 G/C.
 16. The method of claim 13, wherein the oligomer consists of9 purines.
 17. The method of claim 13, wherein the oligomer consists of10 purines.
 18. The method of claim 13, wherein the oligomer consists of11 purines.
 19. The method of claim 13, wherein the oligomer consists of12 purines.
 20. The method of claim 13, wherein the oligomer consists of13 purines.
 21. The method of claim 13, wherein the oligomer consists of14 purines.
 22. The method of any one of claims 1 to 3, wherein theoligomer has a length of 16 nucleobases.
 23. The method of claim 22,wherein the oligomer consists of 8 purines.
 24. The method of claim 22,wherein the oligomer consists of 7 purines and 8 G/C.
 25. The method ofclaim 22, wherein the oligomer consists of 9 purines.
 26. The method ofclaim 22, wherein the oligomer consists of 10 purines.
 27. The method ofclaim 22, wherein the oligomer consists of 11 purines.
 28. The method ofclaim 22, wherein the oligomer consists of 12 purines.
 29. The method ofclaim 22, wherein the oligomer consists of 13 purines.
 30. The method ofclaim 22, wherein the oligomer consists of 14 purines.
 31. The method ofclaim 22, wherein the oligomer consists of 15 purines.
 32. The method ofany one of claims 1 to 3, wherein the oligomer has a length of 17nucleobases.
 33. The method of claim 32, wherein the oligomer consistsof 9 purines.
 34. The method of claim 32, wherein the oligomer consistsof 8 purines and 9 G/C.
 35. The method of claim 32, wherein the oligomerconsists of 10 purines.
 36. The method of claim 32, wherein the oligomerconsists of 11 purines.
 37. The method of claim 32, wherein the oligomerconsists of 12 purines.
 38. The method of claim 32, wherein the oligomerconsists of 13 purines.
 39. The method of claim 32, wherein the oligomerconsists of 14 purines.
 40. The method of claim 32, wherein the oligomerconsists of 15 purines.
 41. The method of claim 32, wherein the oligomerconsists of 16 purines.
 42. The method of any one of claims 1 to 3,wherein the oligomer has a length of 18 nucleobases.
 43. The method ofclaim 42, wherein the oligomer consists of 9 purines.
 44. The method ofclaim 42, wherein the oligomer consists of 8 purines and 9 G/C.
 45. Themethod of claim 42, wherein the oligomer consists of 10 purines.
 46. Themethod of claim 42, wherein the oligomer consists of 11 purines.
 47. Themethod of claim 42, wherein the oligomer consists of 12 purines.
 48. Themethod of claim 42, wherein the oligomer consists of 13 purines.
 49. Themethod of claim 42, wherein the oligomer consists of 14 purines.
 50. Themethod of claim 42, wherein the oligomer consists of 15 purines.
 51. Themethod of claim 42, wherein the oligomer consists of 16 purines.
 52. Themethod of claim 42, wherein the oligomer consists of 17 purines.
 53. Themethod of any one of claims 1 to 3, wherein the oligomer has a length of19 nucleobases.
 54. The method of claim 53, wherein the oligomerconsists of 10 purines.
 55. The method of claim 53, wherein the oligomerconsists of 9 purines and 10 G/C.
 56. The method of claim 53, whereinthe oligomer consists of 11 purines.
 57. The method of claim 53, whereinthe oligomer consists of 12 purines.
 58. The method of claim 53, whereinthe oligomer consists of 13 purines.
 59. The method of claim 53, whereinthe oligomer consists of 14 purines.
 60. The method of claim 53, whereinthe oligomer consists of 15 purines.
 61. The method of claim 53, whereinthe oligomer consists of 16 purines.
 62. The method of claim 53, whereinthe oligomer consists of 17 purines.
 63. The method of claim 53, whereinthe oligomer consists of 18 purines.
 64. The method of any one of claims1 to 3, wherein the oligomer has a length of 20 nucleobases.
 65. Themethod of claim 64, wherein the oligomer consists of 10 purines.
 66. Themethod of claim 64, wherein the oligomer consists of 9 purines and 10G/C.
 67. The method of claim 64, wherein the oligomer consists of 11purines.
 68. The method of claim 64, wherein the oligomer consists of 12purines.
 69. The method of claim 64, wherein the oligomer consists of 13purines.
 70. The method of claim 64, wherein the oligomer consists of 14purines.
 71. The method of claim 64, wherein the oligomer consists of 15purines.
 72. The method of claim 64, wherein the oligomer consists of 16purines.
 73. The method of claim 64, wherein the oligomer consists of 17purines.
 74. The method of claim 64, wherein the oligomer consists of 18purines.
 75. The method of claim 64, wherein the oligomer consists of 19purines.
 76. The method of any one of claims 1 to 3, wherein theoligomer has a length of 21 nucleobases.
 77. The method of claim 76,wherein the oligomer consists of 11 purines.
 78. The method of claim 76,wherein the oligomer consists of 9 purines and 11 G/C.
 79. The method ofclaim 76, wherein the oligomer consists of 12 purines.
 80. The method ofclaim 76, wherein the oligomer consists of 13 purines.
 81. The method ofclaim 76, wherein the oligomer consists of 14 purines.
 82. The method ofclaim 76, wherein the oligomer consists of 15 purines.
 83. The method ofclaim 76, wherein the oligomer consists of 16 purines.
 84. The method ofclaim 76, wherein the oligomer consists of 17 purines.
 85. The method ofclaim 76, wherein the oligomer consists of 18 purines.
 86. The method ofclaim 76, wherein the oligomer consists of 19 purines.
 87. The method ofclaim 76, wherein the oligomer consists of 20 purines.
 88. The method ofany one of claims 1 to 3, wherein the oligomer has a length of 22nucleobases.
 89. The method of claim 88, wherein the oligomer consistsof 11 purines.
 90. The method of claim 88, wherein the oligomer consistsof 10 purines and 11 G/C.
 91. The method of claim 88, wherein theoligomer consists of 12 purines.
 92. The method of claim 88, wherein theoligomer consists of 13 purines.
 93. The method of claim 88, wherein theoligomer consists of 14 purines.
 94. The method of claim 88, wherein theoligomer consists of 15 purines.
 95. The method of claim 88, wherein theoligomer consists of 16 purines.
 96. The method of claim 88, wherein theoligomer consists of 17 purines.
 97. The method of claim 88, wherein theoligomer consists of 18 purines.
 98. The method of claim 88, wherein theoligomer consists of 19 purines.
 99. The method of claim 88, wherein theoligomer consists of 20 purines.
 100. The method of claim 88, whereinthe oligomer consists of 21 purines.
 101. The method of any one ofclaims 1 to 3, wherein the oligomer has a length of 23 nucleobases. 102.The method of claim 101, wherein the oligomer consists of 12 purines.103. The method of claim 101, wherein the oligomer consists of 10purines and 12 G/C.
 104. The method of claim 101, wherein the oligomerconsists of 13 purines.
 105. The method of claim 101, wherein theoligomer consists of 14 purines.
 106. The method of claim 101, whereinthe oligomer consists of 15 purines.
 107. The method of claim 101,wherein the oligomer consists of 16 purines.
 108. The method of claim101, wherein the oligomer consists of 17 purines.
 109. The method ofclaim 101, wherein the oligomer consists of 18 purines.
 110. The methodof claim 101, wherein the oligomer consists of 19 purines.
 111. Themethod of claim 101, wherein the oligomer consists of 20 purines. 112.The method of claim 101, wherein the oligomer consists of 21 purines.113. The method of claim 101, wherein the oligomer consists of 22purines.
 114. The method of any one of claims 1 to 3, wherein theoligomer has a length of 24 nucleobases.
 115. The method of claim 114,wherein the oligomer consists of 12 purines.
 116. The method of claim114, wherein the oligomer consists of 11 purines and 12 G/C.
 117. Themethod of claim 114, wherein the oligomer consists of 13 purines. 118.The method of claim 114, wherein the oligomer consists of 14 purines.119. The method of claim 114, wherein the oligomer consists of 15purines.
 120. The method of claim 114, wherein the oligomer consists of16 purines.
 121. The method of claim 114, wherein the oligomer consistsof 17 purines.
 122. The method of claim 114, wherein the oligomerconsists of 18 purines.
 123. The method of claim 114, wherein theoligomer consists of 19 purines.
 124. The method of claim 114, whereinthe oligomer consists of 20 purines.
 125. The method of claim 114,wherein the oligomer consists of 21 purines.
 126. The method of claim114, wherein the oligomer consists of 22 purines.
 127. The method ofclaim 114, wherein the oligomer consists of 23 purines.
 128. The methodof any one of claims 1 to 3, wherein the oligomer has a length of 25nucleobases.
 129. The method of claim 128, wherein the oligomer consistsof 13 purines.
 130. The method of claim 128, wherein the oligomerconsists of 11 purines and 13 G/C.
 131. The method of claim 128, whereinthe oligomer consists of 14 purines.
 132. The method of claim 128,wherein the oligomer consists of 15 purines.
 133. The method of claim128, wherein the oligomer consists of 16 purines.
 134. The method ofclaim 128, wherein the oligomer consists of 17 purines.
 135. The methodof claim 128, wherein the oligomer consists of 18 purines.
 136. Themethod of claim 128, wherein the oligomer consists of 19 purines. 137.The method of claim 128, wherein the oligomer consists of 20 purines.138. The method of claim 128, wherein the oligomer consists of 21purines.
 139. The method of claim 128, wherein the oligomer consists of22 purines.
 140. The method of claim 128, wherein the oligomer consistsof 23 purines.
 141. The method of claim 128, wherein the oligomerconsists of 24 purines.
 142. The method of any one of claims 1 to 3,wherein the oligomer has a length of 26 nucleobases.
 143. The method ofclaim 142, wherein the oligomer consists of 13 purines.
 144. The methodof claim 142, wherein the oligomer consists of 12 purines and 13 G/C.145. The method of claim 142, wherein the oligomer consists of 14purines.
 146. The method of claim 142, wherein the oligomer consists of15 purines.
 147. The method of claim 142, wherein the oligomer consistsof 16 purines.
 148. The method of claim 142, wherein the oligomerconsists of 17 purines.
 149. The method of claim 142, wherein theoligomer consists of 18 purines.
 150. The method of claim 142, whereinthe oligomer consists of 19 purines.
 151. The method of claim 142,wherein the oligomer consists of 20 purines.
 152. The method of claim142, wherein the oligomer consists of 21 purines.
 153. The method ofclaim 142, wherein the oligomer consists of 22 purines.
 154. The methodof claim 142, wherein the oligomer consists of 23 purines.
 155. Themethod of claim 142, wherein the oligomer consists of 24 purines. 156.The method of claim 142, wherein the oligomer consists of 25 purines.157. The method of any one of claims 1 to 3, wherein the oligomer has alength of 27 nucleobases.
 158. The method of claim 157, wherein theoligomer consists of 14 purines.
 159. The method of claim 157, whereinthe oligomer consists of 12 purines and 14 G/C.
 160. The method of claim157, wherein the oligomer consists of 15 purines.
 161. The method ofclaim 157, wherein the oligomer consists of 16 purines.
 162. The methodof claim 157, wherein the oligomer consists of 17 purines.
 163. Themethod of claim 157, wherein the oligomer consists of 18 purines. 164.The method of claim 157, wherein the oligomer consists of 19 purines.165. The method of claim 157, wherein the oligomer consists of 20purines.
 166. The method of claim 157, wherein the oligomer consists of21 purines.
 167. The method of claim 157, wherein the oligomer consistsof 22 purines.
 168. The method of claim 157, wherein the oligomerconsists of 23 purines.
 169. The method of claim 157, wherein theoligomer consists of 24 purines.
 170. The method of claim 157, whereinthe oligomer consists of 25 purines.
 171. The method of claim 157,wherein the oligomer consists of 26 purines.
 172. The method of any oneof claims 1 to 3, wherein the oligomer has a length of 28 nucleobases.173. The method of claim 172, wherein the oligomer consists of 14purines.
 174. The method of claim 172, wherein the oligomer consists of13 purines and 14 G/C.
 175. The method of claim 172, wherein theoligomer consists of 15 purines.
 176. The method of claim 172, whereinthe oligomer consists of 16 purines.
 177. The method of claim 172,wherein the oligomer consists of 17 purines.
 178. The method of claim172, wherein the oligomer consists of 18 purines.
 179. The method ofclaim 172, wherein the oligomer consists of 19 purines.
 180. The methodof claim 172, wherein the oligomer consists of 20 purines.
 181. Themethod of claim 172, wherein the oligomer consists of 21 purines. 182.The method of claim 172, wherein the oligomer consists of 22 purines.183. The method of claim 172, wherein the oligomer consists of 23purines.
 184. The method of claim 172, wherein the oligomer consists of24 purines.
 185. The method of claim 172, wherein the oligomer consistsof 25 purines.
 186. The method of claim 172, wherein the oligomerconsists of 26 purines.
 187. The method of claim 172, wherein theoligomer consists of 27 purines.
 188. The method of any one of claims 1to 3, wherein the oligomer has a length of 29 nucleobases.
 189. Themethod of claim 188, wherein the oligomer consists of 15 purines. 190.The method of claim 188, wherein the oligomer consists of 13 purines and15 G/C.
 191. The method of claim 188, wherein the oligomer consists of16 purines.
 192. The method of claim 188, wherein the oligomer consistsof 17 purines.
 193. The method of claim 188, wherein the oligomerconsists of 18 purines.
 194. The method of claim 188, wherein theoligomer consists of 19 purines.
 195. The method of claim 188, whereinthe oligomer consists of 20 purines.
 196. The method of claim 188,wherein the oligomer consists of 21 purines.
 197. The method of claim188, wherein the oligomer consists of 22 purines.
 198. The method ofclaim 188, wherein the oligomer consists of 23 purines.
 199. The methodof claim 188, wherein the oligomer consists of 24 purines.
 200. Themethod of claim 188, wherein the oligomer consists of 25 purines. 201.The method of claim 188, wherein the oligomer consists of 26 purines.202. The method of claim 188, wherein the oligomer consists of 27purines.
 203. The method of claim 188, wherein the oligomer consists of28 purines.
 204. The method of any one of claims 1 to 203, wherein atleast about 70% of the internucleoside linkages of the backbone comprisephosphorothioate (PS) internucleoside linkages.
 205. The method of claim204, wherein any non-PS internucleoside linkages are located at one orboth ends of the oligomer
 206. The method of claim 204 or claim 205,wherein any non-PS internucleoside linkages are located in a centralportion of the oligomer.
 207. The method of claim 204, wherein anynon-PS internucleoside linkages are dispersed throughout the oligomer.208. The method of any one of claims 204 to 207, wherein up to 9internucleoside linkages are non-PS internucleoside linkages.
 209. Themethod of any one of claims 204 to 207, wherein up to 8 internucleosidelinkages are non-PS internucleoside linkages.
 210. The method of any oneof claims 204 to 207, wherein up to 7 internucleoside linkages arenon-PS internucleoside linkages.
 211. The method of any one of claims204 to 207, wherein up to 6 internucleoside linkages are non-PSinternucleoside linkages.
 212. The method of any one of claims 204 to207, wherein up to 5 internucleoside linkages are non-PS internucleosidelinkages.
 213. The method of any one of claims 204 to 207, wherein up to4 internucleoside linkages are non-PS internucleoside linkages.
 214. Themethod of any one of claims 204 to 207, wherein up to 3 internucleosidelinkages are non-PS internucleoside linkages.
 215. The method of any oneof claims 204 to 207, wherein up to 2 internucleoside linkages arenon-PS internucleoside linkages.
 216. The method of any one of claims204 to 207, wherein up to 1 internucleoside linkage is a non-PSinternucleoside linkage.
 217. The method of claim 204, wherein allinternucleoside linkages are PS internucleoside linkages.
 218. Themethod of any one of claims 1 to 217, wherein the oligomer is furthercharacterized in that it blocks translocation of mRNA from the nucleusto the cytoplasm of the tumor cell.
 219. The method of any one of claims1 to 218, wherein the oligomer is further characterized in that it ispreferentially taken up by the tumor cell, as compared to its uptake bya non-tumor cell.
 220. The method of any one of claims 1 to 219, whereinthe oligomer is further characterized in that it causes apoptosis ornecrosis of the tumor cell.
 221. The method of claim 220, wherein theoligomer causes more death of tumor cells of the same type as the tumorcell than of non-tumor cells.
 222. The method of any one of claims 1 to221, wherein the oligomer is further characterized in that it binds toone or both of THOC4 and SSB1 with higher affinity than a controloligomer.
 223. The method of any one of claims 1 to 222, wherein theoligomer is introduced into the tumor cell in vivo.
 224. The method ofany one of claims 1 to 222, wherein the oligomer is introduced into thetumor cell in vitro.
 225. The method of any one of claims 1 to 224,wherein the oligomer is further characterized in that has a meltingtemperature (Tm) of at least about 45° C.
 226. The method of any one ofclaims 1 to 225, wherein the backbone of the oligomer comprises at leastone 2′-O-alkyl modified sugar moiety.
 227. The method of claim 226,wherein at least about 50% of the nucleosides of the oligomer are each a2′-O-alkyl nucleoside.
 228. The method of any one of claims 226 to 227,wherein the oligomer consists of 14 nucleobases an comprises from 7 to14 2′-O-alkyl nucleosides.
 229. The method of any one of claims 226 to227, wherein the oligomer consists of 15 nucleobases an comprises from 8to 15 2′-O-alkyl nucleosides.
 230. The method of any one of claims 226to 227, wherein the oligomer consists of 16 nucleobases an comprisesfrom 8 to 16 2′-O-alkyl nucleosides.
 231. The method of any one ofclaims 226 to 227, wherein the oligomer consists of 17 nucleobases ancomprises from 9 to 17 2′-O-alkyl nucleosides.
 232. The method of anyone of claims 226 to 227, wherein the oligomer consists of 18nucleobases an comprises from 9 to 18 2′-O-alkyl nucleosides.
 233. Themethod of any one of claims 226 to 227, wherein the oligomer consists of19 nucleobases an comprises from 10 to 19 2′-O-alkyl nucleosides. 234.The method of any one of claims 226 to 227, wherein the oligomerconsists of 20 nucleobases an comprises from 10 to 20 2′-O-alkylnucleosides.
 235. The method of any one of claims 226 to 227, whereinthe oligomer consists of 21 nucleobases an comprises from 11 to 212′-O-alkyl nucleosides.
 236. The method of any one of claims 226 to 227,wherein the oligomer consists of 22 nucleobases an comprises from 11 to22 2′-O-alkyl nucleosides.
 237. The method of any one of claims 226 to227, wherein the oligomer consists of 23 nucleobases an comprises from12 to 23 2′-O-alkyl nucleosides.
 238. The method of any one of claims226 to 227, wherein the oligomer consists of 24 nucleobases an comprisesfrom 12 to 24 2′-O-alkyl nucleosides.
 239. The method of any one ofclaims 226 to 227, wherein the oligomer consists of 25 nucleobases ancomprises from 13 to 25 2′-O-alkyl nucleosides.
 240. The method of anyone of claims 226 to 227, wherein the oligomer consists of 26nucleobases an comprises from 13 to 26 2′-O-alkyl nucleosides.
 241. Themethod of any one of claims 226 to 227, wherein the oligomer consists of27 nucleobases an comprises from 14 to 27 2′-O-alkyl nucleosides. 242.The method of any one of claims 226 to 227, wherein the oligomerconsists of 28 nucleobases an comprises from 14 to 28 2′-O-alkylnucleosides.
 243. The method of any one of claims 226 to 227, whereinthe oligomer consists of 29 nucleobases an comprises from 15 to 292′-O-alkyl nucleosides.
 244. The method of any one of claims 226 to 227,wherein the oligomer consists
 245. The method of any one of claims 226to 227, wherein the oligomer consists of 15 nucleobases an comprisesfrom 7 to 15 2′-O-alkyl nucleosides.
 246. The method of any one ofclaims 226 to 245, wherein the 2′-O-alkyl nucleoside is a 2′-O-methylnucleoside.
 247. The method of any one of claims 1 to 246, wherein thenucleobase sequence over the length of the oligomer lacks substantiallycomplementarity to the transcriptome.
 248. The method of claim 247,wherein no more than about 95% of the nucleobases of the oligomer areable to engage in base-pairing with the transcriptome.
 249. The methodof claim 248, wherein the oligomer consists of 14 to 29 nucleobases andhas at least one non-complementary nucleobase that is unable tobase-pair with a nucleobase of a reference nucleobase sequence of thetranscriptome.
 250. The method of claim 247, wherein no more than about90% of the nucleobases of the oligomer are able to engage inbase-pairing with the transcriptome.
 251. The method of claim 250,wherein the oligomer consists of 14 to 29 nucleobases and has at least1, 2, or 3 non-complementary nucleobases, depending on the length of theoligomer, as calculated from TABLE 1 supra, which are unable tobase-pair with a nucleobase of a reference nucleobase sequence of thetranscriptome.
 252. The method of claim 247, wherein no more than about85% of the nucleobases of the oligomer are able to engage inbase-pairing with the transcriptome.
 253. The method of claim 252,wherein the oligomer consists of 14 to 29 nucleobases and has at least2, 3 or 4 non-complementary nucleobases, depending on the length of theoligomer, as calculated from TABLE 1 supra, which are unable tobase-pair with a nucleobase of a reference nucleobase sequence of thetranscriptome.
 254. The method of claim 247, wherein no more than about80% of the nucleobases of the oligomer are able to engage inbase-pairing with the transcriptome.
 255. The method of claim 254,wherein the oligomer consists of 14 to 29 nucleobases and has at least3, 4, 5 or 6 non-complementary nucleobases, depending on the length ofthe oligomer, as calculated from TABLE 1 supra, which are unable tobase-pair with a nucleobase of a reference nucleobase sequence of thetranscriptome.
 256. The method of claim 247, wherein no more than about75% of the nucleobases of the oligomer are able to engage inbase-pairing with the transcriptome.
 257. The method of claim 256,wherein the oligomer consists of 14 to 29 nucleobases and has at least3, 4, 5, 6 or 7 non-complementary nucleobases, depending on the lengthof the oligomer, as calculated from TABLE 1 supra, which are unable tobase-pair with a nucleobase of a reference nucleobase sequence of thetranscriptome.
 258. The method of claim 247, wherein no more than about70% of the nucleobases of the oligomer are able to engage inbase-pairing with the transcriptome.
 259. The method of claim 258,wherein the oligomer consists of 14 to 29 nucleobases and has at least4, 5, 6, 7, 8 or 9 non-complementary nucleobases, depending on thelength of the oligomer, as calculated from TABLE 1 supra, which areunable to base-pair with a nucleobase of a reference nucleobase sequenceof the transcriptome.
 260. The method of claim 247, wherein no more thanabout 65% of the nucleobases of the oligomer are able to engage inbase-pairing with the transcriptome.
 261. The method of claim 260,wherein the oligomer consists of 14 to 29 nucleobases and has at least5, 6, 7, 8, 9 or 10 non-complementary nucleobases, depending on thelength of the oligomer, as calculated from TABLE 1 supra, which areunable to base-pair with a nucleobase of a reference nucleobase sequenceof the transcriptome.
 262. The method of claim 247, wherein no more thanabout 60% of the nucleobases of the oligomer are able to engage inbase-pairing with the transcriptome.
 263. The method of claim 262,wherein the oligomer consists of 14 to 29 nucleobases and has at least6, 7, 8, 9, 10, 11 or 12 non-complementary nucleobases, depending on thelength of the oligomer, as calculated from TABLE 1 supra, which areunable to base-pair with a nucleobase of a reference nucleobase sequenceof the transcriptome.
 264. The method of claim 247, wherein no more thanabout 55% of the nucleobases of the oligomer are able to engage inbase-pairing with the transcriptome.
 265. The method of claim 264,wherein the oligomer consists of 14 to 29 nucleobases and has at least6, 7, 8, 9, 10, 11, 12 or 13 non-complementary nucleobases, depending onthe length of the oligomer, as calculated from TABLE 1 supra, which areunable to base-pair with a nucleobase of a reference nucleobase sequenceof the transcriptome.
 266. The method of claim 247, wherein no more thanabout 50% of the nucleobases of the oligomer are able to engage inbase-pairing with the transcriptome.
 267. The method of claim 266,wherein the oligomer consists of 14 to 29 nucleobases and has at least7, 8, 9, 10, 11, 12, 13 or 14 non-complementary nucleobases, dependingon the length of the oligomer, as calculated from TABLE 1 supra, whichare unable to base-pair with a nucleobase of a reference nucleobasesequence of the transcriptome.
 268. The method of any one of claims 1 to267, wherein the nucleobase sequence over the length of the oligomerlacks substantial complementarity to the genome of a mammal from whichthe tumor cell is suitably derived.
 269. The method of claim 268,wherein no more than about 95% of the nucleobases of the oligomer areable to engage in base-pairing with the genome.
 270. The method of claim269, wherein the oligomer consists of 14 to 29 nucleobases and has atleast one non-complementary nucleobase that is unable to base-pair witha nucleobase of a reference nucleobase sequence of the genome.
 271. Themethod of claim 247, wherein no more than about 90% of the nucleobasesof the oligomer are able to engage in base-pairing with the genome. 272.The method of claim 271, wherein the oligomer consists of 14 to 29nucleobases and has at least 1, 2, or 3 non-complementary nucleobases,depending on the length of the oligomer, as calculated from TABLE 1supra, which are unable to base-pair with a nucleobase of a referencenucleobase sequence of the genome.
 273. The method of claim 247, whereinno more than about 85% of the nucleobases of the oligomer are able toengage in base-pairing with the genome.
 274. The method of claim 273,wherein the oligomer consists of 14 to 29 nucleobases and has at least2, 3 or 4 non-complementary nucleobases, depending on the length of theoligomer, as calculated from TABLE 1 supra, which are unable tobase-pair with a nucleobase of a reference nucleobase sequence of thegenome.
 275. The method of claim 247, wherein no more than about 80% ofthe nucleobases of the oligomer are able to engage in base-pairing withthe genome.
 276. The method of claim 275, wherein the oligomer consistsof 14 to 29 nucleobases and has at least 3, 4, 5 or 6 non-complementarynucleobases, depending on the length of the oligomer, as calculated fromTABLE 1 supra, which are unable to base-pair with a nucleobase of areference nucleobase sequence of the genome.
 277. The method of claim247, wherein no more than about 75% of the nucleobases of the oligomerare able to engage in base-pairing with the genome.
 278. The method ofclaim 277, wherein the oligomer consists of 14 to 29 nucleobases and hasat least 3, 4, 5, 6 or 7 non-complementary nucleobases, depending on thelength of the oligomer, as calculated from TABLE 1 supra, which areunable to base-pair with a nucleobase of a reference nucleobase sequenceof the genome.
 279. The method of claim 247, wherein no more than about70% of the nucleobases of the oligomer are able to engage inbase-pairing with the genome.
 280. The method of claim 279, wherein theoligomer consists of 14 to 29 nucleobases and has at least 4, 5, 6, 7, 8or 9 non-complementary nucleobases, depending on the length of theoligomer, as calculated from TABLE 1 supra, which are unable tobase-pair with a nucleobase of a reference nucleobase sequence of thegenome.
 281. The method of claim 247, wherein no more than about 65% ofthe nucleobases of the oligomer are able to engage in base-pairing withthe genome.
 282. The method of claim 281, wherein the oligomer consistsof 14 to 29 nucleobases and has at least 5, 6, 7, 8, 9 or 10non-complementary nucleobases, depending on the length of the oligomer,as calculated from TABLE 1 supra, which are unable to base-pair with anucleobase of a reference nucleobase sequence of the genome.
 283. Themethod of claim 247, wherein no more than about 60% of the nucleobasesof the oligomer are able to engage in base-pairing with the genome. 284.The method of claim 283, wherein the oligomer consists of 14 to 29nucleobases and has at least 6, 7, 8, 9, 10, 11 or 12 non-complementarynucleobases, depending on the length of the oligomer, as calculated fromTABLE 1 supra, which are unable to base-pair with a nucleobase of areference nucleobase sequence of the genome.
 285. The method of claim247, wherein no more than about 55% of the nucleobases of the oligomerare able to engage in base-pairing with the genome.
 286. The method ofclaim 285, wherein the oligomer consists of 14 to 29 nucleobases and hasat least 6, 7, 8, 9, 10, 11, 12 or 13 non-complementary nucleobases,depending on the length of the oligomer, as calculated from TABLE 1supra, which are unable to base-pair with a nucleobase of a referencenucleobase sequence of the genome.
 287. The method of claim 247, whereinno more than about 50% of the nucleobases of the oligomer are able toengage in base-pairing with the genome.
 288. The method of claim 287,wherein the oligomer consists of 14 to 29 nucleobases and has at least7, 8, 9, 10, 11, 12, 13 or 14 non-complementary nucleobases, dependingon the length of the oligomer, as calculated from TABLE 1 supra, whichare unable to base-pair with a nucleobase of a reference nucleobasesequence of the genome.
 289. The method of any one of claims 1 to 288,wherein the nucleobase sequence over the length of the oligomer lackshomology to the genome of a mammal from which the tumor cell is suitablyderived.
 290. The method of claim 289, wherein the nucleobase sequenceover the length of the oligomer has no more than about 95% sequenceidentity to any equal length of contiguous nucleobases defining areference nucleobase sequence in the genome.
 291. The method of claim290, wherein the oligomer consists of 14 to 29 nucleobases and has atleast one nucleobase that is not identical to, or does not have the sameor equivalent nucleobase-pairing ability as, a nucleobase at a matchingposition of the reference nucleobase sequence.
 292. The method of claim289, wherein the nucleobase sequence over the length of the oligomer hasno more than about 90% sequence identity to any equal length ofcontiguous nucleobases defining a reference nucleobase sequence in thegenome.
 293. The method of claim 292, wherein the oligomer consists of14 to 29 nucleobases and has at least 1, 2, or 3 nucleobases, dependingon the length of the oligomer, as calculated from TABLE 1 supra, whichare not identical to, or does not have the same or equivalentnucleobase-pairing ability as, a nucleobase at a matching position ofthe reference nucleobase sequence.
 294. The method of claim 289, whereinthe nucleobase sequence over the length of the oligomer has no more thanabout 85% sequence identity to any equal length of contiguousnucleobases defining a reference nucleobase sequence in the genome. 295.The method of claim 294, wherein the oligomer consists of 14 to 29nucleobases and has at least 2, 3 or 4 nucleobases, depending on thelength of the oligomer, as calculated from TABLE 1 supra, which are notidentical to, or does not have the same or equivalent nucleobase-pairingability as, a nucleobase at a matching position of the referencenucleobase sequence.
 296. The method of claim 289, wherein thenucleobase sequence over the length of the oligomer has no more thanabout 80% sequence identity to any equal length of contiguousnucleobases defining a reference nucleobase sequence in the genome. 297.The method of claim 296, wherein the oligomer consists of 14 to 29nucleobases and has at least 3, 4, 5 or 6 nucleobases, depending on thelength of the oligomer, as calculated from TABLE 1 supra, which are notidentical to, or does not have the same or equivalent nucleobase-pairingability as, a nucleobase at a matching position of the referencenucleobase sequence.
 298. The method of claim 289, wherein thenucleobase sequence over the length of the oligomer has no more thanabout 75% sequence identity to any equal length of contiguousnucleobases defining a reference nucleobase sequence in the genome. 299.The method of claim 298, wherein the oligomer consists of 14 to 29nucleobases and has at least 3, 4, 5, 6 or 7 nucleobases, depending onthe length of the oligomer, as calculated from TABLE 1 supra, which arenot identical to, or does not have the same or equivalentnucleobase-pairing ability as, a nucleobase at a matching position ofthe reference nucleobase sequence.
 300. The method of claim 289, whereinthe nucleobase sequence over the length of the oligomer has no more thanabout 70% sequence identity to any equal length of contiguousnucleobases defining a reference nucleobase sequence in the genome. 301.The method of claim 300, wherein the oligomer consists of 14 to 29nucleobases and has at least 4, 5, 6, 7, 8 or 9 nucleobases, dependingon the length of the oligomer, as calculated from TABLE 1 supra, whichare not identical to, or does not have the same or equivalentnucleobase-pairing ability as, a nucleobase at a matching position ofthe reference nucleobase sequence.
 302. The method of claim 289, whereinthe nucleobase sequence over the length of the oligomer has no more thanabout 65% sequence identity to any equal length of contiguousnucleobases defining a reference nucleobase sequence in the genome. 303.The method of claim 302, wherein the oligomer consists of 14 to 29nucleobases and has at least 5, 6, 7, 8, 9 or 10 nucleobases, dependingon the length of the oligomer, as calculated from TABLE 1 supra, whichare not identical to, or does not have the same or equivalentnucleobase-pairing ability as, a nucleobase at a matching position ofthe reference nucleobase sequence.
 304. The method of claim 289, whereinthe nucleobase sequence over the length of the oligomer has no more thanabout 60% sequence identity to any equal length of contiguousnucleobases defining a reference nucleobase sequence in the genome. 305.The method of claim 304, wherein the oligomer consists of 14 to 29nucleobases and has at least 6, 7, 8, 9, 10, 11 or 12 nucleobases,depending on the length of the oligomer, as calculated from TABLE 1supra, which are not identical to, or does not have the same orequivalent nucleobase-pairing ability as, a nucleobase at a matchingposition of the reference nucleobase sequence.
 306. The method of claim289, wherein the nucleobase sequence over the length of the oligomer hasno more than about 55% sequence identity to any equal length ofcontiguous nucleobases defining a reference nucleobase sequence in thegenome.
 307. The method of claim 306, wherein the oligomer consists of14 to 29 nucleobases and has at least 6, 7, 8, 9, 10, 11, 12 or 13nucleobases, depending on the length of the oligomer, as calculated fromTABLE 1 supra, which are not identical to, or does not have the same orequivalent nucleobase-pairing ability as, a nucleobase at a matchingposition of the reference nucleobase sequence e.
 308. The method ofclaim 289, wherein the nucleobase sequence over the length of theoligomer has no more than about 50% sequence identity to any equallength of contiguous nucleobases defining a reference nucleobasesequence in the genome.
 309. The method of claim 308, wherein theoligomer consists of 14 to 29 nucleobases and has at least 7, 8, 9, 10,11, 12, 13 or 14 nucleobases, depending on the length of the oligomer,as calculated from TABLE 1 supra, which are not identical to, or doesnot have the same or equivalent nucleobase-pairing ability as, anucleobase at a matching position of the reference nucleobase sequence.310. The method of any one of claims 1 to 246, wherein the nucleobasesequence over the length of the oligomer has substantial complementarityto an antisense strand of a selected gene.
 311. The method of claim 310,wherein the nucleobase sequence is complementary to and hybridizes to atarget sequence of the selected gene or transcript thereof under highstringency conditions.
 312. The method of of any one of claims 1 to 311,wherein the nucleobase sequence is selected from any one of SEQ ID NO:1, 2, 3, 5, 6, 7, 10, 12, 14, 15, 16, 17, 21, 22, 23, 24, 25, 27, 28,29, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 44, 45, 51, 52, 53, 54,55, 56, 59, 61, 62, 63, 64, 66, 67, 68, 69, 70, 71, 72, 73, 79, 80, 81,82, 83, 84, 85, 91, 92, 93, 94, 98, 100, 101, 103, 104, 105, 107, 108,109, 110, 111, 113, 114, 115, 117, 118, 119, 120, 121, 122, 131, 132,133, 134, 135, 137, 138, 143, 144, 145, 152, 153, 155, 156, 158, 159,160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174,175, 177, 180, 181, 182, 183, 184, 185, 191, 192, 196, 198, 203, 206,207, 209, 210, 211, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232,233, 234, 235, 236, 237, 238, 239, 240, 244, 245, 247, 248, 249, 250,251, 252, 253, 256, 258, 259, 261, 263, 264, 265, 269, 270, 271, 272,274, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289,290, 291, 292, 293, 295, 296, 297, 298, 299, 300, 301 and
 303. 313. Themethod of of any one of claims 1 to 311, wherein the nucleobase sequenceis selected from any one of SEQ ID NO: 1, 2, 3, 5, 6, 10, 12, 14, 15,16, 17, 21, 22, 23, 24, 25, 28, 32, 31, 34, 35, 36, 38, 39, 41, 44, 52,56, 53, 54, 59, 61, 63, 64, 66, 67, 68, 69, 70, 71, 72, 73, 79, 80, 81,82, 83, 84, 91, 92, 93, 98, 100, 103, 104, 107, 109, 110, 111, 113, 114,117, 118, 119, 120, 121, 122, 131, 132, 133, 134, 135, 143, 144, 145,153, 155, 156, 158, 159, 160, 161, 162, 164, 165, 167, 168, 169, 170,171, 172, 180, 181, 182, 191, 192, 203, 224, 225, 226, 227, 229, 230,233, 234, 235, 236, 238, 239, 240, 245, 247, 251, 252, 253, 258, 259,261, 263, 264, 269, 271, 272, 274, 285, 286, 287, 288, 289, 290, 291,292, 293, 295, 296, 297, 298, 299, 300, 301 and
 303. 314. The method ofof any one of claims 1 to 311, wherein the nucleobase sequence isselected from any one of SEQ ID NO: 1, 2, 3, 5, 14, 16, 17, 31, 34, 35,36, 38, 39, 52, 56, 67, 68, 69, 70, 71, 79, 80, 81, 82, 83, 91, 92, 93,100, 103, 109, 110, 111, 114, 119, 131, 133, 134, 135, 143, 153, 155,158, 159, 161, 164, 168, 169, 171, 181, 182, 203, 253, 272, 300, 301 and303.
 315. The method of of any one of claims 1 to 314, wherein the tumorcell is selected from breast, prostate, ovarian, cervical, pancreatic,colorectal, lung, hepatocellular, gastric, liver, bladder, urinarytract, thyroid, renal, carcinoma, melanoma, brain, non-small cell lung,squamous cell of the head and neck, endometrial, multiple myeloma,rectal, and esophageal tumor cells.
 316. The method of of any one ofclaims 1 to 314, wherein the tumor cell is selected from prostate, lung,pancreatic, breast, ovarian or bone tumor cells.
 317. The method of ofany one of claims 1 to 316, wherein oligomer compound preferentiallybinds to or has affinity for one or both of THOC4 and hSSB1.
 318. Themethod of claim 318, wherein the THOC4 and SSB1 proteins are human. 319.The method of claim 318 or claim 319, wherein the oligomer compoundbinds to THOC4 with a K_(D) of about 50 nM or less in an aqueoussolution containing 10 nM Tris-HCl (pH8.0) and 100 mM NaCl at 37° C.320. The method of claim 318 or claim 319, wherein the oligomer compoundbinds to SSB1 (e.g., hSSB1) with a K_(D) of about 3 nM or less in anaqueous solution containing 10 nM Tris-HCl (pH8.0) and 100 mM NaCl at37° C.
 321. An oligomer as defined in any one of claims 1 to
 314. 322. Apharmaceutical composition that comprises an oligomer as defined in anyone of claims 1 to 314, and a pharmaceutically acceptable carrier. 323.A method for treating or preventing a cancer in a subject, the methodcomprising administering to the subject an effective amount of anoligomer as defined in any one of claims 1 to
 314. 324. The method ofclaim 323, wherein the cancer is a solid tumor or bloodborne tumor. 325.The method of claim 323 or claim 324, wherein the cancer is selectedfrom cancers of skin, tissues, organs, bone, cartilage, blood, andvessels.
 326. The method of any one of claims 323 to 325, wherein thecancer is selected from breast cancer, prostate cancer, ovarian cancer,cervical cancer, pancreatic cancer, colorectal cancer, lung cancer,hepatocellular cancer, gastric cancer, liver cancer, bladder cancer,cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma,melanoma, brain cancer, non-small cell lung cancer, squamous cell cancerof the head and neck, endometrial cancer, multiple myeloma, rectalcancer, and esophageal cancer
 327. The method of any one of claims 323to 326, wherein the cancer i selected from prostate, lung, pancreatic,breast, ovarian and bone cancer.
 328. The method of any one of claims323 to 327, wherein the cancer is a primary cancer.
 329. The method ofany one of claims 323 to 327, wherein the cancer is a metastatic cancer.330. The method of any one of claims 323 to 329, further comprisingconcurrently administering with the oligomer at least one ancillaryagent for treating or preventing the cancer.
 331. The method of claim330, wherein the ancillary agent is selected from an anti-infectiveagent, a chemotherapeutic agent, and an immunotherapeutic agent.